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A STUDY OF SOME SOLUTION EQUILIBRIA OF BIOLOGICAL SIGNIFICANCE
Anna M Fiabane 1976
ABSTRACT
The stability constants of some lead(II)-ligand anion complexes 
already measured have been recalculated and others of some lead(II)
and zinc(II) complexes have been measured by glass and chloride
electrode potentiometry. These constants have been used in computer
models of biological systems in order to assess the suitability of current
and proposed therapeuticals as lead(II) sequestering agents in vivo.
Glutathione is proposed as the most promising ligand for the treatment
of plumbism.
Thermodynamic functions for some lead(II)-ligand anion complexes
have been determined, by calorimetry and temperature variation of
formation constants, and from these some complex structures in aqueous
solution have been suggested..
The interaction of bovine serum albumin with lead(II) and copper(II)
has been studied potentiometrically. The effect of some antirheumatoid
arthritis drugs on the copper(II)-bovine serum albumin interaction has
been observed by visible spectroscopy and molecular filtration. It is
concluded that some of these drugs have the ability to release copper (II)
from this protein bound situation.
A contribution has been made to an interlaboratory potentiometric
study of the nickel(II)-glycinate complexing system and a comparison
of results from several laboratories is presented.
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1LIST OF MAIN SYMBOLS
M mol eta 3 r?
px -log x
T temperature (K)
R the gas constant
F the faraday
z the nimbeer of electrons involved in a redox process
t,Eo standard electrode potential
Eo formal electrode potential
E measured electrode potential
A iignnd
B metal
H proton
ta total concentration of A
tb total concentration of B
th total concentration of H
a enneentaation of free A
b concenrattion of free B
h eencenratteen oO free H
0 natitaty
f activity coefficient
[] ^centra^^n -
I ioneettattion of ionic background salt
pqr the complex ABH where r < O indicates a hydroxyl group pqr
Z the average niumber of ligands, A, bound to central group, B
2z the average number of protons, H, bound to ligand, A
wk ionic product of water
3°pqr thermodynamic stability constant of the.species A B
n
pqr stoichiometric stability constant of the species A®B®H®
p stepwise stability constant for the complexation reaction
A . B + A A Bp-1 p
®corr corrected heat change
AG® Gibbs free energy change*
AH© enthalpy change*
AS® entropy change*
Graphs are plotted in the order
* with 3.00M NaClO. as the standard solvent
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3CHAPTER 1
INTRODUCTION
General
In 1946 the World Health Organisation defined "health" as
"a state of complete physical, mental and social wellbeing and not
merely the absence of disease or infirmity". At least twenty-five 
elements are necessary for man's achievement of this state of-
health. •
The elements of organic matter, H, C, N, O, P and S, constitute 
by far the greatest proportion of the body's atoms. The remaining 
biological elements may be classified as main group, Na, K, Mg, Ca
and Cl, which, as ions, are usually mobile, or trace elements, Zo,
Fe, Cu, Mo„ Co, Mn, Cr, V, Si, Sn, Se, F, Br and I, which usually
have fixed chemical neighbours in a biological system.
People living in a modern industrial society may be exposed to
excessive concentrations of both essential and non-essential metals
as well as to non-metal pollutants such as sulphur dioxide and
ligands such as ettriloatiaccaaae. The metallic pelluaanas causing
most concern at the moment are lead, cadmium and merc^i^^j^.
4Lead Poisoning and its Treatment
industrial death attributed to lead was in 1956
Lead is, and always has been, naturally prrsent in man's
environment and so in man himself. However, as mimi mther m itemc
contaminants, man is redistributing it from fairly remote deposits
to populated areas where it may accumulate to hazardous levels.
2 12World production of primary ore 1 ead i n 1 190 was 3.8 x 10 g
and it is estimated that 2.-4 x lO^g o f i ead e enter the oceenn each 
3year . In spite of this extremely high turnover the last recorded
4
5 .The average adult daily intake of lead from food is 220ug
but onC' 1 i1 o i tmth si aasocbed. Thh fraction of inhaled lead
which is absorbed depends on solubility and particle size and has
been estimated as 10-50% The major source cf this atmospheric
4 6 7lead appears to be the combustion of leaded petrol, " ' the
products of which are complex halides which are converted in the
g
atmosphere tc oxides and carbonates .
Lead is present in the human bcdy only as an environmental
9contaminant and appears to perform no normal biological function . 
A stable isotope study 10 in the normal human has nct been able tc 
discover a homeostatic mechanism for the maintenance of the lead
concentration in blocd.
11The natural mean lead content of blcod has been estimated
-3as 2.5ng cm . However, the mean bleed lead level of 'normal'
12 -3children in Glasgow has been measured as 300ng cm and of a
13 -3control group of Manchester children as 310ng cm . In the U.K
the lower mean blccd lead level in children shewing lead poisoning
514 3 15 *"*"3is 400ng cm but the suggested 'danger level' is 250ng cm .
Thus lead levels in the general population appear to be much closer
to the levels for overt clinical poisoning than for any other-
chemical pollutant.
16About 95% of the body burden of lead is stored in bone as
the relatively insoluble lead triphosphate This is a non-diffusable
form of the metal which is non-toxic:. It is the small fraction of
lead which is mobile in the soft tissues which is responsible for the 
17acute toxic effects .
Inorganic lead is a general metabolic poison which is cumulative 
7in man . It is believed that Head(II) displaces essential transition
metal ions from biologically important groups (predominantly
sulphydryl groups). The inhibition of the enzyme system necessary
for haem formation is thought to operate by the blocking of
6sulphydryl groups but there is no direct evidence for this . Of the
many effects of lead poisoning on intermediary metabolism the
production of anaemia is the most common and may be used diagnostically
In children neural tissue is particularly sensitive to lead
and about 25% of the children who survive an attack of acute
encephalopathy sustain severe permanent brain damage. An even more
worrying factor is that the blood lead level at which central
nervous system injury in children can occur is still debated and
correlations between impaired mental functioning and levels well
below the clinical threshold have been reported
The accepted treatment for plumbism is with calcium disodium
ethylenediaminetetraacetate (CaNa_edta) and 3,3-dimethylcysteine
6(D-penicillin-iine) (for formulae see figure 1). 2,3-Dimetcapai-
propanol(BAL) is not generally used because of its toxic side 
3 19effects ' . Treatment with CaNa^dta, however, causes marked
20,21 „ ndepletion of essential zinc in the body . Computer models
22have been used to show that D-penicillamine also is insufficiently
selective and may remove zinc from the body.
Part of the research reported in this thesis was, thus, to
suggest a ligand of improved selectivity for the removal of lead
from the body.
Ligands Studied
The formulae of the ligands used in this study are shown in
figure 1.
Originally the comptexing of eight representative amino acid 
22anions to lead(II) had been studied i.e. asparagieate, aspartate,
cysteioate, glutaminate, histtdieate, pheoylalaninate, serinate and
tryptophanate. The formation constants for these systems have been
recalculated in the light of new computational techniques and some
additional measurements have been carried out on the lead-aspartate
and lead-cysteteate systems. The ligands normally used for treating
plumbism, edta and D-penicillamine, have also been studied under
the same experimental ceoditie■es, as has glutamate. For purposes
of comparison it was also necessary to measure the zincf.!!) complex
formation constants for some of these ligands.
NH CH COO" 
2 2
GLYCINATE (gly)
NH CH CQNHCHCOO"
2 2 2
GLYCYLGLYCINATE(glygly)
NH CH CONHCH CONHCH COO"
2 2 2 2
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NH CHCOO 
21
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2
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21 2l 21
CH CH COO" CH S" CH CCH
2 2 2 31 3Q”
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o
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\2
-ooc
CHCH CH CONHCHCONHCH COO' 
/ 2 2 I 2
CH S' 
2
CH2C00‘
NCH CH fk 
2 2 \
CH COO' 
2
GLUTATHIONATE (gsh) ETHYLENEDIAMINETETRAACETATE ( edta)
FIGURE 1 : LIGANDS USED IN THE POTENTIOMETRIC OR CALORIMETRIC STUDY
7Determination of Formation Constants
23J. Bjerrum showed that stepwise equilibria are generally set
up when a ligand is added to a solution containing a metal aquo ion.
Most ligands are weak acids and so there is a competition between
the metal ion and the proton for the ligand anion. Thus, the
compiexing equilibria are dependent upon the hydrogen ion concentration
and can be followed by monitoring the emf of an electrode reversible
to hydrogen ions such as the glass electrode.
The emf method for measuring concentrations of metal ions or 
24,25protons was first used at the end of the nineteenth century
and today is the most common technique applied to equilibrium systems.
This method, of course, allows calculation of stability constants
only if the complexes dissociate at pH values for which‘the proton
concentration is accurately measurable. The emf titration method
provides both high precision and a large number of experimental data
points, both of these conditions being particularly required if
other than simple mononuclear species are present.
The sensitivity of the glass electrode to the surrounding medium
26 27was first noted in 1906 but not quantified till 1909 . A
2 8detailed discussion of these electrodes is given by Bates ' .
The glass electrode, which is now an everyday piece of laboratory
equipment, is unusual in not being influenced by oxidising and
reducing agents and not being poisoned by heavy metals. Apart from
the imperfect hydrogen ion response at the end of the pH scale, the
most serious disadvantages of this electrode are its high electrical
resistance and its low durability especially in alkaline solution.
Computer Models
Having obtained formation constants for all the complexing
• ♦ 1~7reactions of interest, it is then possible to simulate the -n Vivo
compiexing competition between essential metal ions and ligands
and to indicate the influence of a polluting metal ion and the
effect of any ligands suggested as therapeuticals for its removal.
Some very powerful computer programs are now available to calculate 
29these equilibrium concentrations of species;. For example, one
can calculate the concentrations of up to 5,000 species present in
a blood plasma model.
These computer models are, of course, far removed from the true
■n V^VO situation and can only be used to make suggestions as to
which ligands it may be worthwhile putting forward for animal trials. 
22Our initial model studies indicated that a more selective
drug for the treatment of lead poisoning might be a peptide
containing cysteinyl,histidyl and aspartyl residues;. The nearest
peptide to this which is commercially available at reasonable cost
is L-Y-glutamyl-L-cysteinylglycine(glutathione) . Thus the lead(II)
and zinc(II) complex formation constants of glutathionate were
measured and their inclusion in further models showed that we
would, indeed, expect glutathione to be more selective than edta
for the removal of excess body lead.
Having focussed attention on glutathionate, it was thought
desirable to obtain further information about its bonding to lead(II)
in solution.
9Determination of Thermodynamic Functions
All processes involving bond breaking or making, be they chemical 
or biological, .are accompanied by heat changes. Measurements of
these heat changes yield values for the enthalpies of reaction and
so can be used in conjunction with potentiometric measurements to
calculate the entropies of reaction. Values of AHS can give information
concerning bond energies in solution and AS° is a measure of the 
31interaction with the solvent .
The preferred method for the determination of AH* values is direct
measurement by incremental titration calorimetry. Calorimeters were 
32first used more than a hundred years ago and many different designs 
33of solution calorimeter have been described , However, a titration 
34procedure was first used only in 1955 and the first description 
35of the incremental thermometric titration technique was in 1959 .
The great advantage of the titration approach is that a large
amount of data can be collected in a reasonable time and then one
can adopt a least-squares approach to data analysis. It is 
31believed that an incremental titration method is more accurate
than the continuous titration technique because it allows the contents
of the calorimeter to reach equilibrium for each point and also
allows the contents to be returned to the initial temperature between
points.
The thermodynamic functions have been determined for the
interactions of protons and lead(II) with glutathionate and, for
purposes of comparison, with glycinate, glycylglycinate, glycylgly­
cylglycinate and cysteinate. Unfortunately, for the lead(Ii)-ligand
10
interactions direct calorimetry could not be used because of the
. 36,37interference of insoluble complexes and lead-hydroxy species .
Thus the van't Hoff method was resorted to i.e. enthalpies were
calculated from the temperature variation of the formation constants.
This method is much less satisfactory because of its inherent, and
often unjustified, assumption that AH does not vary within the
temperature range studied and also because formation constants do
not change greatly over this temperature range and so have to be 
©measured with great accuracy to give reliable values for AH ,
These thermodynamic results have then been used to suggest
structures for the various complexes present in the solution.
29
3 8Since blood plasma is about 0.1009 M in chloride ions, it
was considered pertinent to determine formation constants for the
interaction of chloride ions with lead(II) under our experimental
conditions. This was done by use of a silver/silver chloride
electrode, which responds to the activity of chloride ions in 
39solution , as well as a glass electrode.
Blood also has a high protein content but it has been shown
that this should not effect the distribution of metals among the
small ligand complexes. However, the inclusion of human serum 
40albumin in the copper-zinc-amino acid model system has the effect
of almost halving the concentrations of the zinc-small ligand
complexes.
We have chosen bovine serum albumin as a representative of
the blood proteins and the order of its binding to lead(II), zinc(II)
and copper(II) has been determined potentiometrically.
11
Only 2% of plasma copper is bound to serum albumin the remainder
41,42being bound strongly, in a non-exchangeable form, to caeruloplasmin 
However, this small amount of copper(II)-human serum albumin complex is 
the exchangeable form of copper in vivo and is in rapid equilibrium
43 44 45with copper in the tissues . It is known ' that in blood plasma
46,47there is a negligible amount of free copper(II) and it is considered
that there is an equilibrium between serum albumin and amino acid
' 45bound copper(II) which may be mediated through ternary complexes .
48'It has also been shown that low molecular weight copper(II) complexes
may transport copper between the blood and the tissues.
Copper and Arthritis
A number of folk remedies for arthritis (a disease characterised
by pain and joint inflammation) involve substances of high copper
content and, in fact;, there is now a great deal of evidence connecting
copper with rheumatoid arthritis and other inflammatory diseases-
Rheumatoid arthritis patients show a high level of copper in 
49their serum and an increased urinary excretion of this metal .
50However, there is a suggestion that in this disease there is an
insufficient supply of copper in the right form for the normal
copper-dependent metabolic processes of tissue maintenance.
Most of the drugs used in the treatment of rheumatoid arthritis 
9and other collagen diseases are capable of binding metals and it
12
has been shown that the copper chelates of known anti-arthritic
drugs may be up to twenty times more active than the drugs alone.
Copper chelates of non-active drugs also may be more active than
copper alone.
Several mechanisms for the involvement of copper have been
postulated, for example
51(i) anti-pyretic agents such as salicylate may 
transport copper in i complexed form back 
to its intracellular site.
52(ii) anti-arthritic drugs , posiibly via their 
copper complexes, may inactivate the enzyme
, PGEg synthetase and so divert production to 
the less inflammatory
50(iii) repair at sites oS infl<mnmation requirer 
extracellular cross-linking of collagen 
and elastin and the enzyme responsible for 
this, lysyl oxidase, is copper-dependent.
41It is also known , however, that human serum albumin will bind
to a large variety of drugs, for example, 75% of salicylic acid is
. 53 'bound to plasma protein .
For the drugs used to treat arthritis the following order of 
54potency (for adjuvant arthritis in rats) has been given .
Indomethacin > Naproxen > Ketoprofen > Fenoprofen
> Phenylbutazone > Aspirin.
(The formulae of these compounds are shown in figure 2.)
About 99% of each of these drugs is bound to human serum 
54albumin and so it is possible that they may affect the binding of
copper to human serum albumin in such a way as to release it to take
part in any of the mechanisms (i) - (iii) above.
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Copper-Bovine , Serum Albumin-Drug 'Interactions
The anti-arthritic drugs mentioned above were studied, as was
salicylic acid, since it is believed that this is the active form
of aspirin vn vivo, and histidine and threonine for purposes of
comparison. Unfortunately, these drugs are not sufficiently soluble
to allow the use of the potentiometric technique.
An initial trial using visible spectrophotometry in 90%
ethanolic solution showed that the copper binding might be affected
by some of the drugs. However, under these conditions the
conformation of the protein and hence its complexing behaviour may
be completely different from that in aqueous solution. In order to
carry out a study vn aquo we require
(i) a method for separating protein bound and small 
molecule bound copper fractions
and
(ii) a method for analysing very low concentrations 
of copper.
The separation technique chosen was molecular filtration. This
is simply a method for separating dissolved molecules on the basis
of size by passing a solution through a fine filter. The nominal
molecular weight limit was chosen such that the drug-copper complexes
would pass through but the bovine serum albumin-copper complexes
would be retained.
The filtrate was then analysed for copper by atomic absorption
spectrophotometry and so the fraction of the copper which was bound
to the protein could be calculated.
14
The first publication concerning atomic absorption spectrophotometry
= S 55 .was in 1957 and commercial equipment, capable of routine operation,
was introduced in 1963. The element which is being analysed is
dissociated from its chemical bonds, by burning the sample in a flame,
to give an unexcited, unionised ground state which can then absorb
radiation at discrete lines of narrow band width. This absorption
of radiation is measured and so the concentration of the element
determined.
"Challenge" Project '
. Potentiometric studies of the same system in different laboratories
unfortunately arrive at differing results more often than could be wished
Thus an interlaboratory study has been set up on the 'simple'
nickel(II)-glycinate system in order to perhaps improve general technique
or highlight specific deficiencies.
In February 1975 the Organising Committee of the 'Thermodynamics
of Complexes Group' from Italian Universities met in Rome to discuss
the possibility of studying a single system in different laboratories
in order to compare results obtained using basically the same
experimental methods but with different techniques for preparing and
analysing solutions and computing results. The Group met again in
Padova in June 1975 in order to decide on the experimental conditions
which should be used.
15
The conditions chosen involved the use of 1.00 M sodium chloride
as the ionic background salt. Since our normal background salt is
sodium perchlorate the experiments were repeated in this medium in
order to determine how the change in background ions affects the
formation constants obtained.
"Challenge" project results from several laboratories are now
available and will be discussed in Chapter 9.
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CHAPTER 2
THEORETICALCONSIDERATIONS
Our aim in the study of an equilibrium between protons, ligands
and metals is to completely define the system in terms of formation
constants for all the species present. These formation constants
may then be used to calculate the equilibrium concentration of each
species. The computational methods used to achieve these aims will
be discussed in the following chapter.
Formation Constants
Consider the formation of the species A B . In aqueous solution
P Q
the species A, B and A B will be associated with a number of water p q
molecules and so the overall equilibrium occurring can be represented as
pA(H.O) + qB(H.O) A B (H_0) + (pw + qx - z)H_0 (1)2w 2x pq2z A
(for simplicity, all charges are omitted).
In practice the activity of free water can be assumed constant
and so the water of hydration is omitted from the equations to give
pA + qB — A B p q (2)
17
The activity of the species A B , P Q
a given temperature, can be related to
by the law of mass action
formed in the solution at
the activities of A and B
o (AB) 3 - p q [A B ] p q
(A)P(B)% [A]P [B]q
A B P q
fP fq 
A B
(3)
where 3°^^ is the 'thermodynamic stability constant' for the species
A B and f are activity coefficients. Thus, in order to determine p q
3°^, we must know the activities of all the species present. These 
may be calculated or, since activities and concentrations become equal
at zero ionic strength, a series of measurements at low ionic strength
may be extrapolated to infinite dilution. Both of these processes
require a great deal of work and neither is satisfactory except for
very simple systems. .
However, if activity coefficients can be held constant, to
within the limits of experimental error, then the 'stoichiometric
stability constant' can be defined as
[AB]Bpq =
(4)
Stoichiometric stability constants are used in this work but
this restricts comparisons to constants determined in the same medium.
The Ionic Medium , Method .
23The ionic medium method is basically that of Bjerrum * and
57Leden who suggested that activity coefficients could be held constant
18
if the concentrations of reactants and products were small compared
to those of an inert electrolyte. This method has since been 
thoroughly investigated by Biedermann, Sill£n and Ginstrup 58,59,60
The requirements for the inert electrolyte are
(i) that it does not interfere with the reaction under 
investigation
(ii) it is sufficiently soluble to give the desired 
high background concentrations
(iii) it is available in a state of very high purity.
Since the background salt is present in a great 
excess over the reacting species a small amount 
of impurity may be significant.
In order to avoid ion-pairing effects we choose perchlorate as
. 32the anion since the strengths of ion-pair bonds are in the order
S042" > Cl" > Br” > l" > NOg" > CIO4"
The ionic mobilities of the potassium and perchlorate ions are similar
and thus our first choice of salt would be potassium perchlorate.
However?, this salt is insoluble and so sodium perchlorate is, in fact,
used.
Having decided on an inert electrolyte we now need to choose 
61the concentration to be used. In this laboratory a comparison
has been made between the two sets of conditions 25°C, 3.OOMNaClO
and 37°C, 0,150MNaCl0„.
4
The disadvantages of 25°C, 3.00MNaC104 are
(i) these are far removed from biological blood 
plasma conditions which approximate to 37°C,
0.150MC1*.
(ii) any firnl trcee of impurity left in the Na 
CIO4 is emphasised when the background salt 
is 3.COM.
19
(iii) even though the CIO4“ ion has little tendency 
to ion-pair, at this high concentration some 
ion-pairing may occur 52.
(iv) the lower the temperature, the higher the amino 
group protonation constants and at 25°C they 
may be taken outside the working range of the 
glass electrode.
The disadvantages of 37°C, O.lSOMNaClO. are
(i) a considerable amount of volumetric glassware 
needs, to be recalibrated.
(ii) unless the complete system of vessel and
electrodes is thermostatted at 37°C, condensation 
occurs in the cooler parts of the system and the 
electrothermal effect in the electrodes can cause 
an error of up to 3mV.
(iii) the tubing linking the burette to the titration 
vessel should also be maintained at 37°C to 
minimise temperature fluctuations in the vessel.
(iv) a background salt concentration of 0.150M permits 
a change of only 0.008M in ion concentration 
without a significant variation in the activity 
coefficients 59.
(v) ion-responsive electrodes, such as amalgams, 
are less stable at higher temperatures.
(vi) the higher temperature may accelerate the rate 
of peptide hydrolysis.
(vii) liquid junction potentials are much morei C5 f 4significant at this lower concentration •
(viii) many metal ion hydrolysis constants have been
reported 55 for 25°C, 3.OOMNaClO4 but relatively 
few for 37°0, O.ISOMNaClO4. This means that ion 
hydrolysis studies may be necessary before 
further complexing reactions can be considered.
Clearly,there
certain merits and
is no ideal medium, each set of conditions having 
problems. In this work 25°C, 3.00MNaCl04 was used
so that comparison could be made to earlier results from this laboratory.
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Formation Curves
The degree of formation of a system, Z, was defined by Bjerrum
as the average number of ligands attached to the central gasoipp.
Formation curves are plots of Z vevsus -log a.
Consider the following system of stepwise equilibria forming
mononuclear species only
2 3
r?
Now Z
A + B - AB
AB + A r a_b
P-1
[ligand bound to central group]
[cencrnl grgup'J
[AB] + 2[A2B]+...... +P[ApB]
[b] + Cab] ' + [A2B]+.'...+[ApB]
(5)
(6)
P
Z p [AB] n P
P
Z [A B]
c P
(7)
6 is defined as before i.e. 3 P P
SVl
[B]
Thus [AB] P
= 3 [A].Cb] 
p
B + A v
and so Z
P p
Z p3 Ca] Tb] 
i p
P DE B [A]P[B]
o P
(8)
Z p 3 [A]P
1 p
Z 3 [A]p
o P
(9)
*
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From equation (9) we see that Z is a function of the concentration
of free A, a, only and so formation curves determined at different
total metal concentrations should be identical provided that only
mononuclear complexes are formed. However, if polynuclear species
- 56are present then Z also depends on b .
Bjerrum's Z] Method "5
Approximate formation constants, for mononuclear systems, may 
23be estimated from formation curves using Bjerrum's Z] method
. Ea b]and P j = P-1. j_ n [A BjAs before 3^ = p
[A]P [B] [A]P 1 [B]
Rand so K =
P ft&p-1
[A B]
P
[A _B][A] p-1 (10)
therefore
log '" K = log [A B] - log[A ]B] - log a P P P-1 (11)
At Z = p-0.5; [A B] ~ EA .B] P “ P-1
and so from (11)
log Kp — -log a
The approximate formation constants thus determined can be used as
initial estimates for computer refinement.
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Determination of Experimental Formation Curves
Before beginning the experimental determination of the metal
complexation constants of a ligand we determine the value of its
protonation constants. Thus we have equilibrium constants for
the reactions
H + A - HA e.
2H + A HA
RH + A - HrA 3R
Now in the simple metal complexing system we have the mass-
balance relationship .
Total H H k - "k + [HA] + 2[H_A] +.h
R
,+r[hra]
h - k + E r [H A] 
H 1 r
(12)
(13)
Thus T-h+ Wk 
h ’ Z r [H A] = Z r3 h a t k1 1
(14)
R R
and so
W1
th - h + h
RZ r3 hr 
1
(15)a =
w.
and T. - h +
pa = -log R
Z r$ h2 , r
h (16)
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Also Total A = T_ = a + [HA] + Lh_A]+....+[H_A] + [ligand bound to metal] A Z R
= a + - [HA] + [ligand bound to metal] (18)
2j 5S
1
R
and so [ligand bound to metal] = T. - a - Z [H A] (19)A i U
(17
Thus from equation (5)
R
Z =
T . - a - D [H A] 1 ' r (20)
T_‘B
RT- - a - S 6 hra
A 1 r_____
(21)
th - h +
wk
h R(1 + e e hr: 
1 rRs ue hr
la " J
T
(22)
Thus Z and pa can be calculated and the formation curve drawn
provided that we know the ligand protonation constants, the ionic
product of water, the total concentrations of A, B and H and the
concentration of free hydrogen ion. The measurement of this free
hydrogen ion concentration is the essence of the potentiometric
approach to stability constant determination.
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The Nernst Equation
An electrode in contact with the equilibrium mixture
kK + IL + ze mM + nN (23)
will develop the potential given by the Nernst equation66
e = t, t 'ha ’
° ZF <M)m (IN)"
(24)
where the standard.electrode potential, E], is the potential acquired
when all the species are at unit activity. However, if the activity
coefficients are held constant equation (24) becomes
(25) '
° ZP [M]* [N]"
where the formal electrode potential, Eq, is given by
E = TE 1 f- 1" fR lL
o of -------.m n fM fN
(26)
For the glass electrode equation (25) reduces to
_ RTE = " e + In ho F
and so in a constant ionic medium h can be determined from the
potential of the glass electrode.
(27)
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Thermodynamic Functions
For an isothermal process the Gibbs free energy of reaction,
AG®, is related to the stability constant by the reaction isotherm^®
'AG® = -RT InB (28)
©The enthalpy of reaction, AH , may be measured calorimetrically
or calculated from the temperature variation of the stability constant
by use of the reaction isochore
(29)
which on integration -gives
©In ^2
3-,
-AH
R
_1 - 1 
T T. (30)
©if we assume that AH does not vary with T. This assumption may
often be invalid, for example see reference 67r 
• ©The entropy of reaction, AS , can now be calculated by use of 
66the Gibbs-Helmholtz equation
AG® = AH® - TAS® (31)
©As we can see AG , the value of which determines whether a 
Q 0reaction will proceed, depends on the balance of AH and AS with 
0 0AH < O and/or AS > O favouring reaction.
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CHAPTER 3
r?
COMPUTATIONAL ASPECTS
The mathematical treatment of experimental data in many branches
of chemistry has been greatly aided by the development of electronic 
digital computers with adequate storage capacities and fast computing 
times. Indeed, the use of computers allows systems of greatly
increased complexity to be studied.. These computations have been
the subject of several reviews .
The computer programs used in this work are written in FORTRAN IV
and are loaded on to the St. Andrews University Computing Laboratory's
IBM 360/44 computer.
Potentiometry
Having obtained potentiometric data for a metal ligand system,
our aim is to completely define the system in terms of formation
constants for all the complexes present. Since Bjerrum's 
23 .pioneering work on metal ammine -formation , the methods of
choice for evaluating these constants have used relationships
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involving the formation function, Z, and the free ligand concentration
It is possible to compute formation constants directly from
the potentiometric data, however, there is a risk that, in this way,
systematic errors or, indeed, some complex species, may be over- 
70 71looked and erroneous conclusions drawn ' . Thus we first of
all prefer to obtain a plotted formation curve i.e. a plot of
Z, vevsus ph fou a ligand-proton system ou of Z vevsus pa for a
ligand-proton-metal system. These curves can readily be used to
pick out faulty data, for example an analytical or a caud punching 
error may produce a grossly displaced curve.
ZPLOT 72,73
The ZPLOT program, the mathematics of which have been described
in Chapter 2, will plot either Z, Vevsus ph or Z vevsus pa curves.
It is important to note that the mass balance relations in this
program assume mononuclearity and the absence of hydroxy and
puptpnaled complexes. If these conditions aue not valid then the
calculated Z and pa are really pseudo Z and pseudo pa these
functions being ideal for showing the degree of variation from
mononucleauily etc. Under these conditions the curves may form a
complicated pattern. Although various plots have been used to
II
simplify these patterns, fou example, Osteuberg plotted Y[=(T-h)/A] n
74against ph, the selection of species to describe these curves is
not a simple matter. We have both the qualitative problem of
deciding which complexes aue present and the quantitative problem
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of determining their formation constants. Qualitatively the possible
complexes are limited by the coordination numbers of the metal ion
3 2and by the denticity of the ligand ~ . However, as will be discussed
later in this chapter, the pattern of the formation curves may also
give some indication of species present.
Many computer programs of varying complexity have been written 
68for the determination of formation constants , for all but the very
simple systems a non-linear least-squares approach being necessary.
Several programs of this type have been described in the literature
V5 71 76"”78 79e.g. SCOGS , LETAGROPVRID ' , and MINIQUAD .
Both SCOGS and MINIQUAD have been used in this work in the
hope that there are sufficient mathematical differences between
these programs to highlight spurious formation constants that may
have occurred had just one program been used. Formation constants
produced from the two programs generally agreed to within the
standard deviation.
SCOGS
Our version of the program SCOGS (Stability Constants Of
Generalised Species) has been slightly modified from the published 
version ^0,81,82. can deal with a system of two ligands, two
metals, up to twenty complexes, up to thirty titrations, up to
five-hundred data points, up to three ion-selective electrodes and
can refine constants for polynuclear, hydroxy, protonated or mixed
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complexes provided that the degree of complex formation is ph
dependent.
The Newton-Raphson method of iteration is used to minimise 
i i 2U = %(titre - titre _ ) where titre , is calculatedexpt. calc. calc.
from the current estimates of the formation constants and all
the experimental values of ph. If the value of any constant is
accurately known it may be retained at this value during the
calculation. If, on the other hand, any complex species is
introduced which is inconsistent with the data, then it is
impossible to obtain a converging value for its formation constant
which progressively diminishes while the concentration of the species
becomes negligible.
The estimated standard deviations in the computed formation
constants indicate the error limits for each constant and the
standard deviation in titre is a measure of the ability of the
computed constants to reproduce the experimental titrations.
SCOGS has been shown to have certain mathematical defects which 
83may cause it to fail to converge to satisfactory solutions .
Also, for some complex systems, it was found to be impossible to
refine all the constants together because of the occurrence of
1 exponent overflow1. This problem can be circumvented by the use
of MINIQUAD.
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MINIQUAD
,, MINIQUAD (from the Italian for least-squares, minimi quadrati)
can, in principle, deal with data from systems containing any number
of reactant species and potentiometric electrodes and all commonly
found types of complex.
84The Gauss-Newton method of refinement, which has been shown
to be preferable to the Newton-Raphson method, is used to minimise
the sum of squared residuals for all the mass balance equations, 
i 2U = E ' (‘T _ - T o ( . The least-squares minima are approached£ calc. obs.
using the "Davidon-Fletcher-Powell steepest descent method rather
than a Jacobian matrix.
Formation constants are stored in mantissa and exponent form,
only the mantissa being varied during the refinement so allowing
formation constants of any magnitude to be determined regardless
of the numerical capacity of the computer. In reference 80, nine
advantages of MINIQUAD over other programs, such as SCOGS are
listed.
Finally a statistical analysis of results is made in order
to assess their validity and to assist in hypothesis testing.
Altough least-squares programs, such as SCOGS and MINIQUAD,
produce statistical analyses or numerical values of standard
deviations in titre or sums of squared residuals the human mind
prefers to see differences between calculated and experimental
data in diagrammatic form. If any discrepancies are then found
one may be able to suggest an improvement in the chemical model, 
69As has been pointed out, "the observably good fit of a back-
calculated curve to a set of data is an effective justification
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of a set of stability constants, and presents evidence to an
experimental chemist in a way that tables of residuals and
standard deviations do not".
Our work on the lead(II)-glycylglycinate system produced
the formation curves shown in figure 3 which indicate that other
than simple mononuclear species aue present. The program 
85HALTAFALL , using input formation constants for the species 
*01-1, 04-4, 03-4, 06-8, 110, and 111 as well as the ligand
protonation constants, was used to calculate the concentrations
of species present at each point in the titration. From these
concentrations the program can calculate theoretical volumes of
titrant added and emfs which can then be used as input for ZPLOT 
to give a calculated pseudo Z versus pseudo pa plot. If the 
formation constants input to HALTAFALL completely describe the
system then the curves obtained in this way should be an exact
ueplica of the experimental formation curves. The simulated
curves fou the lead(II)-grycylglycinate system are shown in figure 4
Thus we obtain a graphical representation of how well the
calculated formation constants can reproduce the experimental
data. It was thus thought worthwhile to combine the programs
„ , 61,86 HALTAFALL and ZPLOT to produce the new program PSEUDOPLOT
which will perform the above process in a single step.
* The species 7^ , is represented by pqr where r < O indicates 
a hyduoxyl group ou the removal of a proton.
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HALTAFALL
HALTAFALL (from the Swedish 'half = concentration and
'falla* = precipitate) calculates the equilibrium concentrations
of the species present in a mixture of any number of components,
which can form any number of complexes and solid phases, provided
that the equilibrium constants are known and enough information
is given about the gross composition of the system.
PSEUDOPLOT
In PSEUDOPLOT, the input formats have been greatly simplified
from the original HALTAFALL. The HALTAFALL section has as input
the experimental conditions (i.e. concentrations in titrate and
titrant and volumes etc. (all except the emf ou ph readings)) and
the postulated formation constants. The output is simulated
volume added Versus ph data that would have been obtained had
such a system been titrated experimentally. The program then
uses this data in the ZPLOT section to produce simulated titration
curves which can then be compared with the experimental curves
and additional sets of formation constants can be tried until
the 'best* fit is obtained.
Thus PSEUDOPLOT can provide an alternative to graphical 
56normalised curve fitting as a means of detecting non-simple
complexes.
Normalised, ou standardised, curves aue projection maps of
model functions calculated on the assumption that certain species
33
coexist at equilibrium (as defined by a set of formation constants) 
and these can be compared with plots of experimental data covering
a wide range of concentrations. In this way it is possible to
discover which species are probably present (and the position of
'best’ fit reveals the values of their formation constants).
Alternative sets of formation constants ought always to be tested
but, unfortunately, each set necessitates the calculation of a
unique pattern of normalised curves, each pattern being based on 
87different mathematical relations . For example, for the system 
in which only AH, A^H and A H2 are postulated, the normalised 
curves are calculated from
Eh - (l + h) zh3 Ehd - 2R) - l]
T _ -----------------------------------—~ h[2Zh (1 + Rh) - (1 + 2Rh)32
, „ (2Z, - 1) and T, and h are normalised variables correspondingwhere R = h A — r v
to T^ and h88,89. This represents the case for a fairly simple
system but when more than three formation constants are introduced 
56 90the mathematics becomes much more complicated '
Graphically PSEUDOPLOT is equivalent to the normalised curves
method but by using a common series of relations (as distinct from
a different series of equations for each set of formation constants)
and a graph plotter it is much faster.
By observing the regions of mismatch between the ZPLOT and
PSEUDOPLOT curves it may be possible to suggest a complex whose
presence would improve the fit. For example, the ’curl-back'
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sometimes found at the high Z end of formation curves may be
reproduced by the introduction of a hydroxy species and the
'Z-hump' sometimes found at high pa by a protonated species.
By trial of many sets of formation constants we can thus
find the set which gives the 'best' fit to the experimental
data. We must remember, however, that the 'best' set of
formation constants need not be the 'right' set and a set of
constants, no matter how they are obtained, can never be more
than 'compatible with the available experimental data'.
Having obtained our 'best' set of formation constants we
may now wish to know which of the complexes predominates at any
given pH or we may wish to incorporate the constants into a
model of a biological system. Either of these objectives may 
91be achieved by the use of our program COMPLOT . •
COMPLOT
92COMPLOT is a modified version of the program COMICS which
can deal with up to ten metals, ten ligands, one-hundred complexes
and fifty pH values and is applicable in the presence of all common
types of metal complex.
The basis of this program and, of course, all other equilibrium
programs is the law of mass action and it can be used to calculate
35
the equilibrium concentrations of all species in a multi-metal- 
multi-ligand mixture, given the pH of the solution, the total
concentration of each metal and ligand and the relevant formation r?
constants.
If from the computational analysis the presence of a
particular complex is still doubtful then a COMPLOT model can show
whether it would be present in significant quantities under the
titration conditions.
Calorimetry
Before the calorimetric work is begun the systems have been
studied potentiometrically and so the relevant formation constants
are already known. Thus PSEUDOPLOT can be used to calculate the
concentrations of species present for each point in the calorimetric
titrations. The program CALCO may then be used to apply corrections
to the measured heat changes in order to account for the heats of
formation of water, of hydrolysed metal species and of protonated
ligand species, as appropriate. The corrected heat changes are
then used along with the changes in concentration of each species
in order to calculate enthalpies of formation of the complexes.
36
CALCO
81CALCO is an extended version of the program CALCRD and
can deal with four protonated ligand and four metal-hydroxy species.
The species concentrations from PSEUDOPLOT are used to
calculate the heat corrections mentioned above and the change in
the number of moles (An^) of each complex present for each point 
in the titration. Thus the following equations for the m complexes
are set up
S?
<corP 1
(6corr)2 =
(AH®An1)1 + (AH^i2)1+
(AS^An„ + (Ah)a22)2+
+(AH@An ) 
m m
+(AH^An )o 
mm2
1
and so on to
(Q ) = (AH^An.) + (AH^An ) +,
®oorr r .+(AH An ) m m r
for the r titration points.
©Normally r >> m and so a least-squares set of AH values can
be computed by minimising
XtQcorr.
i ,2 %alc.
0
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CHAPTER 4
REAGENTS AND APPARATUS
Reagents
The reagents used in this work were prepared and analysed as
follows.
WATER
All solutions were prepared using ’Elgastat’ (The Elga Group)
deionised water the resistivity of which was higher than
SODIUM PERCHLORATE
Solutions of sodium perchlorate were made either by dissolving
the monohydrate(Merck 'Puriss', B.D.H.AnalaR or Hopkin and Williams
Analc^) in water, or by neutralising perchloric acid(Fisons A.R.)
with sodium carbonate(Fisons A.R.). The pH of the solution was
adjusted to 9-10 by addition of sodium hydroxide solution(B.D.H. AnalaR)
before allowing it to stand for at least 7 days. The precipitate
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of silica and heavy metal oxides and hydroxides was then removed 
by filtration through micropore filters of pore diameters 3.0 and 
O.45pm(Millipore Ltd.). The solution was then acidified to pH 2 
by the addition of perchloric acid and the carbon dioxide was
removed by boiling and cooling under nitrogen.
From this point one of two alternative methods was used.
(i) Crystals were prepared from the above solution 
by adjusting its pH to 7 and heating in an 
evaporating basin to 140°C. After cooling to 
105°C, the slurry was filtered through a 
sintered glass funnel (porosity 3) and dried 
in an oven at 11O°C.
(ii) A standard solution was prepared by adjusting^^a 
the pH to 7 and analysing by cation exchange
■ and flame photometry 93b.
r?
PERCHLORIC ACID
A stock solution of perchloric acid (~3M) was prepared by
dilution of concentrated perchloric acid (60% w/w, Fisons A.R.).
This was standardised by titration with sodium carbonate, which
had been heated at 260-270°C for 30 minutes and dried in a .
93cdesiccator, using methyl orange as indicator and checked
against standard sodium hydroxide solution 93d
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SODIUM HYDROXIDE
l.OOM and O.1OOM solutions of sodium hydroxide were prepared
from ampoules(B.D.H. concentrated volumetric solutions) and were 
93dchecked against standard acid solution .
57
SODIUM CHLORIDE
Sodium chloride(Fisons A.R.) was dried at 200°C before use.
HYDROCHLORIC ACID
l.OOM solutions of hydrochloric acid were prepared from
arnpoules(B.D.H. concentrated volumetric solutions) and were 
93dchecked against standard sodium hydroxide solution .
METAL ION SOLUTIONS
All metal ion solutions were prepared and analysed by two
independent methods.
(i) Lead Perchlorate
Lead oxide(Pbo, Hopkin and Williams) was dissolved in
perchloric acid(60%), allowed to stand for several days and
40
Analysis was by edta
93e. , and by
filtered through a micropore filter(0.45pm).
titration, with xylenol orange as indicator
93felectrodeposition .
(ii) Zinc Perchlorate
Zinc perchlorate(G.F, Smith, Chemical Co.) was dissolved in
perchloric acid, allowed to stand for several days and filtered
through a micropore filter(0.45pm). Analysis was by edta 
93gtitration, with eriochrome black T as indicator , and 
gravimetrically as quinaldinate 93h.
(iii) Nickel Perchlorate
Nickel perchlorate(G.F. Smith, Chemical Co.) was dissolved in
perchloric acid, allowed to stand for several days and filtered
through a micropore filter(0.45pm). Analysis was by edta
93i 93jtitration, with murexide as indicator , and by electrodeposition .
(iv) Nickel Chloride
Nickel chloride(B.D.H. AnalaR) was dissolved in hydrochloric
acid(lM), allowed to stand for several days and filtered through
a micropore filter(O.45pm). Analysis was by edta titration, with
93i 931murexide as indicator , and by electrodeposition .
(v) Copper Chloride
Copper oxide(Hopkin and Williams AnalcR)
hydrochloric acid(35%), allowed to stand for
filtered through a micropore filter(0.45pm).
edta titration, with fast sulphon black F as 
931by electrodeposition .
was dissolved in
several days and
Analysis was by
. . 93kindicator , and
*
41
The hydrogen ion concentration of each of these solutions was
obtained by means of Gran plots 94
ETHYLENEDIAMINETETRAACETATE
The disodium salt of ethylenediaminetetraacetic acid(B.D.H.
AnalaR) is a primary standard and, therefore, solutions were prepared 
by direct weighing 93m.
LIGANDS
The following ligands were used without further purification.
(i) Aspartic acid(B.D.H. Biochemicals) m.p. decomposes 
at>210°C; lit. 271°C. Found C, 35.9; H, 5.4;
N, 10.5%. Calc;, for C4H7NO4 C, 36.1; H, 5,3;
N, 10.5%.
(ii) Cysteine(E. Merck A.G.) m.p. decomposes 179°C; 
lit. 175-178°C decomp. Found C, 29.8; H, 5.9;
N, 11.4%. Calc for C_H_NO_S C, 29.7; H, 5.8;N, 11.6%. J
(iii) Glutamic acid(B.D.H. Biochemicals) m.p. 197-199°C;
lit. 224-225°C. Found C, 40.8; H, 6.3; N, 9.5%
Calc, for CgH_NO. C, 40.9; H, 6.2; N, 9.5%, by 4
(iv) Glycine(Fisons A.R.) m.p. decomposes 244°C; 
lit. 262°C decomp. Found C, 32.1; H, 6.5;
N, 18.5%. Calc, for C_H_NO9 C, 32.0; H, 6.7;N, 18,6%. 2
(v) Glycylglycine(Koch Light) m.p. decomposes 250°C; 
lit. 260-262°C decomp. Found C, 36.3; H, 6.4;
N, 21.1%. Calc, for C .H_N 0. C, 36.4; H, 6.1;N, 21.2%. 4823
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(vi)
(vii)
(viii)
(ix)
(x)
(xi)
(xii)
(xiii)
(xiv)
(xv)
(xvi)
'(xvii)
(xviii)
(xix)
Glycylglycylglycine(Koch m.p. decomposes
236°C; lit. 246OC decomp. Found C, 38.1; H, 5.9?
N, 22.3%. Calc, for C_H. N _O. C, 38.1; H, 5.9;N, 22.3%. 6 11 3 4
Glutathione(Cigma) m.p. decomposes 192-194OC;
lit. 190-192°C decomp. Found C, 38.8; H, 5.8;
N, 13.5%. Calc, for Cn H^N nO_S C, 39.1; H, 5.6; 10 17 3 6
Disodium ethylenediaminetetraacetate (B.D.H. AnalaR) 
m.p. decomposes 246°C; Found C, 32.5; H, 5.2;
N, 7.5%. Calc, for C_ H_ON_Na_O.C, 32.3;
a -w-r r r, XO _LO Z Z ±(J
D-penicillamine(Koch Light) m.p. decomposes 2O9°C; 
lit. 2O3°C decomp. Found C, 40.3; H, 7.8; N, 9.2%. 
Calc, for C5HooNOoS C, 40.2; H, 7.4; N, 9.4%.
Bovine serum albumin(B.D.H. Biochemicals).
Found C, 47.93; H, 6.7; N, 14.8%. Calc, for
C29O6H4749N778°883S39 % C' 52'9' «' 7’3f N' 16‘5%‘
Histidine(Koch Light) m.p. decomposes 25O°C;
lit. 27O-28O°C. Found C, 46.2; H, 5.9; N, 27.1%.
Calc, for CHNO C, 46.5 ; H, 5.9); n, 27.1%.
6 9 3 2
Threonine(B.D.H. Biochemicals) m.p. decomposes 245°C 
lit. 251-253°C. Found C, 40.5; H, 7.8; N, 11.6%. 
Calc, for CoHgNO; C, 40.3; H, 7.6; N, 1L.8%.
Aspirin(Lilly Research Centre Ltd.) m.p. 128-132OC;
lit;. 135Oc. Found C, 60.; ; H, 4.4%. Calc. for
CgHQO. C, 60.0; H, 4.5%. y o 4
Salicylic acid(B.D.H. AnalaR) m.p. 156-157°C; 
lit. 159°C. Found C, 60.;; H, 4.3%. Calc, for
CoHgOo C, 60.9; H, 4.4%.7 6 3
1ndomethacin(Merck, Sharp and Dohme) m.p. 154-155OC; 
lit. 153-154°C, Found C, 63.8; H, 4.4; N, 3.7%. 
Calc, for COgH14NO4Cl C, 63.8; H, 4.5; N, 3.9%.
Naproxen(Cyntex Labs.) m.p. 150-152°C; Found 
C, 73.1; H, 6.1%. Calc, for C14H,4O_ C, 73.0; 
H, 6.1%.
Ketoprofen(May and Baker Ltd) m.p. 9--9°C;; 
Found C, 73,0; H, 6.0%. Calc, for Co^^O
Calcium fenoprc)fen (Lilly Research Centre Ltd.)
m.p). 120-124°C; Found C, 64.5; H , ..%. ; Calc,
for CigHgiOcCa C, 69.0; H, 5.0%.
30 26 6
Fhenylbutazone(Lilly Research Centre Ltd.) 
m.p. 103-104°C; lit. 105°C. Found C, 74.1;
H, 6.5; N, 9.0%. Calc, for C4gHloN4O4 C, 74.0; 
H, 6.5; N, 9.1%.
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NITROGEN
Oxygen free nitrogen(British Oxygen Company) was bubbled 
through 3.00M sodium perchlorate solution thermostatted at 25°C
before use.
Apparatus
GLASSWARE
All pipettes and volumetric flasks(Technico Grade A) were
provided with calibration certificates. All glassware, was cleaned
regularly with Quadralene(Quadralene Chemical Products) and with
alcoholic potassium hydroxide if required. '
POTENTIOMETRY
Potentiometric studies were carried out using the vessel
shown in figure 5(Pye Ingold 604) the working temperature being
maintained by water from a thermostatted water bath (Grant 
Instruments). For work at 10°C a back-up cooler unit was used 
('Paxman' Cooler Manufacturing Company).
The electrode pair(normally Russell pH Ltd.; glass SF 711/
B14; calomel CR4/5/Na/Bl4) was used in conjunction with a digital 
voltmeter(Solartron LM1867) to give readings reproducible to
O.lmV. For the 'challenge project' work a silver/silver chloride
0 3 cmt hermometer
glass
electrode
calomel electrode
to piston burette
FIGURE 5 : POTENTIOMETRIC VESSEL
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reference electrode was used(Russell pH Ltd.; UMA5) and was 
prepared by the method of reference 97. In this case the liquid 
junction was made through a closed ground glass tap. For the 
study of the interaction of chloride with lead(II) a glass
electrode, a chloride sensitive electrode (prepared as above)
and a silver/silver chloride reference electrode were used.
The potential between the reference and the chloride sensitive
electrode was measured on a digital voltmeter(Radiometer pHM52).
Titrant was added from a 10ml piston burette(Metrohm E274)
and the solution was mixed by slow magnetic stirring.
r?
CALORIMETRY ®
The calorimetric vessel-, shown in figure 6, is of the 
97Gerding, Leden and Sunner constant environment type.*
The complete system was suspended in a thermostat bath 
controlled to +_ 0.0005°C(LKB 7502 controller on a 76O3A bath) 
which was located in a thermostatted room (19 + 0.5°C).
A glass inner reaction vessel was used and the inside of
its lid was coated with epoxy resin(Bostic quick hardener).
Calibration was electrical using a heater coil of non­
inductively wound resistance wire(22.380) coated with epoxy
resin(Araldite). The voltage across the heater was measured
on a digital voltmeter(Solartron LM1420.2). The current
flowing through the heater resistor also passed through a
to piston 
’burette
vibro-stirrer
/
I__t--- !--- J
0 1 2 3 cm
reaction vessel
calibration 
heater
weights
FIGURE 6 : CALORIMETRIC VESSEL
r?
water level
^/prewarming coils
rubber seals
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IO.OOOOI standard resistance and the voltage across this was
measured to give the current in the circuit:. The time for
which the heating current flowed was recorded automatically
to within 0.02s using a stopwatch(Jaquet 3O9e).
Vibro-stirring was used(Chemap AF, El), the stirrer tube
being hollow to allow insertion of an aluminium rod cooled in
liquid nitrogen in order to lower the solution temperature
between additions of titrant:.
Titrant, from a 10ml piston burette^etrohm E274), was
prewarmed in a spiral of narrow bore nylon tubing(Fortex CFD
Nylon C) before being added to the reaction vessel through
a glass burette tip.
The temperature change caused by the addition of the
titrant, or by the calibration heater, was measured by a quartz
thermometer(Hewlett-Fackard 2801A) and was printed out(Hewlett- 
Fackard digital recorder 562A) to the nearest 0.0001°C at 18s 
intervals.
ULTRA-V1OLET/V1C1BLE CFECTROCCOFY
90% ethanol solutions had their pHs adjusted by addition
of O.1M sodium hydroxide from an 'Agla' micrometer syringe
(Burroughs Wellcome and Co.) before measurement of their spectra
using a Fye Unicam CF 800B spectrophotometer. 1n the visible
range 40mm glass cells were used and in the ultra-violet range
lOmm silica cells(Fye Unicam).
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MOLECULAR FILTRATION
The cell used for molecular filtration(Millipore Ltd., 25mm cell)
is shown in figure 7.
5 -2A pressure of 2.8 x 10 Nm was applied using oxygen free nitrogen
The filters used(Millipore Ltd., PSED 25,000) have a nominal
molecular weight cut-off of 25,000 and between uses were cleaned
in 5% acetic acid and stored under water.
Solution pHs were adjusted by the addition of O.IM sodium
hydroxide from an 'Agla' micrometer syringe.
Analysis for copper was by atomic absorption spectrophotometry
(Perkin-Elmer 360) using a multi-element lamp(Perkin-Elmer 303-6102)
and a chart recorder(Perkin-Elmer Model 056) as well as a digital
display(Perkin-Elmer UDR-3).
I-- 1-- 1-- L
0 12 3
nitrogen pressure
I
inlet cap 
gasket
L
r .. (
extension barrel
r  * I ■----------------- sum ng bar
--j ------------------• gasket
-’ -------------------------------- filter
------- ------- --------support screen
—j
/ 5 cm
S7
outlet
FIGURE 7 : MOLECULAR FILTRATION CELL
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CHAPTER 5
r?
RESULTS - FORMATION CONSTANTS
All of the potentiometric experiments described in this chapter
were carried out at 25°C, in an ionic background of 3.00M sodium 
perchlorate, using the apparatus described in Chapter 4.
The electrochemical cell used for the glass electrode work was
glass A, B and H solution under NaCl
electrode study, I - 3.00M(Na+)C10. (saturated)
Hg.Cl.^-HgU)
Electrode Calibration
As we have seen in Chapter 2, the above electrode pair gives a
RTpotential described by E = Eq + —Inh and so, if Eq is constant;, then 
measuring E for a series of solutions of known h and plotting E
versus -log h ought to give a straight line of slope -2.303RT/F 
mV(-log h) 1. In practice, however, when an acid ionic background 
solution is titrated with an alkaline ionic background solution an
S-shaped curve is obtained which indicates that traces of surplus
base are being introduced from an unknown source. For the experimental
data see table 1 and figure 8a (values of -log h > 7 were calculated 
98using a value of -log = 44.22) .
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TABLE 1
Experimental data for the calibration of a glass/calomel electrode pair
Titrate : 20.01ml of 10.74mM HC1O4, I = 3.OQM(Na+)ClO 
Titrant ; 50.40mM NaOH, 1 = 3.OOM(Na+)C104“
Titre E -logh Titre E -logh
(ml) (mV) (ml) (mV)
0.20 334.6 1.99 4.31 —76.6 9.70
1.50 323.5 2.19 4.35 -116.1 10,27
2.70 307.8 2.45 4.39 -138.4 10.51
3.20 297.8 2.63 4.45 -160.7 10.72
3.60 285.3 2.83 ■ 4.55 -179.4 10.94
3.85 273.1 3.03 4.70 -194.5 11.13
4.00 261.7 3.21 4.90 -206.2 11.30
4.15 240.2 3.52 5.30 -220.2 11.52
4.21 221.5 3.75 5.90 -232.1 11.71
4.25 192.8 4.03 7.10 -246.0 11.93
4.27 149.4 4.28 8.50 -255.1 12.09
4.29 -16.3 4.97 10.00 -261.5 12.20
*
E(mV)
340
180-
20 -
140'
- 300
0
r?
8
-log h
10 12
—j
14
FIGURE 8 : GLASS/CALOMEL ELECTRODE PAIR CALIBRATION
a CALIBRATION LINE b : BUFFER , LINE
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A straight line is obtained in the -log h ranges 2.0 - 3.5
99and 11.0 - 12.2. It has been suggested that the traces of
alkali arise from slight dissolution of glass from the electrodes
and the titration vessel (v5 x 10 6M alkali).
In buffered solutions, however, a linear response is found.
For experimental data see table 2 and figure 8b.
• TABLE 2
Experimental data for glass/calomel electrode pair response 
in buffered solutions
E pH
.'(mV)
171.2 4.00
29.1 6.50
8.0 6.865
-0.1 7.00
-129.7 9.20
All formation constant determinations take place in buffered 
solutions and so the glass interference is swamped by the buffering
capacity of the system.
At the beginning of a series of titrations the electrodes are
checked by the measurement of a buffer line. This line is in terms
of activities, is not at constant ionic strength and is displaced
50
away from but parallel to the E vevsus -log h calibration line. The
purpose of this buffer line is to choose the best of the available
glass electrodes. A calibration line can then be constructed py
which is extrapolated to -log h = O, using a simple least-squares
procedure, to produce the best Eq value. This Eq value is checked
before and after each titration by measuring E for a solution of
known -log h (which must be in the range 2.0 - 3.5 because of the
glass interference at other values).
Tolerances
1n general all errors are kept to So.1%. Some typical values
are shown in table 3.
TABLE 3
Experimental errors
Stock solution cnneenrrttions + 0.1%
Weights + O.OSmg
Flasks 2 0,05%
Pipettes + 0.1%
Piston burette + 0.005ml
Solution temperature 4 0.05°C
E + O.lmV
E + 0.2mV
*
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Recalculation, of Formation Constants , from. Reference 22
The work on lead(II) complexing to amino acid anions, reported
in reference 22, was carried out before the program MINIQUAD was
available or PSEUDOPLOT was devised. The data has thus been
recalculated using our current approach to give the log formation
constants shown in table 4. In each case the species Pb(OH)+ ,
4+ 2+ 4+Pb. (OH) , Pb.(OH) . and Pb.(OH)o with log formation constants 4 4 j 4 o o
*of -7.9, -19.25, -22.87 and -42.14 respectively were included
in the computational analysis.
TABLE 4
Recalculated log formation constants for lead(II) - amino acid
O ""I** “anion complexes at 25C, I - 3.0OM(Na )ClO^
r
loa 3
110 210 310
Asparaginate 4.902 + 0.018 7.802 + 0.031 8.84 + 0.28
Glutaminate ■ 4.132 + 0.086 7.08 + 0.14 9.805+ 0.084
Histidinate 6.901 + 0.004 9.80 + 0.10
Phenylalaninate 4.314 + 0.069 8.045 + 0.060
Serinate 4.949 + 0.025 8.145 + 0.046 9.873+ 0.097
Tryptophanate 4.52 + 0.29 9,58 + 0.11
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It was decided that the data available for the lead(II) -
aspartate and lead(II)-oysteinate systems was inadequate and
so further work was done on these before the formation constants
were recalculated.
Ligand Protonation Constants
For each ligand several experiments were performed,using 
different ligand concentrations,in which a solution of ligand
and acid was titrated with a solution of alkali or of ligand
and alkali,.
. All experimental data for the ligand protonation work is
given in appendix 1 and the determined constants, with their
standard deviations and the number of experimental observations,
in table 5. -
In general, protonation curves at different ligand concentrations
are superimposable indicating the absence of polynuclear species,
edta is an exception which will be discussed in the appropriate
section.
GLUTAMATE -
Experimental results are shown in appendix 1 - table 1 and
in figure 9. (Plotted symbols represent titrations in the order
shown on page 2.)
The computed log K values are 9.895, 4.518 and 2.572 the
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first of which may be assigned to the protonation of the amino group
However, the other two values cannot be definitely assigned to the
protonation of any one site since some concurrent occupation of the
two carboxylate sites will occur. Nevertheless, glutamate has
donor oxygens separated by five other atoms and it appears that the
4.518 value refers predominantly to a carboxylate group such as 
occurs in acetate (4.52) 100 (i.e. the y carboxyl group) and the 
2.572 value to a carboxylate group that is ot to an amino group 
such as occurs in glycinate (2.68) or cysteinate (2.44) J'°1.
The formation constants reported here are generally higher 
than those of other workers ^5,102 104, this is as expected
for our work at higher background ionic strength.
ETHYLENEDIAMINETETRAACETATE
Experimental results are shown in appendix’ 1 - table 2 and 
in figure 10.
It was found that if the starting solution was made very acid
then some non-superimposability of formation curves occurred.
However, this problem was avoided, and high Z still attained, by
titrating acid into an alkaline ligand solution. This displacement
of curves may be due to protonation of the amino nitrogens and the
setting up of a non-equilibrium state. The possibility of these 
105nitrogens becoming protonated was discussed as early as 1947
and has been shown to occur more recently . Anderegg ,
in fact, has found all six groups to be protonated at low pH.
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amino and two carboxyl groups
The computed log K values are 9.060, 7.040, 2.580 and 2.273
which again cannot be assigned to individual sites. These values 
~ 65are in general agreement with those reported in the literature .
The sites of protonation of the edta molecule are thought to
depend on the extent of protonation. AH. may be protonated on two 
105-107 , possibly with some hydrogen
109bonding to the two free carboxyl groups , or on the four carboxyl
groups However, it is generally thought that AH. is protonated
. 106,107,110-113 . . 106,110,112on two amino groups and AH on one amino group
although in each case hydrogen bonding may be involved 109
GLUTATHIONATE
Experimental results are shown in appendix 1 - table 3 and in
figure 11.
The computed log K.values are 9.881, 9.162, • 3.819 and 2.595 the
first two of which can be assigned to the protonation of the
sulphydryl and amino groups and the second two to the carboxyl
groups although some concurrent site occupation will occur and so
these are composite values.
These constants generally agree with those of other workers when 
65 114the different conditions are taken into account ' .
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GLYCINATE
Experimental results are shown in appendix 1 - table 4 and in
figure 12.
The computed log K values arr 10.070 ancl 2.622 whihh may lee
assigned to the protonation of thh amino ond the carboxyl groups
respectively. These values are higher than those obtained by other
workers but this is as we would expect at higher ionic
strength.
GLYCYLGLYCINATE
Experimental results are shown in appendix 1 - table 5 and in
figure 13.
The computed log K values aar 8.562 and 3.510 which can be
assigned to the protonation of the 2mino arnd carboxyl groups
respectively. These values are in agreement with other workers
results ' ' considering "the different condiuons used
GLYCYLGLYCYLGLYCINATE
Experimental results are shown in appendix 1 - table 6 and in
' figure 14.
The computed log K values are 8.601 and 3.634 which again may
be assigned to the prohonahoon of the amino and carboxyl groups
respectively. These values are in general agreement with those of 
65,122,124other workers
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Metal-Ligand Complex. Formation.Constants
A solution of metal, ligand and acid is titrated with a solution
of alkali. For each metal-ligand system several experiments were
performed using different ratios of ligand: metal in order to
identify hydroxy, protonated or polynuclear species. In all cases
non-superimposable formation curves were obtained indicating the
presence of one or more of these non-simple complexes.
All experimental data for the metal-ligand complex formation
work is given in appendix 2 and the determined constants, with their
standard deviations and the number of experimental observations in
table 7. In all cases the four lead-hydroxy complexes found by 
36Olin were included in tt^he calc^ul^^t^jLons^
LEAD(II)-ASPARTATE
Experimental results are shown in appendix 2 - table 1 and in­
figure 15. -
The maxima seen in the formation curves at high pa are
characteristic of the presence of protonated species. The complexes,
pqr, which were searched for in the computer analysis were those
with pi,2; ql and r-1 to 4 and those which gave convergence were
110, 210, 111, 112, 211 ann 212 with log g values of 6.878, 10.014,
12.695, 16.167, 19.181 aad 24.985 respectively. It was found -
impossible to refine all of these constants together in SCOGS because
of exponent overflow and so the results were determined from MINIQUAD
only.
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FIGURE 15 : ZPLOT OF DATA FROM APPENDIX 2 - TABLE 1
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A simulated set of formation curves obtained from PSEUDOPLOT
using the above constants and the aspartate protection constants
from reference 101 is shown in figure 16. As can be seen, good —
agreement is found between the experimental and simulated curves.
Other workers have reported log formation constants only for 
125the species 110 and 210 with values of 5.88 and 7.38 and 6.02 
126and 8.18 respectively. These constants are considerably lower
than those reported here which may be partly explained by the
difference in conditions used. However, a . COMPLOT model of the
system (figure 17) shows that at no pH are the 110 and 210 species
present alone and failure to consider the other species present
will effect the constants calculated.
The relatively high log formation constant found for the 110
complex compared to other amino acids (e.g. asparaginate = 4.202
and peenylalanndate = 4.314 from table 4) suggests that aspartate
is bound tridentately to lead(II) in this species. However?, we
cannot reach any definite conclusions regarding structures from
formation constant data alone.
LEAD(II)-CYSTEINATE
Experimental results are shown in appendix 2 - table 2 and in
figure 18.
With this ligand it was possible to work at only low
concentrations of lead(II) and at ligand to metal ratios of more
than 2:1 because of precipitation. A portion of the precipitate
was collected and its analysis was in close agreement with that of
the 110 species which is uncharged and so might be expected not to
be very soluble.
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The complexes searched for were those with p 1 to .3; q 1, 2 and
r -2 to 2. Those which gave convergence in MINIQUAD were 110, 210,
111, 211 and 21-1 with log 3 values of 13.213, 18.571, 17.347, 27.476
and 7.33 respectively. The last of these, however?, has a high standard
deviation, only marginally improves the sum of squared residuals and
does not improve the PSEUDOPLOT fit. A COMPLOT model of the system
(figure 19) shows that this species would be of only minor importance
and then only at high pH. Thus its actual presence in the system is
very doubtful.
A simulated set of formation curves obtained from PSEUDOPLOT using
the formation constants from table 7 and the cysteinate protonation
constants from reference 101 is shown in figure 20.
Other workers have reported formation constants for the 110, 210 
127-130and 310 species but there are no reports of the protonated
species. Literature values of log 3^Q range from- 11.39 to 12.75 and 
of log 3*io from 16.60 to 16.91. These constants have all been 
measured at J < 0.15M and so are lower than those reported here.
Proposed structures for these complexes will be discussed in
Chapter 8. .
ZINC(II)-CYSTEINATE
Experimental results are shown in appendix 2 - table 3 and in
figure 21.
By comparison with figure 18, we see that these formation curves
are a completely different shape to those for the lead(II)-cysteinate
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interaction. In figure 21 the curves show no tendency to level off
at Z = 1.0 indicating that the 110 complex is not very stable with
respect to the 210. Also there is some crossing over of the formation
curves which suggests that some polynuclear species are present.
The complexes searched for were those with p O to 4; q 1 to 3 and
r -1 to 2 and those giving convergence were 210, 211, 212, 430 and 431
with log 3 values of 19.395, 25.856, 31.879, 46.247 and 52.50
respectively.
A simulated set of formation curves obtained from PSEUDOPLOT using
these constants is shown in figure 22.
The fact that no 110 complex is found means that log < log
and so complexation does not occur stepwise but simultaneously.
Similar behaviour has been found previously for nickel (II) and 
• 129 131zinc(II) ' and the explanation is thought to lie in the ability 
132of sulphur to accept electrons from the metal ion by / bonding
thus facilitating the addition of a second sulphur atom to the metal.
Several workers have determined formation constants for the 110,
_ * -i 65,129,130, 133 . n . , «,™-131210 and 310 complexes , , , . However, only Perrin and Sayce
have found evidence of protonated and polynuclear species. The formation
constants reported here agree well with theirs considering that their 
working conditions were 20°C, I = O.lM NaClO..
Since no 110 complex is found, it is likely that cysteine acts
as a bidentate ligand to zinc(II) to give a stable tetrahedral structure
for the 210 species. The high value of the formation constant for this
species suggests that it is the amino and sulphydryl groups which are
involved in the bonding so leaving the carboxyl group free to be
protonated. Bidentate binding of cysteinate to zinc(II) has been
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postulated by several other workers 127-129,133-135
LEAD (II)-GLUTAMATE
Experimental results are shown in appendix 2 - table 4 and in
figure 23.
Again we see evidence of a Z maximum at high pa suggesting the
presence of protonated species although this is not as marked as in
the lead(II)-aspartate case. The complexes which were searched for
were those with p 1,2; q 1 and r -1 to 2 those giving convergence being
110 and 111 with log g values of 5.344 and 12.173 respectively.
A simulated set of formation curves obtained from PSEUDOPLOT
using these formation constants is shown in figure 24 and fits the
experimental data well.
Other workers have reported formation constants for the 110 and 
210 species .5,136 an(^ again the values are generally lower than those 
reported here. The formation constant for the 110 species is nearer the 
expected value for a bidentate amino acid than in the lead(II)-aspartate
case and so this ligand may only be bidentate to lead(II).
LEAD(II)-ETHYLENEDIAMINETETRAACETATE
Experimental results are shown in appendix 2 - table 5 and in
figure 25. In this case a solution of metal, ligand and alkali was
titrated with acid.
The formation curves form a complicated pattern indicating the
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FIGURE 23 : ZPLOT OF THE DATA FROM APPENDIX 2 - TABLE 4
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presence of non-simple complexes. The complexes searched for were those 
with p 1 to 4; q 1 to 4 and r -1 to 4. The ’best’ PSEUDOPLOT fit is
obtained with 110 and 111 which converge to log 3 values of 15.186
and 18.010 respectively. As can be seen from figure 26, the simulated
curves using these formation constants fit the experimental data very
badly. Convergence in MINIQUAD also occurred with species of the type
120, 230 etc but these did not significantly improve either the sum of
squared residuals or the PSEUDOPLOT fit. Obviously some other species
must be present but these have not been determined.
137The 111 complex has been detected by other workers as have
138 65hydroxy complexes . Literature values for the formation constant
of the 110 species are generally higher than those reported here.' A 
' 91similar effect has been found by Sanderson for cadmium(II)-edta
O “complex formation constants determined at 25C, I — 3.OOM(Na )CIO. .
ZINC(II)-ETHYLENEDIAMINETETRAACETATE
Experimental results are shown in appendix 2 - table 6 and in
figure 27. In this case a solution of metal, ligand and alkali was
titrated with acid.
The formation curves show a striking similarity to those found
for the lead(II)-edta system (figure 25) and the complexes searched for
were those with p 1 to 5; q 1 to 5 and r -1 to 4. Again species of
the type x(x+l)o were found to give convergence but with no improvement
in the PSEUDOPLOT fit. The ’best* fit was found with llO and 111 having 
log 3 values of 14.873 and 17.965 respectively. A simulated set of
formation curves using these constants is shown in figure 28 but they
do not satisfactorily fit the experimental data.
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139 138The 111 complex and 11-1 complex have been reported by
65other workers. Again published formation constants , generally
determined at lower ionic strength, are higher than those reported here.
LEAD(II)-D-PENICILLAMINATE
Experimental results are shown in appendix 2 - table 7 and in
figure 29. The D-penicillaminate protonation constants used were from
reference 30.
The pattern of formation curves found is reminiscent of that for
the lead(II)-cysteinate system showing superimposability at Z < 1 but
divergence at higher Z.
The species searched for were those with p 1,2; q 1,2 and r -1 to 2, 
and those giving convergence were 110, 210, 111, 211, 212 and 21-1 with
log 0 values of 14.321, 19.049, 17.723, 27.978, 34.0 and 7.551 respectively 
The log $022 2ias a standard deviation and its inclusion does not
improve eether the ssun of squared residuals or the PSEUDOPLOT fit. A
COMPLOT model of the system (figure 30) obtained using the above constants
shows that the compeers 122 and 1-11 would ee present only in very small
amounts annl so the values determined for their formation constants are
unreliable.
A simulated set of foronhton curves obtained from PSEUDOPLOT using
the constants from table 7 is shown in figure 31.
Formation constants, which are lower than those determined from this 
65 129work, have been reported ' for the 110, 210 and 310 complexes but
not for any of the p^onat^ species.
As is the case for the lean(II)-cysheiaate system, log K >> log KX z-
suggesting that the carboxyUate group is involved in the
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bonding in the 110 complex thus causing steric hindrance to forming 
the 210 complex. Thus we expect D-penicillaminate to be tridentate
to lead(II).
LEAD(II)-GLUTATHIONATE
Experimental results are shown in appendix 2 - table 8 and in
figure 32. .
In order to avoid precipitation the lead(II) concentration had to
be kept below about 2.5mM and a ligand ; metal ratio of >4:1 had to be
used. A sample of the precipitate, which occurs around pH4 was collected
and analysed. The analysis was consistent with the 111 complex which
would be uncharged and so might be insoluble. A COMPLOT model of the
system, figure 33, shows that this is indeed the predominant species -
around pH4.
The species searched for were those with p 1 to 3; q 1, 2 and
r -2 to 2, those giving convergence being 110, 210, 111, 211, 212 and
21-1 with log 3 values of 10.57, 15.00, 17.136, 24.664, 32.10 and
4.5 respectively. The inclusion of the 21-1 complex improves the sum
of squared residuals only slightly and does not improve the PSEUDOPLOT
fit. Also, figure 33 shows that this is only a minor species and then 
only at high pH. Thus the value determined for log j is no-k reliable.
A simulated set of formation curves obtained from PSEUDOPLOT using
the formation constants from table 7 is shown in figure 34.
The log formation constant for the 110 complex reported here agrees 
127well with the value of 10.6 found by Li and Manning . No other workers
have reported constants for the protonated species.
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The ligand glutathionate has eight sites at which binding to
a metal ion may occur and so more information is required before any
predictions of structures can be made. Proposed structures for these 
r?
complexes will be discussed in Chapter 8.
ZINC(II)-GLUTATHIONATE
Experimental results are shown in appendix 2 - table 9 and in
figure 35.
The spreading of the formation curves indicates that protonated
species are present in this case also. The complexes searched for were
those with p O to 3; q 1, 2 and r -2 to 2 those giving convergence
being 110, 210, 111, 11-1, 211, 212 and 21-1 with log $ values of
8.568, 13.586, 14.762, -0.074, 23.271, 30.616 and 3.63 respectively.
The complexes 11-1 and 21-1 have high standard deviations but their
inclusion improves the PSEUDOPLOT fit at high Z and a COMPLOT model
of the system (figure 36) shows that they would be present to a
significant extent at higher pHs.
A simulated set of formation curves obtained from PSEUDOPLOT
using the above constants is shown in figure 37.
140Other workers have reported log values ranging from 5.1
127to 8.30 so again our values, at higher background ionic strength,
114are slightly higher. Perrin and Watt report formation constants
for the species 110, 210, 111, 11-1, 211, 212, 21-1 and 120 with which
the values reported here are in general agreement considering that their 
working conditions were 37°C, I - 0.15MKN0^^. However, it was found
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impossible, using either SCOGS or MINIQUAD, to refine a constant for 
the 120 species from our data.
From our formation constants one might postulate binding sites
r?114similar to those suggested by the Canberra workers although the
prediction of binding sites from formation constant values alone is
an unreliable process for such a complicated ligand.
LEAD(II)-GLYCINATE
Experimental results are shown in appendix 2 - table 10 and in
figure 38.
The formation curves only reach a Z of around 1 because of the
precipitation of lead hydroxides at higher pHs. The spread of the
curves is characteristic of hydroxy species and is caused mainly by 
+ 4+ 2+the four lead hydroxy complexes PbOH , Pb. (OH). , Pb_(OH). and
Pb6(°H)84+.
The complexes searched for were those with p 1 to 3; q 1, 2 and
r -4 to 2 those giving convergence being 110, 111 and 11-1 with log (
values of 5,600, 11.40 and -2.142 respectively. A simulated set of
formation curves obtained from PSEUDOPLOT using these constants is
shown in figure 39.
65Other workers have reported formation constants for the 110
and 210 complexes but not for the protonated or hydroxy species. In
general their values are lower than those reported here.
Proposed structures for these complexes will be discussed, in
the light of thermodynamic data, in Chapter ' 8.
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LEAD (II) -GLYCYLGLYC INATE
Experimental data are shown in appendix 2 - table 11 and in
figure 40,
Again a marked pattern of formation curves is obtained the
curve position depending both on the metal concentration and on the
ligand : metal ratio.
The complexes searched for were those with pi, 2; q 1, 2 and 
r -2 to 2 those_giving convergence being llO and 111 with log 3 values
of 3.375 and 9.907 respectively. In this case the inclusion of a 11-1
species prevented convergence in either SCOGS or MINIQUAD. A simulated
set of formation curves obtained from PSEUDOPLOT using these constants
is shown in figure 41.
For this ligand, log formation constants for the protonated species
' 141 122have been reported by other workers these being 9.71 and 9.51
determined using polarography and nuclear magnetic resonance spectroscopy
respectively. Our work is in general agreement with these and other 
literature values Considering the different conditions of temperature
and background ionic strength.
Proposed structures for these complexes will be discussed in
Chapter 8.
LEAD (II)-GLYCYLGLYCYLGLYCINATE
Experimental results are shown in appendix 2 - table 12 and in
figure 42.
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FIGURE 41 : PSEUDOPLOT USING THE FORMATION CONSTANTS FROM TABLE 7
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- The complexes searched for were those with p 1, 2; q 1, 2 and 
r -2 to 2 those giving convergence being 110, 111 and 11-1 with log , 
values of 3.767, 10.403 and -3.762 respectively. A simulated set of
formation curves obtained from PSEUDOPLOT using these constants is
shown in figure 43.
122A value for log of 9.54 has been reported as well as
65 . -formation constants for the 110 and 210 species but no literature
value is available for the hydroxy complex.
Proposed structures for these complexes will be discussed in
Chapter 8.
LEAD(II)-CHLORIDE ’
For the study of the interaction of chloride ions with lead(II),
a chloride sensitive electrode was used and a silver/silver chloride
reference cell.
solution under study AgCl (s)-Ag (s), O.lOOM NaCl
Ag (s)-AgCl (s) 3.COM NaClO.4
J = 3.0OM(Na"’)C104 J = 3.00M (Na+)C104
This electrode pair gives a potential described by E=E - — ln[Cl o F
and was calibrated by the measurement of E for solutions of known ECl”].
A calibration line is thus constructed, see table 6 and figure 44 for the
experimental data, which can be extrapolated to -log[Cl ] = O using a
simple least-squares procedure in order to obtain the value of E . This o
value is checked before and after each titration using solutions of
known chloride concentration.
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TABLE 6
EXPERIMENTAL DATA FOR THE CALIBRATION OF THE CHLORIDE SENSITIVE ELECTRODE
Titrate : 2O.OOml of 3.OOM NaClO.4
Titrant : 19.92mM NaCl, T = 3.OOM(Na+)C10'
Titre E -logCci
(ml) (mV)
1.10 -106<1 2.98
1.40 -101.0 2.88
1.80 -95.9 2.78
2.20 -91.9 2.70
2.70 -88.0 2.63
3.40 -83.7 2.54
4.20 -79.9 2.46
5.20 -76.0 2.39
6.20 -73.0 2.33
Titre E -logLci
(ml) (mV)
7.70 -69.4 2.26
9.20 -66.6 2.20
12.30 -62.6 2.12
14.50 -60.4 2.08
17.50 - -58.1 2.03
23.50 -54.8 1.97
26.50 -53.7 1.95
30.50 -52.3 1.92
-50i
70*
E (mV)
90'
110
18 2-2. 26
~log[Cr]
30
FIGURE 44 CHLORIDE SENSITIVE ELECTRODE CALIBRATION
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Experimental results for the interaction of lead(II) with chloride 
ions are shown in appendix 2 - table 13 and in figure 45.
Non-superimposable formation curves are found, their position
depending on the lead(II) concentration.
The working pH range was 2.0 to 2.3 and so inclusion of Olin's four
lead-hydroxy species in the calculations was not necessary. The complexes
searched for were those with p 1 to 4; q 1 to 3 and r -2 to O and those
giving convergence were 110, 210, 410, 11-1 and 41-1 with log g values of
1.14, 2.602, 5.410, -0.977 and 2.943 respectively. The HALTAFALL program 
was used to * calculate the equilibrium concentrations of species present 
during the titrations and shows that all of the above complexes are
significant.
Formation constants are reported in the literature for the species
1LO to 610 the values of which are generally lower than those reported here
and solubility products are given for the species 11-1. Haight and 
142Peterson have shown, from solubility and spectroscopic work, that lead(II)
has a preference for even numbers of chloride ligands and this is borne out
by our inability to determine a formation constant for the 310 complex.
The lead(II)-glycinate system was also examined again in the presence
of chloride ions in order to determine whether any ternary lead(II)-
glycinate-chloride complexes could be detected. However, no ternary
species were found since as the pH is raised to allow lead(II)-glycinate
complex formation then the chloride ion is displaced from the lead(II) by
hydroxide in order to form either binary lead(II)-hydroxy species or
ternary lead(II)-glycinate-hydroxy species.
The results from the metal-ligand interaction work are summarised
in table 7.
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TABLE 7
Log formation constants for ligand anion-metal-proton interactions
at 25°C, I = 3.00M(Na+)C104"
Lead (II)-aspartate
Lead(II)-cysteinate
Zinc(II)-cysteinate
Lead(II)-glutamate
Lead(II)-ethylenediamine­
tetraacetate
pqr log £5pqr n*
110 6.878 + 0.021 198
210 10.014 + 0.044
111 12.695 + 0.030
112 16.167 + 0.053
211 19.181 + 0.046
212 24.985 + 0.045
110 13.213 + 0.016 137
210 18.571 + 0.045
111 17.347 + 0.053
211 27.476 + 0.043
210 19.395 + 0.019 218
211 25.856 ± 0.058
212 31.879 + 0.057
430 46.247 + 0.095-
431 52.50 + 0.10
110 5.344 + 0.027 146
111 12.173 + 0.018
110 15.186 + 0.078 272
111 18.010 + 0.069
72
Table 7 continued.
Zinc(II)-ethylenediamine­
tetraacetate
Lead(II)-D-penicillaminate
Lead(II)-glutathionate
Zinc(II)-glutathionate
Lead(II)-glycinate
110
111
110
210
111
211
110
210
111
211
212
110
210
111
11-1
211
212
21-1
110
111
11-1
14.873 + 0.050 335
17.965 + 0.034
14.321+0.023 199
19.049 + 0.050
17.723 + 0.053
27.978 + 0.074
10.57 + 0.19 151
15.00 + 0.23
17.136 + 0.034
24.664 + 0.07!
32.10 + 0.11
8.568+0.015 168
13.586 + 0.098
14.762 + 0.058
-0.074 + 0.054
23.271 + 0.017
30.616 + 0.018
3.63 + 0.27
5.600 + 0.034 289
11.40 +0.13
-2.142 + 0.035
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Table 7 continued
Lead (II)-glycylglycinate 110 3.375 + 0.039 176
111 9.907 + 0.032
Lead(II)-glycylglycylglycinate no 3.767 + 0.039 192
111 10.403 + 0.037
-
11-1 -3.762 + 0.040
Lead (II)-chloride 110 1.14 + 0.11 200
210 2.602 + 0.093
410 5.410 + 0.046
11-1 -0.977 + 0.039
41-1 2.943 + 0.069
n = number of experimental observations
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CHAPTER 6
RESULTS - THERMODYNAMIC° FUNCTIONS
JT
Calorimetry
All calorimetric work was carried out at 25°C, I = 3.00M(Na°)C10.
using the apparatus described in Chapter 4.
CALORIMETER CALIBRATION ’
For each volume of solution under study a calibration constant, E,
is required so that the measured temperature rise, AT, can be converted
into the quantity of heat, E, liberated by the chemical reactions.
Thus, for a series of volumes, a known amount of electrical energy is
added from a heating coil (electrical energy = voltage x current x time
for which the current flows) and the temperature rise is measured. A
calibration line is then plotted i.e. E/AT versus volume, which can
be analysed by a least-squares procedure to give the ’best* value of
the calibration constant for each volume. For an example of the
experimental data see table 8 and figure 46.
75
TABLE 8
EXPERIMENTAL DATA FOR CALORIMETER CALIBRATION
Volume E/AT Volume E/AT
-1 -1(ml) (J K ) (ml) (J K
100.57 486.7 123.57 605.5
103.57 507.4 126.57 611.8
107.57 524.4 130.57 640.7
111.57 543.0 134.57 655.6
114.57 551.9 138.57 668.6
117.57 564.3 142.57 681.2
120.57 580.2
17
Volume (ml)
FIGURE 46 : CALORIMETER CALIBRATION LINE
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TOLERANCES
In general, experimental errors, some values of which are shown
in table 9, are <0.1% of the typical measured values.
TABLE 9
EXPERIMENTAL ERRORS
Calibration voltage
Calibration current
Calibration time
Room Temperature
Bath Temperature
Temperature Change
+ 0.001 V
+ 0.0001 A
+ 0.01s
+ O.5°C 
+ 0.0005°C 
+ O.OOOO5°C
4!
f
i
. j
f
i
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EXPERIMENTAL PROCEDURE
The reaction vessel is charged with the titrate from a silicone
lined flask, calibrated to deliver 99.57mtl, and is allowed to equilibrate 
"7in the water bath overnight. About two hours before starting a titration,
the stirrer and the quartz thermometer are switched on and the system
allowed to reach a steady state.
For each point in the titration we allow a lO minute fore period, 
a 6 minute reaction period (after the addition of about 3ml of titrant)
and a 10 minute aft period. Between titration points the solution is
cooled so that each addition is made at the same temperature. Since
the fore and aft periods show approximately the same variation of
temperature with time, they are simply extrapolated to the half reaction
time in order to calculate the temperature rise.
The composition of the system for each titration point is calculated
using the program PSEUDOPLOT and so the change in the number of moles of
each species caused by the titrant addition can be determined.
GLYCINATE PROTONATION
Experimental data are shown in appendix 3 - table 1 and enthalpic
curves in figure 47.
If only simple species are present then the enthalpic curve should 
143be independent of the concentration of ligand used . The curves
found are parallel but not superimposable, this being because each
titration has a different initial Z. If a correction is made for this, 
then very good superimposability is found up to Z = 1.0). Above this,
however, there is some scatter due to the enthalpy of protonation of
64
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the carboxylate group being smaller and so less accurately measurable.
The enthalpy values determined from the program CALCO are -51.2
-1and -9.0 kJ mol which may be assigned to the protonation of the
amino and carboxylate groups respectively. The protonation of an
amino group is an enthalpy dependent process whereas the protonation
of a carboxylate group, essentially an electro-static phenomenon,
is entropy dependent.
144Other workers have reported values of AEL ranging from -41.9
„ 121* -1 . 145 , - _ 146to -46.7 kJ mol and of AH_ _ ranging from -4.0 to -6.01, z
-1kJ mol . However, these values invariably apply to lower ionic
strengths than those reported here.
GLYCYLGLYCINATE PROTONATION •
Experimental data are shown in appendix 3 - table 2 and enthalpic
curves in figure 48.
The enthalpy values determined by CALCO are -48.7 and -5.6 kJ mol "" 
which may be assigned to the protonation of the amino and carboxylate
groups respectively. These results are in general agreement with those
- _ ' 123,147,148 .of other workers considering the different conditions
employed.
GLYCYLGLYCYLGLYCINATE PROTONATION
Experimental data are shown in appendix 3 - table 3 and enthalpic
curves in figure 49.
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The enthalpy values determined by CALCO are -49,5 and -4.0 kJ mol
which may be assigned to the protonation of the amino and carboxylate
groups respectively. Values reported in the literature for AH^ are
149 147 -1 -1 147-23.0 and -42.3 kJ mol x and for AH_ _ -0.8 kJ mol . The
results from reference 147 are in good agreement with those reported
here considering that they were measured in anionic background of
O.IM NaClO..4
GLUTATHIONATE PROTONATION
Experimental data are shown in appendix 3 - table 4 and enthalpic
curves in figure 50.
The enthalpy values determined by CALCO are -37.1, -35.1, -1.8 and
-4.6 kJ mol 1. These are composite values which cannot be assigned to
the protonation of individual groups since some concurrent protonation
of the sulphydryl and amino groups and of the two carboxylate groups 
150will be occurring. Vander Jagt et al report the following
calorimetrically determined values;- AH. -34.87, AH. _ -31.65,J. _L , 2
AH. - -0.71 and AH. -1.88 kJ mol with which our values are in 2,-3
good agreement when one considers the difference in ionic strength.
A summary of the Ah values for ligand protonation, their standard
deviations and the numbers of experimental observations is given in
table 10
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TABLE 10
ENTHALPIES OF LIGAND ANION PROTONATION (kJ mol S 
at 25°C, J = 3.00M(Na+)Cl0.“
)
AHle AH.1
e
2 AH2,3* AH3 ,® n*3,4
Glycinate - —51.2 + 1.3 -9.0 + 0.4 40
Glycylglycinate -48.7 + 1.6 -5.6 + 0.3 37
Glycylglycylglycinate -49.5 + 1.4 -4.0 + 0.2 34
Glutathionate -37.1 + 1.0 -35.1 + 1.4 -1.8 + 1.9 -4.6 + 3.4 36
* n = number of experimental observations
From these values of AH® and the log g values already measured, AG® 
and AS® were calculated as shown in Chapter 2, All three thermodynamic 
functions for the protonation of these four ligands are summarised in
table 11.
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LEAD (II)-LIGAND INTERACTIONS
For the lead(II) complexing reactions calorimetry could not be
used for the following reasons. For glycinate and its peptides, the
maximum Z attainable before precipitation of lead hydroxides is about
1.0 and, even below this, the heat contribution from lead(II)-hydroxy 
36 37species ' is considerable thus making the net heat output low and 
the Heats of the complexation reactions insignificant compared to the
corrections which Had to be applied. For tHe cysteinate and
glutathionate-lead (H) system--, only very low concentrations of metal
(vlmM) could be used in order to avoid precipitation of insoluble
complexes and so again sufficient Heat output to be accurately measurable
could not be realised.
Thus, for the lead(II) complexing reactions, potentiometric studies 
have been carried out at 10, 25 and 40®C and tHe enthalpies of reaction 
calculated from the temperature variation of the formation constants.
Variation of Formation Constants with Temperature
Potentiometric work was carried out at 10, 25 and 40°C, I = 3.00M 
(Na )C10. using tHe equipment and techniques described in Chapters 2
and 5. THe enthalpies of ligand protonation, calorimetrically determined
above and from reference 101, were used to calculate ligand protonation
constants at 10 and 40°C. Similarly, formation constants for tHe four
lead(II)-hydroxy species at 10 and 40°C were calculated from tHe 
37enthalpies determined by Carell and Olin (see table 12).
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TABLE 12
ENTHALPIES OF LEAD (II)-HYDROXY COMPLEX FORMATION AT 25°C, J = 3.OOM(Na+.^glO4' 37
AH01-l 20.93 kJ mol 4
AH04-4 84,01 kJ mol 4
44o3-4 110.9 kJ mol l
aH05-8 207.0 kJ mol"4
Having obtained log g values at different temperatures a plot of
log 3 versus 1/T was drawn for each complex and the 'best' straight line
drawn to give a gradient equal to
-AH®
2.3O3R
from which AH® is calculated.
A summary of the measured enthalpies of complex formation, and the
calculated free energies and entropies, is shown in table 18.
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LEAD (II)-GLYCINATE
Experimental data are shown in appendix 3 - tables 5, 6 and 7.
Our normal computational approach was used to give the .log g values
shown in table 13.
TABLE 13
LOG FORMATION CONSTANTS AT 10, 25 AND 40°C FOR LEAD(II)-GLYCINATE COMPLEXES
log pqr
110 111 11-1 n
10 C 5.883 0+ 0.034 12..21 0+ O^T) -2.071 + 0.038 165
25®C 5.775 + 0.045 H^O 0- O..L2>35 -1.88(5 + ..050 131*■“
40°C 5.877 + 0.007 11.872 0+ O..^ -1.781 + 0.026 173
From these formation constants AH® values for the 110, 111 and 11-1 
complexes were determined as -12.4, -25.1 and 16.5 kJ mol respectively.
No literature values are available for comparison but AH. for zinc(II)--1 121 1
glycinate has been measured as -8.71 kJ mol and for cadmium(II)-..  151
glycinate as -8.87 kJ mol at considerably lower background ionic
strengths.
85
LEAD (II)-GLYCYLGLYCINATE
Experimental data are shown in appendix 3 - tables 8, 9 and 10.
The log 3 values determined from these results are shown in table 14.
r?
TABLE 14
LOG FORMATION CONSTANTS AT 10, 25 AND 40°C FOR LEAD(II)-GLYCYLGLYCINATE
COMPLEXES
log gpqr
110 n111
10°C
25°C
40°C
4.005 + 0.034
3.824 + 0,036
3.782 + 0.043
10.405 + 0,059
10.007 + 0.063
9.739 + 0.077
139
99
156
From these formation constants AH values for the 110 and 111 complexes
were determined as -12.7 and -37.8 kJ mol 1 respectively.
6
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LEAD (II)-GLYCYLGLYCYLGLYCINATE
Experimental data are shown in appendix 3 - tables 11, 12 and 13, 
The log g values determined from these results are shown in table 15.
TABLE 15
LOG FORMATION CONSTANTS AT 10, 25 AND 40°C FOR LEAD(II)-GLYCYLGLYCYLGLYCINATE 
.COMPLEXES
log gpqr
HO 111 11-1 n
10®C 4.143 + 0.038 10.840 + 0.046 -3.524 + 0.061 96
25°C 3.967 + 0.022 10.618 + 0.021 -3.401 + 0.024 103
40°C 3..379 + OJ32O 10.352 + 0.020 -3.132 + 0.017 97
From
complexes
these formation
were determined
constants AH® values for the 110, 
as -15.0, -27.5 and 22.0 kJ mol 1
111 and 11-1
respectively.
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LEAD (II)-CYSTEINATE
Experimental data are shown in appendix 3 - tables 14, 15 and 16.
The log 3 values determined from these results are shown in table 16.
TABLE 16
LOG FORMATION CONSTANTS AT 10, 25 AND 40°C FOR LEAD(II)-CYSTEINATE COMPLEXES
. 110 111 210 211 n
10®C 13.579 + 0.027 17.974 + 0.069 17.84 + 0.44 28.417 + 0.065 96
25®C 13.207 + 0.041 17.43 + 0.11 18.23 + 0.12 27.30 +0.12 147
40®C 12.828 + 0.019 16.968 + 0.047 17.547 + 0.052 26.445 + 0.058 179
From ' these formation constants AH® values for the 110, 111 and 211 
complexes were determined as -42.4, -56.9 and -111.8 kJ mol 1 respectively. 
For the 210 complex, which figure 19 shows to be present only at high pH,
however, formation constants could not be obtained with sufficient accuracy
to allow the enthalpy to be calculated.
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LEAD(II)-GLUTATHIONATE
Experimental data are shown in appendix 3 - tables 17, 18 and 19.
The log g values determined from these results are shown in table 17.
TABLE 17
LOG FORMATION CONSTANTS AT 10, 25 AND 40°C FOR LEAD(II)-GLUTATHIONATE COMPLEXES
log
t----------
110 111 ,
lo®c 10.769 + 0.032 17.618 + 0.015——
25®C 9.913 + 0.035 16.821 + 0.017
40®C 9.583 + 0.028 16,167 + 0.013
8fPqr
211
------------s
212 n
24.453 + 0.023 33.765 £ 0.020 147
23.400 + 0.025 32.313 + 0.022 128——
22.665 + 0.026 31.234 + 0.019 113
From these formation constants AH® values for the 110, 111, 211 and 
212 complexes were determined as -67.6, -82.2, -101.4 and -143.5 kJ mol 1 
respectively. Again formation constants for the 210 complex, present only 
at high pH, could not be determined with sufficient accuracy to allow the
enthalpy to be calculated.
The thermodynamic functions, which are summarised in table 18, are i
used to propose structures for the various complexes, as will be
discussed in Chapter 8.
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CHAPTER . . 7
RESULTS - BOVINE SERUM ALBUMIN k?
The amino acid sequence for bovine serum albumin(BSA) shown in
reference 95 gives 578 of the 581 residues and leads to a molecular
weight of approximately 66,000 and so this is the value used in
subsequent work.
Potentiometry
It was found that BSA solutions precipitated around pH 4 to 5 in
perchlorate or nitrate, even at background concentrations as low as
0.150M, and in chloride at concentrations of greater than l.OM. Thus
the ionic background chosen for the potentiometric work was 0.150M
(Na )C1 . Since this change to plasma ionic strength was necessitated, 
it was decided also to use the biological temperature, 37°C.
A glass electrode and a calomel reference electrode were used,
as in Chapter 5, but, of course, these had to be recalibrated under
the new experimental conditions. Unfortunately, a relevant value of 
pwk was not available and so this was calculated from the calibration
*
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line. The theoretical slope of the calibration line at 37°C is
-61.544mV(-logh) and this is also assumed to be the slope for the
experimental line above pH 7. Thus, by applying a least-squares
analysis to several calibration lines, pw, is calculated as -13.30 
+ 0.04 and this value is used in subsequent work.
BOVINE SERUM ALBUMIN PROTONATION
Experimental data are shown in appendix 4 - table 1 and in figure 51 
86The ZPLOT program had to be slightly modified in order to be able
to deal with a ligand with such a large number of protonatable sites.
95Brown’s analysis shows 38 aspartate residues and 57 glutamate
residues as well as 5 residues which may be aspartate or asparaginate
and 7 residues which may be glutamate or glutaminate. This means that
the number of protons which the BSA molecule can release, within the 
.. 152pH range studied, is between 95 and 107. Osterberg has assumed
99 carboxylate groups on the BSA molecule which agrees with Brown’s
analysis and so this value for the number of dissociable protons has
been used in this work.
The formation curves in figure 51 show maximum Zs of 189 +. 2.
From the observed changes in curve slope it is possible to estimate
the numbers of the main types of electron donor groups present.
(i) At ph 5,5, Z = 93 and so the number of carboxylate 
groups present is 189 - 93 = 96 _+ 3 which agrees with the number found by Osterberg and Brown ^5.
200.0-r BSA PROTONATION
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FIGURE 51 : ZPLOT OF DATA FROM APPENDIX 4 - TABLE 1
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(ii) At ph 8.0/ Z = 75 and so the number of imidazole 
groups present is 93 - 75 = 18 +. 2. This again 
agrees well with other analyses which find 17 
histidinate residues 95,153-155.
(iii) This leaves 75 other protonatable sites
unaccounted for which must include lysinate, tyrosinate and cysteinate side chains. Brown’s„ 
analysis gives 59 lysinate, 19 tyrosinate and 
1 cysteinate residues, making a total of 79.
LEAD(II)-BOVINE 'SERUM ALBUMIN INTERACTION
Several titrations were carried out in which a solution of lead(II),
BSA and acid was titrated with alkali, with varying ratios of metal to
protein being used. For high ratios of lead(II) to BSA precipitation of
insoluble complexes occurs around ph 4 but these redissolve at about ph 9.
152The insolubility of lead(II)-BSA complexes has been previously reported .
Experimental data are shown in appendix 4 - table 2. Since protonation
constants are not available for each site on the ligand, it was not possible
to compute a Z versus pa curve. However, figure 52 shows the effect that
the presence of lead(II) has on the BSA protonation curves. As can be
seen, from ph 5 upwards the presence of lead(II) tends to move the curves
to lower Z at any given ph i.e. protons are apparently being released
from BSA by the metal. The extent of the shift in the curves depends
on the ratio of lead(II) to BSA.
Table 19 shows the number of protons released for each titration 
at biological ph (7.4) and at ph 10.0.
It appears that the number of protons released is approximately 
proportional to B/A and that at ph 10.0 twice as many are released as 
at ph 7.4. It is possible that at these phs the formation of lead(II)-
hydroxy species, as well as lead(II)-BSA species, is causing proton release.
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TABLE 19
THE APPARENT DISPLACEMENT OF PROTONS FROM BSA BY LEAD(II)
Ph B : A Z AZ .
7.4 0 : 1 78.7 O
5 : 1 75.3 3
9 : 1 72,5 6
45 : 1 precipitate present
10.0 0 : 1 52.3 O
5 : 1 46.6 6
9 : 1 38.5 1-4
45 : 1 -14.6 66
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COPPER (II)-BOVINE SERUM ALBUMIN INTERACTION
Experimental data are shown in appendix 4 - table 3 and ligand
protonation curves drawn from these results in figure 53. Again some
' JT7precipitation of metal-BSA complexes occurred around the centre of
the ph range.
These curves are shifted from the true ligand protonation curve
even at very low ph (-2) and the shift is much more marked than in
the lead(II) case, although the extent of the shift still depends
on the ratio of copper (II) to BSA. Table 20 shows the number of
protons released for each titration at ph 4.0, 7.4 and 10.0.
As can be seen, many more protons are released by copper(II)
than by lead(II) and at lower ph and so it can be stated that
copper(II) complexes to BSA more effectively than lead(II). This;,
obviously, is due to the presence of the specific copper(II) binding
site on albumin,whereas lead(II) is believed to bind only to 
152 86carboxylate groups . Zinc(II) was found to have an intermediate
effect (see figure 54).
Copper(II)-Bovine Serum Albumin - Drug, Interactions
ULTRA-VIOLET/VISIBLE SPECTROSCOPY
Aqueous solution
Preliminary investigations of bovine serum albumin (O.lmM), in
0.150M NaCl at pH 7.4, produced ultra-violet absorption peaks at
BSA COPPER PROTONATION
l>h
FIGURE 53 ZPLOT OF DATA FROM APPENDIX 4 - TABLE 3
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TABLE 20
THE APPARENT DISPLACEMENT OF PROTONS FROM BSA BY COPPER (II)
ph B : A Z Z
4.0 0 : 1 131.4 0
1:1 133.2 -2
4 : 1 127.4 4
9 : 1 118.0 13
22 : 1 109.6 22
7.4 0 : 1 78.7 0
1 : 1 78.0 1
4 : 1 70.5 8
9 : 1 a/52 a/26.
22 : 1 precipitate present
.0.0 0 : 1 52.3 0
1 : 1 49.0 3
4 : 1 39.1 13
9 : 1 10.6 42
22 : 1 -29.7 82
BSA LEAD ZINC COPPER PROTONATION
hh
FIGURE 54 : THE EFFECT OF LLAD(II), ZINC(II) AND COPPER(II) ON BSA
A = BSA/H+ ; = Pb : BSA =9:1
□ = Zn : BSA = 20:1 J = Cu : BSA =9:1
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2O5(strong) and 278(weak) nt. One of the more water soluble of the
drugs shown in figure 2, from the middle of the potency order,
(Fenoprofen) was studied under similar conditions and exhibited peaks
at 209 and 270nm, the latter having shoulders at 263 and 278nm.
When copper (II) chloride (O.lmM) was introduced into these
solutions there was negligible effect on the BSA spectrum and an
immediate precipitate with Fenoprofen. Lower concentrations, although
producing soluble systems, did not exhibit any copper influence upon
absorption peak positions. Higher concentrations (2rnM Cu) did show
the influence of copper(II) on BSA (a shoulder appeared on the 278nm 
peak at 357nm) but exceeded the solubility of the Fenoprofen. Thus, 
in order to investigate the influence of the drugs on the binding of 
copper (II) to BSA, more concentrated solutions are necessary and so
a change of solvent is indicated.
Ethanolic solution
The conditions chosen were 90% ethanol/water at pH 2.4 (BSA is
insoluble in ethanol above pH 3). These permitted higher concentrations
of drugs to be used (up to lOmM) and eliminated interference from direct 
copper(II)-drug interactions although it did introduce the possibility
that the BSA would be denatured by the alcohol.
Under these conditions it is not possible to use the BSA ultra­
violet absorption peaks because they are swamped by drug and copper•
peaks but studies of the visible spectrum are feasible. Such
investigations show that when BSA (0.200mM) was introduced into a
copper(II) solution (H,17mM) the wavelength of the absorption peak
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maximum decreased (780 to 759nm) and the absorbance increased
(0.770 to 1.215). Fenoprofen (lO.CXOmM), on the other hand, does not
affect the absorption of the copper(II) solution but does influence
copper(II)-BSA solutions by moving the peak back towards the free 
copper(II) peak (i.e. to 764nm). Thus it would appear that Fenoprofen
liberates copper (II) from BSA.
Similar investigations were carried out with the other anti­
arthritic drugs as well as with salicylate and histidinate.
Table 21 shows the copper(II)-drug interactions in the absence
of bovine serum albumin and it is clear from the shifts in X thatmax
only salicylic acid and histidine are appreciably complexed to
copper(II) at pH 2.4. At pH 3.9, however, it is seen that adding 
the drugs to a copper(II) solution lowers the X and increases the 
absorbance (Phenylbutazone is a slight exception in terms of ^max).
The absorbance of a solution of copper(II) ions, at 780nm say, 
is given by abs_o_ = d C 1 where G’ Q ~ the absorption
coefficient for copper (II) ions at 780nm, d = path length and 
[ ] = concentration of copper(II) ions. For example, at pH 2.4 for 
a copper(II) chloride solution & _ can be calculated as 0.0171 1 mmol 
cm and this value does not vary significantly between pH 2.1 and
-1
pH 4.0.
When a drug is added to this solution, then
abs780 = e‘780 d(C 3 -x) + e 11 a " '780 U
where *7qq “ the absorption coefficient for the copper-drug complex 
and x = the concentration of copper(II) transferred from ions in
solution into the drug complexed form.
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TABLE 21
SPECTRAL RESULTS FOR COPPER(II)-DRUG INTERACTIONS r?
Concentrations used (mM) Spectral data
------—
X (nm)
------A,
abs abs^,„ abs„Copper(II) Drug max max 780 700
11.17 780 0.770 0.770 0.440
11.17 Fenoprofen 10.00 780 0.815 0.815 0.480
11.17 Indomethacin 10.00 780 0.820 0.820 0.485
11.17 Naproxen 10.00 780 0.820 0.820 0.500
11.17 Ketoprofen 10.00 779 0.820 0.820 0.495
11.17 Phenylbutazone 10.00 780 0.790 0.790 0.470
11.17 Aspirin 10.00 779 0.825 0.825 0.505
11.17 salicylic acid 10.00 776 0.925 0.920 0.590
11.17 histidine 10.00 692 1.480 1.190 1.475
11.17 histidine 1.000 776 0.840 0.835 0.590
11.17 histidine 0.200 778 0.795 0.795 0. 490
11.17 780 0.770 0.770 0.440
11.17 Fenoprofen 10.00 766 1.225 1.200 0.925
11.17 Indomethacin 10.00 769 1.225 1.210 0.905
11.17 Naproxen 10.00 768 1.180 1.165 0.865
11.17 Ketoprofen 10.00 769 1.170 1.160 0.850
11.17 Phenylbutazone 10.00 782 0.810 0.810 0.480
11.17 Aspirin 10.00 772 1.145 1.135 0.695
11.17 salicylic acid 10.00 765 1.360 1.330 1.010
11.17 histidine 1.000 774 0.875 0.870 0.620
11.17 histidine 0.200 779 0.810 0.810 0.525
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Thus from table 21 it would appear that €'' > S’ ./ou / oU
that any variation in S' ' from drug to drug is not large,/oO
copper(II)-drug complexing order is seen to be
Provided
then the
histidine >> salicylic acid > Indomethacin ~ Fenoprofen
> Naproxen ~ Ketoprofen > Aspirin > Phenylbutazone.
Table 22 indicates the effect of BSA on these results, data being
recorded at pH 2.4 in order to avoid the above copper(II)-drug interactions
noted at pH 3.9.
TABLE 22
SPECTRAL RESULTS FOR COPPER(II)-BSA-DRUG INTERACTIONS AT pH 2.4
Concentrations used (mM) Spectral data
Copper(II) BSA
------------ v
Drug
Amax
(nm) absmax abs...,-,780 abs700
7 .11.17 780 0.770 0.770 0.440
11.17 0.200 759 1.215 1.175 1.040
11.17 0.200 Fenoprofen (10.00) 764 1.160 1.135 0.955
11.17 0.200 Indomethacin (10.00) 764 1.240 1.205 1.030
11.17 0.200 Naproxen (10.00) 761 1.240 1.210 1.050
11.17 0.200 Ketoprofen (10.00) 760 1.210 1.175 1.025
11.17 0.200 Phenylbutazone(10.00) 764 1.155 1.140 0.950
11.17 0.200 Aspirin (10.00) 762 1.240 1.205 1.040
1OO
Clearly, there is extensive copper(II)-BSA complexing even at
pH 2.4, since, when BSA is added to the copper (II) solution, Xmax
Cu—BSA ’changes from 780 to 759nm. Further, at all wavelengths €■ > E .
r?Since no copper(II)-drug interactions occur at this pH the absorbance,
and peak position, changes must arise from copper ions being transferred
between BSA and solution. So, a peak shift towards higher wavelengths
and a decrease in absorbance indicates a release of albumin bound
copper (II), not through direct copper(II)-drug complexing, but, rather,
through the drug acting remotely on the BSA molecule. An approximate
remote copper(II) releasing order would thus read
Fenoprofen ~ Phenylbutazone > Ketoprofen > Indomethacin
~ Aspirin ~ Naproxen
Histidine and salicylic acid, on the other hand, are capable of
direct competition for the copper(II) ion at pH 2.4 as can be seen from
the data in table 23. i
Thus, we see that salicylic acid and especially histidine are
much more effective at releasing copper(II( from BSA than the remote
copper(II) releasing drugs.
Finally we considered the effect of a remote copper(II) releasing
drug (Fenoprofen) and a direct copper(II) complexing ligand (histidine)
acting in unison, see table 24.
Surprisingly, it appears that the presence of histidine prevents
Fenoprofen from having its remote copper(II) releasing effect. However,
this may be accounted for since any copper(II) released by Fenoprofen
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TABLE 23
SPECTRAL RESULTS FOR COPPER(II)-BSA-HISTIDINE AND -SALICYLIC ACID 
INTERACTIONS AT pH 2.4
Concentrations used (mM) Spectral data
_____ --------------- 1
Copper(II) BSA Drug
11.17
11.17 0.200
11.17 Salicylic acid
11.17 0.200 Salicylic acid
11.17 histidine
11.17 0.200 histidine
11.17 histidine
11.17 0.200 histidine
Amax
(nm) absmax abs78O ^OO
780 0.770 0.770 0.440
759 1.215 1.175 1.040
(10.00) 776 0.925 0.920 0.590
(10.00) 765 1.220 1.200 0.975
(10.00) 692 1.480• 1.190 1.475
(10.00) 690 1.675 1.320 1.665
(1.000) 776 0.840 0.835 0.590
(1.000) 760 1.235 1.200 1.075
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TABLE 24
SPECTRAL RESULTS FOR COPPER(II)-BSA-FENOPROFEN-HISTIDINE INTERACTIONS
AT pH 2.4
Concentrations used (mM) Spectral data
— --- - - - -.. ... Xmax abs abs„~ abs„Copper(II) BSA Histidine Fenoprofen (nm) max •780 700
11.17 780 0.770 0.770 0.440
11.17 0.200 759 1.215 1.175 1.040
11.17 1.000 10.00 775 0.910 0.905 0.64
11.17 0.200 1.000 10.00 758 1.210 1.170 1,040
would not be free in solution but would be bound to histidine thus
lowering X as can be seen from table 23. max
There is no guarantee that these spectral investigations, conducted
in conditions far removed from biological fluids and pH values, reflect
the reactions occurring in vivo and so the observations were checked
using the molecular filtration technique at pH 7.4.
MOLECULAR FILTRATION
An equimolar aqueous solution of copper(II) chloride and drug
“1C0.1475rnM). is adjusted to pH 7.4 and filtered at a flow rate of 1 ml min ,
each 1ml fraction being collected, diluted to 10ml and analysed for
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copper by atomic absorption spectrophotometry. The process of filtration
disturbs the equilibrium in the solution under study and so only the first
fraction is considered. Measurements at different pH values show that as
the pH is raised more copper is retained as precipitated copper hydroxides.
Thus correction factors to account for this have to be applied to the drug
binding data.
Next a solution of copper(II), drug and BSA is filtered at pH 7.4
and so the .Ability of the drug to release copper(II) from BSA is quantified
The experimental data is summarised in table 25.
From these results, the ability of the drugs to bind copper(II) at
pH 7.4 is in the order
histidine >> " threonine » salicylic acid ~ Naproxen
> Indomethacin > Fenoprofen ~ Ketoprofen ~ Phenylbutazone
Table 26 summarises the percentages of copper (II) bound to BSA in
the presence of the drugs studieci.
Thus the order of ability of the drugs to release copper(II) from'
bovine serum albumin at pH 7,4 is
histidine >> Indomethacin > Phenylbutazone > threonine
Ketoprofen ~ Fenoprofen > Naproxen ~ salicylic acid > Aspirin
This order, of course, does not discriminate between direct and remote
release of copper(II) ions. „
A comparison of the results of the spectral and molecular filtration
studies with the drug effectiveness order will be found in Chapter 8.
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TABLE 25
MOLECULAR FILTRATION DATA FOR COPPER (II)-BSA-D'RUG INTERACTIONS
(x = O.1475mM)
r?
Concentrations used % copper(II)
A. ! *1 in not bound bound
pH Copper(II) BSA Drug(s) filtrate .to BSA to BSA
Aspirin 4.0 X X 77
6.0 X X 45
7.4 X X 41-47
4.0 X X 36 47 53
6.0 X X <1 >99
7.4 X X <1 >99
4.0 X X 4x 35 45 55
7.4 X X 4x <1 >99
histidine 7.4 X 2x 93 1OO 0
7.4 X X 2x 33 35 65
threonine 7.4 X 2x 78 100 0
7.4 X X 2x 5 6 94
histidine and 7.4 X x+x 86 100 0
threonine 7.4 X X x+x 16 19 81
salicylic acid 7.4 X 2x 44 100 O
7.4 X X 2x 1.1 2.5 97.5
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Table 25 continued
Fenoprofen 7.4
7.4
X 2x
2x
26
1.4
100
5.4
0
95X X
Indomethacin 7.4 X 2x 33 100 0
7.4 X X 2x 4.2 13 87
histidine and 7.4 X 2x+2x 93 100 0
Indomethacin 7.4 X X 2x+2x 38 41 59
Naproxen 7.4 X 2x 43 100 0
7.4 X X 2x 1.1 ■ 2.6 97
Ketoprofen 7.4 X 2x 24 100 o
7.4 X X 2x 1.1 4.6 95
Phenylbutazone 7.4 X 2x 22 100 0
7.4 X X 2x 2.2 10 90
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RESULTS FROM THE MOLECULAR FILTRATION STUDY AT pH 7.4
TABLE 26
Ratio of Concentrations % copper (II)
Cu : BSA : Other components bound to BSA
1 1 0 >99
1 1 4 Aspirin >99
1 1 2 histidine 65 + 2
1 1 2 threonine 94 + 1
1 1 1 histidine : 1 threonine 81 + 1
1 1 2 salicylic acid 97.5 ± x
1 1 2 Fenoprofen 95 + 1
1 1 2 Indomethacin 87 + 1
1 1 2 histidine : 2 Indomethacin 59 + 2
1 1 2 Naproxen 97 + 1
1 1 2 Ketoprofen 95 + 1
1 1 2 Phenylbutazone 90+1
4
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CHAPTER 8
DISCUSSION 17
For the purposes of discussion the work reported here will be
divided into its three major sections and the ’Challenge’ project
results will be discussed separately in Chapter 9.
Computer Models of Relevance to the Treatment of Lead Poisoning
The COMPLOT program and the formation constants whose determination
has been described in this thesis have been used to construct model systems
in order to evaluate the effectiveness of current and proposed treatments
for lead poisoning.
Plumbism can be diagnosed at blood lead concentrations of 2.89yM but, •
regrettably, levels considerably higher than this are common. Normal
levels of other species present in blood are shown in table 27.
Firstly, we considered the complexing of a representative amino
acid, serine, to the metals shown in table 27 in the presence of lead(II)
concentrations of O, 10 and 50pM. The formation constants used are
listed in table 28.
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TABLE 27
38Total concentrations of species used in blood plasma models
yM yM
Asparagine 43.9 Tryptophan 58.2
Aspartic acid 2.2 Mn(II) 0.73
Cysteine 108.0 Fe (II) 23.3
Glutamine 62.3 Co(II) 1.72
Histidine 81.5 Cu(II) 18.25
Phenylalanine 55.3 Zn(II) 45.88
Serine 106.5
Log formation
TABLE 28 -
constants for serinate complexes 73
pqr log 3pqr pqr log 3pqr
H 101 9.574 Cu(II) 110 8.950
102 12.133 210 16.230
Mn(II) 110 2.893 Zn(II) 110 4.898
210 4.791 210 9.279
Fe(II) no 4.299 310 11.909
210 7.377 Pb(II)* 110 4.948
310 10.299 210 8.145
Co(II) 110 4.584 310 9.873
210 8.568 * this work
310 11.554
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These models show that the lead(II) complexes are formed almost
entirely at the expense of the zinc(II) complexes.
17
Now all eight amino acids are considered complexing with zinc(II) 
and lead(II), the formation constants used being shown in table 29.
These calculations show that it is predominantly the zinc(II)- 
cysteinate complexes which are robbed by lead(II) to give high 
concentrations of lead(II)-cysteinate species. The zinc(II) which is
thus released is now free to complex with the other amino acids and,
indeed, increased concentrations of zinc(II) complexes, such as
zinc(II)-histidinate, are found. So we must realise that increased
concentrations of an essential metal ion’s complexes may be an
indication of the presence of a polluting metal ion.
We then consider the effect of the ligands D-penicillaminate(D-pen) 
and ethylenediaminetetraacetate(edta), which are currently used to treat 
lead poisoning, on the lead(II), zinc(II), cysteinate, histidinate
complexing system. The formation constants used in these models are
shown in .table 30.
In these models we find a high concentration of lead(II)-D-pen 
complexes, as we require, but also, unfortunately, a high concentration 
of zinc(II)-D-pen complexes. The concentrations of the lead(II)-cysteinate 
complexes decrease as the ligand is replaced by the drug. This allows
the zinc (II) to return to the cysteinate complexed forms again and so
these concentrations increase while the levels of the other zinc(II)
complexes fall because of the competition from the drug.
A very similar situation arises in the case of edta.
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TABLE 29
Log formation constants for amino acid anion*-proton, -lead(II) 
and -zinc(II) complexes
pqr log 3%qr pqr log 3 pqr
. 101Asparaginate 101 9.303 158Histidine H 101 9.630
102 11,888 102 16.600
Pb(II)* 110 4.902 103 18.882
210 7,802 Pb (II)* 110 6.901
310 8.841 210 9.797
Z (II)lSG Zn(II) IIO 5.070 _ ,__,158 Zn(II) 110 7.068
210 9.426 210 12.741
310 12.300 Phenylalaninate H^°^lOl 9.610
Aspartate H101 101 10.008 102 12.364
102 14.074 Pb(II)* 110 4.314
103 16.419 210 8.045
Pb(II)* 110 6.878 Zn(II) 110 4.863
210 10.014 210 9.598
111 12.695 73Serinate H 101 9.574
211 19.181 102 12.133
212 24.985 Pb(II)* IIO 4.948
112 . 16.167 210 8.145
157Zn(II) 110 6.379 310 9.873
210 11.539 ' 73Zn(II) 110 4.898
111 11.927 210 9.279
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Table 29 continued
pqr log pqr pqr log pqr
101Cysteinate H 101 10.709 310 11.909
102 19.493 158Tryptophanate :i 101 9.923
• 103 21.933 102 12.676
Pb(II)* 110 13.213 Pb(II) *110 4.517
210 18.571 210 9.580
111 17.347 Zn(II)158 110 - 5.013
211 27.476 ' 210 9.779
Zn(II)* 210 19.395 310 13.498
211 25.856
212 31.879
430 46.247
431 52.503
73Glutaminate H 101 9.640
102 12.361
Pb(II)* 110 4.132
210 7.083
310 9.805
73Zn(II) ' 110 4.826
210 9.165
310 11.843
* this work
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TABLE 30
Log formation constants for drug - proton, - lead(II) and
r?zinc(II) complexes
pq.r log pqr pqr log 3pqr
D-penicillaminate Ethylenediaminetetraacetate
H30 101 00.000 H* loi 9.060
102 19.612 102 16.100
103 22.044 103 18.680
Pb(II)* 110 14.321 104 20.953
210 19.049 Pb(II)* 110 15.186
111 17.723 111 18.010
211 27.978 Zn(II)* 110 14.873
Zn(II)30 210 20.521 111 17.965
211 26.794
212 32.724
430 47.582
431 53.826
21-1 8.563
* this work
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These results show that the drugs are insufficiently selective 
and that the -n vivo cysteinate seriously challenges the therapeutic
system.
For effective treatment of lead poisoning we require a ligand
which will be more selective than D-pen or edta, which is, preferably,
naturally occurring and so less likely to be toxic, and which is
easily degraded and excreted by the body. Glutathionate, blood
159 . .levels of which have been shown to be lowered during lead poisoning,
or indeed cysteinate itself, fulfills these criteria and so further
models were computed considering these as the added therapeuticals.
The formation constants used were those determined in this work.
The four ligands edta, D-pen, cysteinate and glutathionate were 
compared using the model system; [Zn(II)] = 45.88yM; [Pb(II)] = lO.OyM; 
and [ligand] = 20.0yM at pH 7.4, see table 31(a).
n
COMPLOT models were also computed over a range of lead.(II)
concentrations and glutathionate to lead(II) ratios, see table 31(b).
Thus the most effective ratio of glutathionate : lead(II) is 2 : 1,
the higher ratios removing more of the essential zinc(II). However, no
matter which ligand is used some zinc(II) will be removed and so will
have to be replaced by zinc supplementation. To be successful the
administered glutathionate would have to be kept in the reduced form,
perhaps by administering it along with a physiologically acceptable
reducing agent such as ascorbic acid. -
Although these computer models are a gross simplification of the 
situation 'n vivo, for example we assume that all of the metals are in
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TABLE 31
The selectivity of existing and proposed drugs for lead(II) over zinc ill)
[a) edta D-pen cys gsh
% zinc(II) complexed 33 10 9 14
% lead(II) complexed 50 lOO lOO 94
(b)
glutathionate : lead(II) 2:1
.. . ... -. A.. ......
1:1 3:1
c... "[lead (ill (Ml) 3.0 7.0 10.0
. 1 .. .IT. J-||
15.0 10.0 10.0
% zinc(II) complexed 5 10 14 19 3 25
% lead(II) complexed 83 92 94 96 76 97
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low molecular weight forms, they can narrow the field of possible
therapeuticals from random screening down to 'key' molecules for 
animal studies. However, one can not always extrapolate in vitro
r?
calculations to the clinical treatment situation and exhaustive
animal and clinical trials will always be necessary.
Structures of Some Lead(II) Complexes in Aqueous Solution
The thermodynamic functions for lead(II)-glycinate, -glycylglycinate, 
-glycylglycylglycinate, -cysteinate and -glutathionate complex formation, 
reported in Chapter 6, are used to suggest structures for the various
complexes present in solution.
GLYCINATE AND ITS PEPTIDES 
T60Evans and Monk , from potentiometric studies, suggested thiat
the binding of lead(II) to glycine peptides was through the amino group
and either, the nitrogen or oxygen atom of the first peptide link.
122 141Rabenstein and Libich , from n.m.r, stddee,, and Ngg and Banerjee ,
from polarography, show that nS low pH the metal is bound to the
carboxylate end of the ligand with She amino end still protonNted and
at high pH the amino end and the peptide oxygen are bound to the metal.
RNbenstedn and Libich consider that at high pH the carboxylate group
is probably also bound to the metal and that polynuclear complex
formation may be occurring. Their work also suggests that very little
ionisation of the peptide hydrogen can be present.
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From this work, table 18, we see that AH®®Qe values for glycinate 
and its peptides vary by less than 3 kJ mol 1, the differences in 
formation constants being entropy determined. This indicates that
the binding is the same in all three cases and so the peptides are
probably bound by their amino and peptide oxygen groups. The large
positive entropy change in the case of lead(II)-glycinate complexation
reflects the more effective charge neutralisation caused by bonding
of the carboxylate group), the smaller values for the peptides suggesting
that their carboxylate groups are not bound to the metal.
There are two bonding possibilities for the 111 species found at
lower pHs
(i) Binding of the glycinate by the carboxylate group 
to the lead(II) with the amino group protonated.
For the protonation of the glycinate amino group we 
found AH® = -51.2 kJ mol_1 and for lead(II)-acetate
complexation AH® = -0.25 kJ mol" 161has been reported
-51.4 kJSo for this type of binding we expect AH®( mol-l. 111
(ii) Binding of the glycinate by the amiino group to the 
•• lead(II) with the carboxylate group protonated. For
the protonation of the glycinate carboxylate group we 
found AH® = -9.0 kJ mol-\ For the binding of 
cadmium(II) to ammonia or ethylamine AH ~ -14.8 kJ 
mol“l 162,163 and we would expect the corresponding
value for lead(II) to be similar. So for this type -1-23.8 kJ molof bonding we would expect AH®®®
The value found experimentally for AH®®® is -25.1 kJ mol and so
it would appear that the second type of bonding is occurring contrary 
122to the view of Rabenstein and Libich .
In the species 111 in the case of glycylglycylglycinate it would
appear that it is the free carboxylate group that is being protonated 
but for glycylglycinate AH®®® is more negative than we would expect.
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The lead(II)-glycylglycinate system is also unusual in that a 11-1
species is not detected and a similar situation occurs in the case of
zinc(II)-glycylglycinate The reason for these differences is not
known.
In the lead(II)-glycinate 110 complex there are no ionisable protons
other than those of coordinated water molecules which may ionise to give
a lead(II)-hydroxy bond. For the formation of this bond Carell and Olin 37
found AH® between +20.9 and +41.8 kJ mol 1 and AS® between -81.1 and -1.1 J 
mol 1 K 1. These can be compared with our values for the reaction 110-11-1 
of AH® = +28.9 kJ mol 1 and AS® = -49.4 J mol 1 K 1 which certainly fall 
within these ranges.
In the lead(II)-glycylglycylglycinate system there is the possibility
that ionisation of the peptide proton is occurring with binding of the
peptide nitrogen to the metal. However, our values of = +37.0
—1 e —1 -1kJ mol and of AS^^^ _ _ = -16.8 J mol K still fall within the ranges
for lead(II)-hydroxy bond formation.
CYSTEINATE
For the lead(II)-cysteinate 110 complex we find a high negative 
enthalpy (-42.2 kJ mol S showing that bonding is not merely through 
the oxygen and nitrogen atoms as in the glycinate case but that the 
sulphur atom is also involved. The large positive value of AS® indicates 
that effective charge neutralisation has occurred and so both the sulphydryl
and the carboxylate groups are probably bound to the metal. The tridentate
nature of cysteinate towards lead(II) is also shown by its reluctance to
form a 210 species whereas zinc(II) forms a 210 in preference to a 110
speciesH. Tridentate binding of cysteinate to lead(II) but not to zinc(II) 
127-129,134,135.has also been proposed by other workers
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e -1For the reaction 110+111 we find AH = -14.5 kJ mol and there
are three bonding possibilities
(i) Nitrogen and oxygen atoms bound to leacl(H) with the 
sulphur atom protonated. For the binding of the 
glycinate N and O to lead(II) we have AH® = -12.4 kJ 
mol”1 and for the protonation of the cysteinate 
sulphydryl group we have AH® = -40.4 kJ mol"l. So 
for this type of bonding we expect AH®n ~ -52.8 kJ 
and so AH®,_ ,,, to be approximately -10,4 kJmol'
mol-1 110+111
(ii) Nitrogen and sulphur: atoms bound to lead(H) with the
carboxylate group protonated. For the reaction 110+111 
for the glycinate case, where the carboxylate group is 
being protonated, we have AH® = -12.7 kJ mol-1 and we 
would expect a similar value here.
(iii) Sulphur and oxygen atoms bound to the lead(II) with the 
amino group protonated. We would expect Ah® for the 
reaction 110+111 to be approximately equal to the enthalpy 
of protonation of the amino group (-38.8 kJ mol~1) minus 
the value for the binding of the amino group to lead(II) 
(-14.8 kJ mol”1) which gives approximately -24.0 kJ mol"1.
Thus our experimental value is closest to that for carboxylate
protonation but no definite assignment can be made.
For the 211 species, if we assume that one ligand is tridentate then 
© -1this leaves AH = -69.4 kJ mol to be accounted for. This is closest
to the expected value for the second ligand being bound to the metal
through the sulphur and oxygen atoms with the amino group protonated
-1 -1 i.e. -66.4 kJ mol for (iii) rather than -52.8 kJ mol for (i) or 
-55.1 kJ mol 1 for (ii).
GLUTATHIONATE
In the ligand glutathionate, I, there are eight sites through
which bonding to the metal ion may occur.
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NH OH.
3
0 0
' 5
I
' 164 'Fuhr and Rabenstein found no detectable binding of lead(II) to
group 2* but only to 2 snd to 1_ and 2 in some regions of pH. For example, 
they found 2 bound up to high pH where it was replaced by a hydroxy group. 
Also they found no evidence for lead(II) promoted ionisation of the peptide
protons.
The results reported here show more negative than for lead(II)-
cysteinate complex formation showing that more bonding is occurring. The
negative value of may be due to strain in the rings formed due to
this multiple bonding. To obtain such a highly negative enthalpy of
formation we believe, contrary to Fuhr and Rabenstein, that the amino 
group 2_ must be bound to the metal ion along with _1 and 2* To make up 
the remaining enthalpy, group 2 may be involved, as they suggest, or 
alternatively the peptide links. We have shown from our studies of
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glycine peptides that the oxygen of the peptide link rather than the 
nitrogen tends to bind to lead(II) and so groups 2 or £ are more 
likely to be bound than 4_ or 7*
For the reaction 110+111, for cysteinate we have AH® = -14.5 kJ
— 1 © “1mol and for glutathionate AH = -14.6 kJ mol suggesting that the
same process is occurring in each case, probably carboxylate protonation.
For the complex 211, AH® = -101.4 kJ mol whereas AH®^Q + AH®^
= -149.8 kJ mol . Thus, the bonding to the metal must be different
for the second ligand with fewer groups being bound, presumably for
steric reasons. If we assume that the first ligand is complexed as
in the 111 species then the binding of the second ligand has to account 
© -1only for AH = -19.2 kJ mol which is too low for the involvement of
both the nitrogen and the sulphur atoms.
For the reaction 211+212, AH = -42.1 kJ mol which would
correspond approximately to the protonation of a free nitrogen or
sulphur atom on the second ligand.
Antirheumatoid Arthritis Drugs
It is suggested that antirheumatoid arthritis drugs may function
by releasing copper(II) from serum albumin either by a direct competitive 
complexing mechanism or through a remote mechanism whereby the drug
becomes bonded to a site some distance from the copper (II) ion. It may
then facilitate the copper(II) release through allosteric effects
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possibly by distorting its binding site to a non-regular geometry so 
that circulating amino acid anions etc. can successfully compete with
the protein.
The order of potency of the drugs in rat adjuvant arthritis is 
54gxven as
Indomethacin > Naproxen > Ketoprofen > Fenoprofen (1)
>: Phenylbutazone > Aspirin
16!and the order of potency against carrageenan induced rat foot oedema as
Indomethacin > Naproxen > Ketoprofen > Phenylbutazone (2)
> Aspirin > Fenoprofen
These results are in remarkable agreement considering that (2) represents
activity against an acute inflammatory response whereas (1) is thought
to be a better mimic of chronic lesions.
The following conclusions can be drawn from the experimental results
reported in Chapter 7.
(i) The order of copper(II)-ligand complexing at pH 3.9 is
histidine >> salicylic acid > Indomethacin ~ Fenoprofen (3)
> Naproxen ~ Ketoprofen > Aspirin > Phenylbutazone
(ii) The order of copper(II)-ligand complexing at pH 7.4 is
histidine >> salicylic acid ~ Naproxen > Indomethacin (4)
> Fenoprofen ~ Ketoprofen ~ Phenylbutazone
(iii) The ability of the drugs to release copper (II) from bovine 
serum albumin by remote action is
Fenoprofen ~ Phenylbutazone > Ketoprofen > Indomethacin (5)
~ Aspirin ~ Naproxen
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(iv) The ability of the ligands to release copper (II) from
bovine serum albumin by either mechanism is 
histidine >> Indomethacin > Phenylbutazone > Ketoprofen (6)
~ Fenoprofen > Naproxen ~ salicylic acid > Aspirin
Clearly scheme (6) paraieels- scheme (1) with the exceptions
of Naproxen and Phenylbutazone whose positions are reversed. This adds 
support to the suggestion that antirheumatoid arthritis drugs exhibit 
a serum albumin copper (II) releasing effect -nn vivo.
Both of the nn vitro determinations of the copper (II) releasing 
properties of Naproxen and Phenylbutazone, (5) and (6) , are in agreement
concerning the relative efficacy of these agents but give the opposite
order to the biological trials, (1) and (2). Perhaps these two drugs 
act on arthritis by a different mechanism to the others. The relative 
ineffectiveness of Phenylbutazone according to schemes (1) and (1) is
not reflected by the large number of formulations of this agent listed
in the British Pharmacopoeia. This suggests that perhaps the animal
screening tests are not accurate models of rheumatoid arthritis.
Aspirin, as a copper(II) releaser from BSA directly, (3), or
remotely, (5) and (6), is virtually useless and it also is placed very
low in both potency orders, (1) and (2). However, Aspirin is by far
the drug in most common use in rheumatoid arthritis treatment and so
we see that much more information is required regarding its mode of
action. There is the distinct possibility that Aspirin is converted
into salicylic acid in plasma and then it could either have a direct
copper (.II) releasing effect, (3) and (4), or be removed as an
analgesic functioning through the central nervous system. There have 
166 167been literature reports ' that it is the 15% of the salicylic
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acid which is not bound to serum albumin that determines the drug
efficacy. .
1 Indomethacin, Fenoprofen and Ketoprofen are all capable of 
releasing bovine serum albumin bound copper(II) both remotely, (5) 
and (6), and directly, (3) and (4), although the latter mechanism is 
probably hindered by the competition from the high concentrations of 
amino acids present in vivo.
It would be of considerable interest to repeat these i-n vitro
studies with human serum albumin and to obtain further objective
evaluations of the relative drug potencies.
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CHAPTER . 9
"CHALLENGE" PROJECT - RESULTS AND DISCUSSION
Results
Formation constants for protonating glycinate and for nickel(II) 
O “h “glycinate complexing were determined at 25.0 C, I = 1.C0)M(Na )<Cl as
a contribution to the "challenge" project and the measurements were 
+ -repeated with I = 1.00M(Na )C10, in order to determine whether the 
background anion has a significant effect on the formation constants.
. The concentration limits set for the "challenge" project were
nickel(II) concentration between 1.0 and•lO.OmM and
glycinate to nickel(II) ratio less than or equal to 5 : 1.
The electrochemical cell used was
glass solution under study l.OOM
electrode I = l.OOM(Na+)C1~ Na Cl
AgCl(s) - Ag(s)
l.OOM NaCl
This system was calibrated, for each background salt, as in Chapter 5
and pw, was determined, as in Chapter 7, to give
pw, (l.OOM NaCl) = 13.68 and
pw, (l.OOM NaClO,X = 13.70
Our normal computational approach was adopted.
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GLYCINATE PROTONATION
I = l.OOM(Na*) Cl"
Experimental results are shown in appendix 5 - table 1 and in
figure 55.
The formation curves at different ligand concentrations are 
superimposable and the formation constants determined from these are
shown in table 32(a).
I = 1.00M(Na+)C104“
Experimental results are shown in appendix 5 - table 2 and in
figure 56.
The calculated formation constants are shown in table 32(b).
TABLE 32 •
■ • _ oLog formation constants for glycinate - proton interactions at 25 C
.(a) J = l.OOM (Na+) Cl
(b) I = 1.00M (Na^dO.
Mr log £pqr n
101 9.6379 + 0.0012 278
102 12.0448 + 0.0023
101 9.6558 + 0.0027 329
102 12.1232 + 0.0054
GLYCINATE PROTON INTERACTION 1M Cl’
2.0
Z-
BA
R
FIGURE 55 : ZPLOT OF DATA FROM APPENDIX 5 - TABLE 1
GLYCINATE PROTON INTERACTION 1M CL 0~
2.0
1.5-
1.0-
2-
Bf
iR
0.5-
0.0
8^0 lO.’O2,0 4,0 6.0
f>h(l,E,-LOG h )
12.’0
'J
0.
FIGURE 56 : ZPLOT OF DATA FROM APPENDIX 5 - TABLE 2
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NICKEL(II)-GLYCINATE INTERACTION
I = 1.00M(Na*)Cl"
Experimental results are shown in appendix 5 - table 3 and in
figure 57.
A spread of formation curves is found depending on the glycinate
to nickel(II)' ratio. The 'curl-backs’ found at high Z indicate the
presence of hydroxy species.
The complexes searched for were those with p O to 3; q 1 and r 
-2 to 1, those giving convergence being 110, 210, 310, 11-1, 21-1,
31-1 and 01-1 with log g values of 5.813, 10.581, 14.318, -3.30,
-0.65, 3.72 and -8.32 respectively. Arnek's 04-4 complex was
offered for computer refinement but no convergence was achieved.
A COMPLOT model of the system, figure 58, shows that the complexes
21-1, 31-1 and 01-1 are present only in small amounts at high pH and so
the values obtained for their formation constants- will not be reliable.
The computed log formation constants, their standard deviations 
and the number of experimental observations are given in table 33(a).
A simulated set of formation curves obtained from PSEUDOPLOT using
these formation constants is shown in figure 59 and gives a very good
fit to the experimental curves.
I = 1.00M(Na+)Cl04“
Experimental results are shown in appendix 5 - table 4 and in
figure 60.
These formation curves are very similar to those found in the
other ionic background and the same complexes were searched for.
Those which gave convergence were 110, 210, 310, 11-1, 21-1, 31-1 and
GLYCINATE-NICKEL INTERACTION 1M Cl"
5.0
aua~z
FIGURE 57 : ZPLOT OF DATA FROM APPENDIX 5 - TABLE 3
NICKEL-GLYCINATE MODEL
5.0
Ph
INi' 2 NlGly* .3 NlG-Ly, 4 NlGly” SNiGlyOT 6 NlGlyJOH!
?N|Gly,«W' 8 N <OH)‘ ’
FIGURE 58 : A COMPLOT MODEL USING THE FORMATION CONSTANTS 
FROM TABLE 33(a) PLUS LOG ^21_-L = -0.65, LOG £ x = 3.72
AND LOG g = -8.32 
01-1
5*0—r
GLYCINATE-NICKEL 1M Cl' PSEUDOPLOT
4.0-
0 O
o
2-
Bf
lR
FIGURE 59 : PSEUDOPLOT USING FORMATION CONSTANTS FROM TABLE 33(a)
GLYCINATE-NICKEL INTERACTION 1M CLD;
5.0-r
4.0-
G
3.0-
2-
Sf
lR
2.0-
1.0-
0.0-
0. 2.0
O o
.fflQ 12
V v
TKF4 V V
8.04.0 6.0
ha(I.E.-L0G a )
io;o 12.0
FIGURE 60 : ZPLOT OF DATA FROM APPENDIX 5 - TABLE 4
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Ol-l with log0 values of 5.895, 10.728, 14,516, -3.00, 0.61, 3.56 and 
-8.07 respectively. Again a COMPLOT model shows that the last three
of these complexes are not significant.
The results are summarised in table 33(b) and a simulated set of
formation curves obtained from PSEUDOPLOT using these constants is
shown in figure 61,
TABLE 33
Log formation constants for nickel(II)-glycinate complexes at 25 C
(a) I = 1.00M(Na+)Cl
pqr
110
210
310
11-1
log 3pqr
5.813 ± 0.020
n
349
10.581
14.318
-3.30 +
0.030
0.052
0.43
(b) I = 1.00M(Na )Cl0. 110 5.895 0.016 199
210 10.728 + 0.026
310 14.516 + 0.047
11-1 -3.00 + 0.35
Thus it would seem that formation constants are lowered slightly
by the use of chloride as the background anion.
Z-
BA
R
FIGURE 61 : PSEUDOPLOT USING FORMATION CONSTANTS FROM TABLE 33 (b)
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Discussion
Groups of workers from the Italian Universities of Florence,
Naples, Parma, Rome and Turin are taking part in the "challenge"
project. Results are not yet available from all of the groups but
those that are are summarised in tables 34 and 35,
Detailed experimental data is available only from Professor Paoletti’s 
group in Florence and this has been used in our ZPLOT program to give the 
formation (curves shown in figure 62. These results show
(i) curves of a lower gradient thnn this work
(ii.) none of the ’cur1-backs’ found in this work
(iii) one'displaced curve •
(iv) the curve levelling off at Z = 3.0 has been 
. achieved by using concentrations outside the.
originally set limits i.e. glycinate to 
nickel (II) ratio of 6 : 1.
The displaced curve, which was at the very high glycinate to
nickel(II) ratio of 11 : 1, can probably be assigned to an analytical.
or card punching error. However, a much more serious discrepancy is
the lack of ’curl-back’ on the Florence curves which in our work leads
to a formation constant for the 11-1 complex.
In St Andrews several repeat titrations and variations in the
computational input have been carried out but no experimental error
which could have been responsible for causing the ’cur1-backs’ has been
found.
For the lower ratios of glycinate to nickel(II) the Florence
titrations have been stopped at pHs less than 7 and no points at
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• TABLE 34
"Challenge" project - reagents and apparatus
ST ANDREWS CATANIA FLORENCE TURIN
Reagents and 
analyses
NaCl (Fisons A.R.) 
dried at 200°C
NaCl (C. Erba R.P.) 
dried
NaCl (Merck-superpure) NaCl prepared by bubbling 
HC1 into NaOH
NiCl^I^O analysed NiCl26H2O (C. Erba NiCl26H2O analysed NiCl2 prepared from the
by edta and electro­
deposition
R.P.) analysed gravimetrically by 
dimethylglyoxime
basic carbonate + HC1 and 
analysed photometrically
Gly(Fisons A.R.) Gly(C. Erba R.P.) Gly(Merck)
Meter Solartron LM1867 Radiometer PHM52 Radiometer PHM4A Metrohm E338
Reference
electrode Ag/AgCl Saturated calomel
Ag/AgCl Saturated calomel
Measuring
electrode Glass (Russell pH) Glass (Ingold)
Glass (Orion 91-01-00) Glass (Metrohm EA1O9/7)
Liquid
junction
Salt bridge, 1M NaCl Wilhelm bridge,lMNaCl Wilhelm bridge, 1M NaCl
Burette Piston (Metrohm E274) Piston (Metrohm Dosimat piston (Metrohm.Dosimat • 
E412) E415)
Microsyringe
Other Bubbling N^ through Bubbling N2 through N2 on surface N2
conditions solution.
Both cells at 25 C.
solution.
Single cell at 25 C. Both cells and room at 25°C. Both cells and bridge
at 25°C.
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TABLE 35
"Challenge" project -
pqr
101
ST ANDREWS
9.6379 + 0.0012
CATANIA
9.652 + 0.012
102 12.0448 + 0.0023 12.110 + 0.010
110 5.813 +0.020 5.600 + 0.015
210 10.581 +0.030 10.325 + 0.025
310 14.318 +0.052 13.650 + 0.040
11-1 • -3.30 + 0.43
results
a
FLORENCE ROME TURIN
9.6535 + 0.0024 9.67 + 0.04 9.656 + 0
12.0666 + 0.0033 12.14 + 0.06 12.076 + 0
5.6247 + 0.0045 5.53 + 0.03 5.625 + 0—“
10.3555 + 0.0070 10.26 + 0.04 10.398 + 0
13.7538 + 0.1251 13.58 + 0.05 13.911 + 0
'■J
014
010 •
01
04
087
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pH ■ >9.5 have been considered. Thus, probably, the titrations have 
been stopped before the 'curl-backs' occurred. The question now
arises - why was this the case?
In the work reported in this thesis a white lamp and light 
scattering was used to detect precipitates and a titration was 
discontinued as soon as precipitation occurred. No drifting in the 
emf readings was seen before the first sighting of precipitate.
Thus we believe that the data points in the ’curl-back’ regions 
do represent a true solution at equilibrium and so should be included 
in the computational analysis to give a formation constant for the
11-1 complex.
CHAPTER 10
CONCLUSION
*
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CHAPTER 10
CONCLUSION
As we have seen, the average concentration of lead in blood
plasma and its clinical threshold are very close to each other and 
so, in comparison to the low concentration of the in vivo essential 
metals, relatively large quantities of lead may have to be removed.
The accepted treatment for plumbism employs the calcium disodium
salt of ethylenediaminetetraacetate and D-penicillamine but these
are not particularly selective. .
We have thus suggested glutathione as an alternative therapeutical
and a considerable amount of work can still be done on this ligand
in vitro. Lead removal requires the presence of neutral complexes 
for effective lipid-protein membrane solubility and permeability and
COMPLOT models have shown that these are present in the lead(II)-
glutathionate system. However, partition studies involving n-octanol,
or another membrane model, would give a further indication of the
in vivo behaviour of lead- and essential metal-glutathionate complexes.
The use of a microcalorimeter would allow more accurate enthalpy
determinations and so improve structural predictions.
Animal experiments would then be necessary to establish such
factors as toxicity, dose-response relationships and excretion rates.
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Further in vitro work to find other lead specific ligands
which would be non-toxic in vivo would be of value, for example,
the determination of the formation constants of the complexes of
other short peptides containing a cysteinate residue.
Much more work on the interaction of drugs and metals with
serum proteins and on the composition of biological fluids and
tissues, in normal and pathological states, is also necessary in
order to allow us to improve the realism of our biological models.
This inclusion of protein binding necessitates a considerable amount
of alteration to computer programs to allow them to deal with such
a large number of electron donor groups and requires accurate amino
acid analyses of the major serum proteins.
As far as the • studies on rheumatoid arthritis are concerned, more
realistic animal models are required to compare the efficacies of the
drugs and double-blind trials on rheumatoid arthritis patients
themselves are necessary. In general, there should be an awareness
that many drugs interact with serum albumin and so may effect the
binding of metal ions to this protein. Even the mode of action of
Aspirin, , a very widely used drug, is not adequately understood.
We must remember that biological models can only be as accurate
as the data used to compute them and there is a great need for
accurate formation constants determined under standard conditions.
However:, at the same time, approximate formation constants are better
than none at all..
Further interlaboratory cooperation and the publication of detailed 
experimental data will enable steps to be made towards improving
techniques and so ultimately achieving more accurate models of
134
biological systems. These models, of course, are very far from 
completely predicting in vivo behaviour but they can, at least, 
suggest hopeful areas for clinical studies.
I
I
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APPENDIX 1 : EXPERIMENTAL DATA FOR LIGAND PROTONATION CONSTANT DETERMINATION
lalle 1 E3IEBIKERIAL E2TA fCB GLUTAMATE EHCTCNATICM
Tita. Starting Solution Titrating Solution Initial EO
lie. A role E i M H m K A mM E HIM H mM Vcl. ml HV
1 19.96 21.49 19.98 -80.06 20.0 1 4 5 1 . 1
2 9.979 10.75 9.988 -40.02 2 0.01 452.5
3 10.06 21. 48 9.973 -80.10 20.01 452.5
4 5.031 10,74 4.990 -40.08 20.01 45111
5 10.06 -40.05 10.10 21.48 20.01 4 5 1.1
Added E Added E Added E Added E
Vol.ml K V V C 1 . ID 1 mV Vol.ml mV Vol.Bll m V
Titraticn Nc. 1
0.20 322.6 6.40 190.2 13.75 48.8 17.00 -109.6:
1.C0 312.2 9.30 179.4 13.80 26.6 1.8.50 -12 2.5.:
1.80 301. 2 1C.CO 170.9 13.82 16.5 20.00 -132.7^
2.60 289.6 10.90 159.5 13.85 2. 4 22.00 -14 4 ,.8:
3.50 275.5 11.60 149.3 13.88 — 8.0 24.00 -156.5
4. 10 2 65.0 12.20 138.7 13.95 -24. 3 26.00 -168.7
4.70 253.2 12.70 127.2 14.05 -38.0 28.00 -183.1s
5.20 24 3.1 13.00 118.0 14.20 -50.8 30.00 -2CC .5:
5.80 ' 230.7 13.50 104.7 14.40 -61.8 32.10 -219.63
6.30 221.C 13.50 90.7 14,70 -72. 8
J
6.90 210.9 13.60 80. 1 15.20 -85. 1 ]
7.60 200.6 13.70 62.7 16.00 -98. 1 11
Titraticn Kc. 2
C. 1C 312.5 9.40 177.4 13.75 28. 6 16.30 -100.6i
1.20 300.8 1C.CO 170.3 13.78 14.0 17.30 -110.d,4
2.40 286.4 11.C0 157.5 13,81 1. 5 18.70 j-122.1
3.50 271.0 12.CO 141.8 13.85 -11.0 20 .-CO -130.6
4.30 257. 6 12.70 125.8 13.90 -21.9 22.00 -142.6
5. 10 242. 1 13.20 107.1 14.00 -35.8 24.60 -157.1
5.80 228.3 13-45 90.2 14.20 -52.0 27.00 -171.6■■4 ' 3
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Table 1 cent.
Added E Added E Added E Added E
Vcl.ml m V Vcl.ml m V Vcl.ml ml Vcl.ml IT V
Titration Kc. 2 cent.
6.50 215.7 13.60 72.0 14.40 -61.9 30.00 -190.8
7.20 205.0 13.65 62.4 14.80 -75.2 32.50 -207.2
8.20 191.8 13,70 48.6 15.40 -87.9
Titraticn Kc. 3
0. 10 3 42.4 5.90 219. 1 9.0 0 69.7 10.40 -113,5
1.CC '3 3 3.2 6.30 206,0 9.05 24.7 11.00 -127.3
2.CO 320 .4 6.80 191.8 9.10 -21.0 11.80 -143.5
2.80 307.7 7.30 178.3 9.15 -39.0 12.60 -160.1
3.50 294.3 7.90 160.9 9.20 -49.7 13.20 -174.5
4. 10 2 80.6 6.40 141.4 9.30 - 63. 5 13,90 -194.6
4.60 2 6 6 .9 8.70 122.8 9.40 -72.8
5. 10 2 49. 6 6.90 98.4 9.60 -85.5
5.50 2 34.0 8.95 87.7 10.00 -101.8
Titraticn Kc. 4
0. 10 3/4.9 6.20 205.4 • 8.95 68,5 10,00 -103.1
0.50 321.5 6.60 193.9 9.00 35. 1 10,40 -114.0
2.CO 30 5.9 7.00 183.3 9.05 -14. 1 11.00 -127.4
3.10 2 90.5 7.50 169.6 9.10 -35. 6 12.10 -148.5
3.90 276. 1 7.90 157.4 9.15 -47. 5 13.00 -165.9
4.60 256.9 8.30' 141.9 9.20 -55.7 13.80 -183.2
5.00 2 4 6 .6 8.60 124. 4 9.30 -67.4
5.40 2 3 2.2 £.80 104.6 9.50 -82. 3
5.80 218. 1 6.90 85.6 9.70 -92.0
Titraticn Kc. 5
9.50 -189.6 17.00 -68.0 18.90 62,4 23.00 160.8
10.00 -179.0 17.50 -76.9 19.10 83. 3 24.50 171.6
10.50 -169.7 18.00 -60.8 19.30 96.6. 26.50 183,5
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Table 1 cent.
Added E Added E Added E Added E
Vcl.ml mV Vcl.ml mV Vcl.ml mV Vcl.ml m V
Titraticn Kc, 5 cent,
11.00 -161.8 18.30 -43.8 19.50 106.2 29,00 156. 5
12,CO -148.8 18.50 -21.7 19.80 116.5 31.00 206 . 5
13.CC -137.6 18.60 0.4 20.00 121. 8 3 3,30 2 16. 1
14.00 -126.9 18.70 30.5 20.50 132.3
15.CC -116.C 18.75 42.7 21.20 142. 8
16.CO -103.8 18.80 51.9 22,00 151.9
Table 2 ■ EXEEBTMEKTAL EATA fCB ETHIEENEEIAKIKETETBAACETAIE
EBCTCKATICN
Titn. Starting Scluticn ' Titrating Solution Initial 1°
Kc. A mM I mM H mM A iM B mM H' mM Vcl. ml aV :
1• 10.00 24 .94 10.00 -50.04 2C.01 4 3C.&
2 5.001 12 .47 5.005 -25,04 2C.01 432,3
3 30.00 49 .91 29.98 -200.2 20.01 432.7
■■
4 7.9T67 — 40 • 06 124,6 20.01 4 3 4.6
Added I Added E Added E Added E
Vol.ml nV Vcl.ml m V Vol.ml mV Vol.ml m V
Titraticn Kc. 1
<3. 10 309.8 9.05 220.7 10.17 85. 3 15.50 -13.4
1.00 304.5 9.20 214.0 10.25 80.7 15.90 -19.5
1.60 300.8 9.30 2C8.3 10.45 71.5 16,30 -2(5.;
2.40 295.9 9.35 204,8 10.60 66. 1 16.60 -31.3'Ij
3.20 290.9 9.40 20 1. 1 10.80 59.9 16.90 -36.6:
4.CO 265.6 9.45 196.6 11.00 54.7 17.20 -41.8
4.80 279.9 9.50 191.4 11,20 50. 1 17.50 -47.2
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Table 2 cent .
Added I Added E Added E Added E
Vcl.nl nV Vcl.ml f i Vcl.ml mV Vcl.ml fi
Titraticn Kc. 1 cent.
5.40 275.3 9.55 185.1 11.40 45.9 , 17.80 -52.1
5.90 271.1 9.59 178.9 11.65 ' 41. 1 18.10 -56.9<
6.50 265.5 9.62 173.4 11.95 36.0 18.45 -62.2 >
7.00 260. 3 9.66 164.4 12.30 30.5 18.80 -66.9'
7.40 Z c c q2 5 5.5 9.70 153.7 12.60 26. 1 19.20 -72.0
7. 80 249.9 9.74 143, 1 13.00 20.7 19.60 -7 6,61
8. 10 245.0 9.78 132.6 13.40 15. 2 20.00 -80.94
8.35 240.3 9.82 123. 4 13.90 8.7 20.50 -85.9y
8.55 235.8 9.88 112.8 14.30 3.4 21.00 -90.5
8.75 230.7 9.95 103.7 14.70 -2.0
8.85 224.5 10.05 93.9 15. 10 -7.6
Titraticn Nc. 2 -
<.10 299. 1 8.60 227.8 11.15 51.2 17.70 -49.3?
0.50 297. 2 8.75 22 3.7 11,40 46.0 18,05 -55.0
1.CC 294.6 6.90 218.8 11.70 40.6 18.40 -60.2:
1.60 2'1.5 9.00 215.1 12.00 35.6 18.80 -65.7 1
2.20 288.3 9.10 210.7 12.35 30.2 19.60 -75.3
2.70 285.6 9.20 205.5 12.75 24.5 20.00 -79.;
3.40 281.5 9.30 199.1 13. 15 19. 1 21.00 -89,0
4. 10 277.4 9.45 185.7 13.55 13.8 22.00 -97.5
4.70 273.4 9.55 172.1 13.95 8. 6 23.00 -105.4
5. 10 270.6 9.6 5 151.7 14.35 3.4 24.00 -113.1
5.60 266.8 9.75 128.3 14.75 -1.9 25.00 -120.8
6. 10 262.7 9.85 111.3 .15,20 -8.2 26,00 -129.0
6.70 257.0 S.95 99.9 15.65 -14,9 27.00 -137,9j
7.20 251. 5 10.05 91.4 16.05 -21.1 28.00 -148.3,
7.60 2 '4 6.4 10.20 81.9 16,40 -26. 9 29.00 -161.%1
8.00 240.3 10.40 72.7 16.75 -32.9 30.00 -177.7
3
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latle 2 cent.
Added E Added E Added E Added E .
Vci. «1 O Vcl.il Hl Vcl.il iV Vcl.ml m V
Titraticn Sc. 2 cent.
8.30 234. I 14.75 61. 1 17.10 >-39.C
8.45 251.4 10.95 55.8 17.40 -44. 3
Titraticn Sc. 3,
0. 1C 303,7 4.80 173.2 10.50 -74.7 14.80 -156.9-
0.40 300.5 4.85 150.3 10.70 -78.8 14.95 -162.9:
4.70 297.3 4,88 134.3 11.00 -84. 4 15.05 -167.5: •
1.C0 29 4.0 4.91 122.5 11.20 -88. 1 15.15 -173.0'
1.30 290.6 4.98 104.8 11.45 -92. 4 15.20 -176.oi
1.60 287.2 5.04 95.0 11.70 -96.4 15.25 -179.4;
1.90 283.5 5.18 80.2 11,95 -100.4 15.30 -183.0:
.2 20 279.7 5.45 63.0 12.20 -104.4 15.35 -187.1J
2.50 275.5 5.80 48.9 12.50 -109.2 15.40 -191.7
2.80 271.0 6.50 29. 1 12.75 -113.2 15.45 -156.3:
3.CC 267.8 7.20 13.0 13.0-0 -117.2 15.50 -2C1.7J
3.20 26 4.2 8.20 -10.4 13.25 -121.5 15.55 -206.9
3.40 26C.3 9.20 -39.8 13.50 -125.9 15.60 -212.2J
3.60 255.9 9.-80 -57.8 13.75 -130.6 15.70 -222.4'
3.80 250.9 S.90 -60.5 14.00 -135.6 15.80 -2 30.4:
4.35 230.4 10.0 0 -63. 1 14.20 -140.2 ,]
4.60 211.9 10.15 -66.8 14.40 -145.2 1j
4.75 188.5 10.35 -71.5 14.60 -150.9
I
Titraticn Sc. 4
jj
3.85 -172.3 5.20 -32.5 6.51 145. 1 7.40 2 6 8.3'1i
3.88 -165.2 5,40 -9.6 6.52 156.6 7.70 276.d
3.92 -157.C 5.60 8. 1 6.53 166.5 8.10 284.7 i^
3.96 -150.C 5.72 17.5 6.54 175. 6 8.60 292.7j
4.01 -142.4 5.85 27.0 6.55 182.7 9.20 300.41
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Table 7 cent.
Added £ Added E Added E Added £ '
Vol.ml mV Vcl.ml mV Vol.ml mV Vol.ml mV
Titraticn Kc. 4 cent.
4.07 -124.9 5.98 37.0 6.57 . 194.3 10.00 308.5
4.14 -127.3 6. 13 49.9 6,59 202.4 10.80 315.1
4.24 -118.1 6.23 60.3 6.62 211.2 11.70 321.2
4.35 -109.1 6.23 74.0 6.67 221.3 12.70 326.7
4.47 -100.2 6.40 87.6 6.73 230.2 14.00 332.5
4.60 -90.6 6.45 102.9 6.81 238.7 15,50 3 37.7'
4.73 -80.6 6.48 118.2 6,91 246. 4 17.50 3 43,1
4.86 -69.9 6.49 125.9 7.05 254.6 •
4.98 -56.5 6,50 134.7 7.20 261. 3
Table 3 EXEEBIMENTAL EATA ECB GLUTAT8ICKATE EEC TCKATIGK
Titn. Starting Scluticn , Titrating Solution Initial £0
Kc. A mK E mM H mH A mM E mM H mM Vol. ml mV =
1 9.986 12. 47 9.986 -30.04 20.01 453.1
2 4.967 12. 47 4.986 -60.08 20.01 453.1
3 8.039 24. 94 8.CIO -150.1 20.01 453.4
4 1.998 12. 47 2.002 -60.08 20.01 453.5
Added E Added £ Added E Added £
Vol.ml mV Vcl.Bl mV Vol.ml mV Vol.ml m V =
1
Titraticn Kc. 1
I
0.20 318.6 11.00 24 1.5 21.00 154.6 22.45 19.d1
1.C0 313. 1 12.CO 2 35.2 21.30 145.5 2 2.60 1C.51
1.50 309.6 13.CO 229.0 2 1.60 132.5 22.80 1.6I
2.CO 305.9 14.00 222.8 21.80 1 19. 2 23.10
■4-7.91
3.00 298 .5 15.00 216.5 2 1.90 109.3 23.50 -17.C
I,1j
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Tatle 3 cent.
Added E Added E Added E Added E
Vcl.nl BE V Vcl.ml mV Vol.ml mV Vol.ml mV
Titraticn Kc. 1 cent.
4.CO 291.1 16.CO 209.9 22.00 94.9 24.00 -25.0
5.CO 283. 6 17.00 202.8 22.05 84. 8 25.CO -36.2
6.00 276. 1 18.CO 194.9 22.10 72.9 26.CO -44.1
7.CO 266.6 19.CO 185.5 22.15 60. 8 28.00 -55. 1
8. CO 261. 6 19. £0 176. 1 22.20 49.9 30.00 -62.8
S.CC 254.7 20. CO 173.4 22.25 41.5
10.CO 247.9 20.50 165.3 22.35 28.9
Titraticn Kc. 2
0.20 330.3 5.20 218.8 6.30 -3.2 1C.00 -129.2
1.C0 321.C 5.40 210.3 6.35 -14.9 10.60 -142.3
2.00 306. 1 5.60 2C0.2 6.40 -23.1 11.20 -158.3
2.50 296.7 5.80 187.5 6.50 -34.5 11.60 -172.1
3.CO 286. 1 5.90 179.0 6.60 -42.7 11.90 -183.9
3.50 273.4 6.00 167.5 6.80 -54. 3 12.10 -191.8
3.90 2 6 2.3 6.10 148.0 7.00 -62.9 12.40 -2C2.5
4.20 253.2 6.15 130.0 7.40 -76.2 12.70 -210.8
4.50 . 243.5 6.20 79.9 7.80 -86.2 13.10 -219.1
4.5C 243.5 6.22 44.7 8.30 -97.C
4.80 233.6 6.25 17.2 8.90 -108.5
S.CC 226.6 6.27 7.4 9.50 -119.7
Titraticn Kc. 3 1
0.20 348.6 3.50 245.9 4.65 -20.2 7.00
4
-143.4
0.60 343. 1 3.70 234.8 4.70 -31.2 7.10 -148.4i
1.CC 336.3 3.90 222.9 4.75 -39. 1 7.20 -154.CIj
1.40 328.C 4.CO 216.3 4.85 -50.2 7.30 -160.2<rj
1.80 318. 1 4.10 208.7 4.95 -58. 6 7.40 -167.^J
2. 10 308.9 4.20 199.9 5.10 -68.6 7.50 -175.*;
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latle 3 cent.
Added 5 Added Z Added E Added E
CJ.Rl E V Vcl.h1 i V Vcl.wl mV Vol.ml iV
Titraticn Kc. 3 cent.
2.30 301.9 4.30 189.0 5.30 *-79.1 7.60 -185.0.
2.50 294.2 4.40 173.1 5.50 -87.9 7.70 - 194.6
2.70 285.9 4.50 139.9 5.80 -99.0 7.80 -2C3.8
2,90 277.0 4.54 87.4 6.10 -109.5 7.90 -211.8'
3. 11 266. 8 4.58 9.7 6-40 -12C.C 8.10 -223.8
3.30 256.9 4.60 -2.2 6.70 -130.9 8.30 -232,%
Titraticn Kc. 4
2.CO 315.7 4.55 210.5 4.98 -30. 4 6.10 -122.9
2.50 306.7 4.65 197.5 5.02 -40.2 6.30 -135.1
3.CO 295.2 4.70 189.6 5.06 -47,7 6.45 -145.6
•3.40 282. 5 4.75 179.1 5. 10 -53.8 6.55 -153.5
3.6C 274.6 4.80 163.3 5. 15 -60.0 6.65 -162.2
3.80 265.3 4.84 140. 1 5.20 -65.5 6.75 -171.1
4.CO 2 54.2 4-86 115. 1 5.30 -74. 6 6.85 -181,2
4. 15 24 4.4 4.8 8 57.3 5.40 -82. 1 6,95 -189.2
4-25 237.1 4.90 13.2 5.55 -92.0 7.05 -196.0
4.35 229.3 4.92 -4.9 5.70 -1CO.6 7.20 -204.1
4.45 220.6 4.95 -20.2 5.90 -111.6
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Table 4 EXEEBIEENTAL tATA BOB GLYCINATE PBCTONATICB
Titn. Starting Scluticn Titrating S olution In itial E°
Kc, m mM E eK h mM A mM E hK H eK Vol. ml nl
1 39.90 26 .83 -39.90 24.98 457.7
r?2 33,9C 26.83 -39.90 24.98 457.7
3 U0. <0C -39 .90 53.60 24.98 410.3
Added B Added E Added . E Added E
Vol.El mV Vcl.ml ID V Vcl.ml El Vol.ml mV
Titration Kc. 1
0.0 307.8 7.00 282.0 18.40 -62.1 28.00 - 133.%
1.CC 304.5 8.CO 277. 9 19.00 -73.8 30.00 -140.9
2.CO 300.8 10.00 268,9 20.00 — 86.8 32.00 -14 8.5
3.00 297. 1 14.00 243.4 21.00 -95.9 34.CO -156.3
4,00 293.4 16.00 215.5 22.00 -103.3 36,CO -16 4,6
5.00 289.7 18.CO -49.8 24,00 -115.1
6.00 285.9 18.10 -53.6 26.00 —124.6
Titraticn Kc. 2
0.0 306. 1 16.85 166.3 17.20 4.8 22,00 -105.4J
2.00 300.7 16.90 158,4 17.22 -0.4 24.10 -1-l'.1.
4.CO 293.4 16,95 148.0 17.25 -6. 6 26.00 -126.31
8.00 277.8 17.00 133.0 17.30 -14.6 28.00 -134.6
12. CO 257.8 17.05 108.8 17.40 -26.0 30.CO -142.4
14.00 242.5 17.07 93.3 17.60 -39.7 33.00 -153.9'
15.CO 231.C 17.08 83.4 17.80 . -48, 8 36.00 -166.2i1
15.60 221,2 17. 10 63.9 18.CO -55. 8 38.00 -175.4i
16.CO 212,3 17.12 45.6 18.40 -66. 1 40.CO -186.1j
16.35 200.9 17,14 30.1 19.00 -76.6 :}
16.55 191.6 17. ■ 16 19.6 20.00 -68. 8
'i
J
16.70 181.7 17.18 10.9 21.00 -98. 1 1
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Table 4 cent.
Added E Added 2 Added E Added E
Vol.ml mV Vcl.ml mV Vcl,ml mV Vcl.ml fi
Titration Kc. 3
0,0 -260. 1 14.50 --151.3 18,04 -5,0 18.60 137.0
0,50 -253.3 15.50 -•140,4 18.06 2.5 18,70 145.5
1.50 -241,4 16.50 -•124,6 18,08 9, 3 18.90 157,3
2.50 -231. 6 16,90 -•115.4 18.10 1l.fi 19.20 169.0
3,CO -227.2 17.20 --107.2 18, 15 29.2 19.50 177.2
4,CO -219.6 17.50 -95.3 18,20 42,9 20,00 187.1
5,50 -209.6 17,65 -86.7 18,25 57, 2 20,50 194.4
6,50 -201.9 17.80 -72,4 18,30 72,7 21,00 200.4
8.CO -193, 6 17.90 -56.3 18.35 89.3 2.2.00 21C.1
10.00 -182.5 17.95 -43,2 18,40 104.5 24.10 2 24.8
12.CO -170.6 18.CO -23,4 18,45 116. 1 26.10 235.5
13,00 -163.7 18.02 -13,9 18.50 124.8 28.00 244,1
Table 5 UEEBIKEBTAL EATA ECE GL1CYLG1YC1NATE EECTCNAT-ICK
Tim. Starling Scluticn Titrating Scluticn Initial E° ‘
Kc, A Jf E ttM H 1M A bK B fi H mM Vcl. ml mV
1 37,10 26. 80 -39.90 24,98 409.6
2 37,40 -40. 00 53.60 24,98 409.
3 99,71 -200 ,0 99. 75 268,5 20,01 453.!
Ad ded E Added E Added E Added E ,
Vcl.ml mV Vcl.ml mV Vcl'al ffll Vol.ml m V
Titration Kc. 1 •
0,0 220.5 15,60 128.5 17.30 15.2 26.00 -86,
0.50 218.4 16,00 119,6 17,40 7.4 28.00 -9 5;
3.00 207.6 16,30 110.2 17,55 -1.5 30,00 -104.
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Table 5 cent.
Added E Added E Added E . Added E
Vcl.nl Vcl.ll mV Vol.ml mV Vol.ml mV
Titraticn Kc. 1 cent.
5.5C 196.9 16.50 101.9 17.70 — 8. 3 32.00 -113.0-
7.00 190.6 16.70 89.9 17.90 -15. 3 34.CO -12 2.6'
9.50 179. 1 16.85 76.4 18.25 -24.6 36.CO -13 3 . 98
11.5C 168.5 16.95 64. 1 18.70 -33.2 37.50 -144.6
13.00 158. 4 17.05 47.6 20.00 -49.8 38.50 -153.7;
14.00 149.8 17. 10 39.4 21-00 -58. 4 39.30 - 16 3. G!
15.00 138.3 17.20 25.4 24.00 -76.9
Titraticn Kc, 2
1.30 -19 3. 4 12.00 -85.9 18.50 56.9 2-150 15 9.0
1.50 -184.8 13.50 -75.6 18.60 72.7 23.00 172.2
1-90 -172.6 15.00 -63. 1 18.70 85.5 25 .CO ’ 185.8
2.50 -160.0 16.00 -52.2 18.80 94.9 27.00 197.5
3.00 -152. 1 17.00 -36.4 18.95 105.5 29.00 2 08.6
4.00 -140.5 18.00 -2.7 19. 15 115.3 30.00 214.4
5.00 -1*31. 4 18.20 13.8 19.40 124.2 32.00 226.2
6.50 -120.1 18.30 25. 1 19.80 134.4 34.CO 239.0
8.00 -110.4 16.40 40.0 20.00 138.5 36.00
•j
5 5 2.2
10.00 -98.4 16.45 48.2 20.50 146.8 36.C0 263 .E
Titration Kc. 3
5.35 -160.7 8.50 -69. 1 14.50 56.0 16.CO 18 5.(
5.45 -148. 3 9.50 -57.4 14.60 77.4 16.50
1
193. j
I
5.55 -139.4 10.00 -51.9 14.65 91.4 17.50 205.‘•
5.70 -129.8 11.00 -40.6 14.70 105. 4 19.00 219-1v
5.90 -120.0 12.00 -28.0 14.80 125.9 20.10 2 2 6.?
6.20 -109.4 13.00 -11.8 14.90 138.7 22.10 238 .41
6.50 -101.3 13.50 -0.5 15.00 147.4 24.10 249.1
7.00 -91.0 14.00 16.0 15.20 159. 6 27.10
5 6 4.1
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Tatle 5 cent.
Added E Added E Added E A dsd e d E
Vol.ml mV Vcl.ml mV Vcl•El mV Vol.ml mV
Titraticn Kc, 3 cent,
7.50 -82.6 14.30 33.4 15.50 171. 4 30.10 281.
Tafcle 6 EXIEBIMENTAL IATA EOE GLICILGLyCYLGLICINA'IE 
EBCTCKA1ICN
Titn. Starting Scluticn Titrating 5 elutien Initial E°
Kc. A mK E &K H mM A mM E mM H mM Vol. ml mV
1 40.’70 -40 .00 53.60 19.99 454.3
#•»z 40.30 53 .70 -39.90 24.98 452.8
3 40.30 53 .70 40.10 -40.00 ■19.99 454.4
Added E Added E Added E Added E
Vol.ml mV Vcl.il mV Vol.ml mV Vol.ml mV
Titraticn Nc, 1
0.80 -157.5 7.50 -56.9 14.60 68.8 16.30 180.1
1.C0 -145.7 9.CO -45.4 14.70 83.2 17.20 194.4
1.40 -129.7 10.50 -32.5 14.80 99.4 18.50 208.8
1.80 -119.C 12.00 -16.8 14.90 114.8 20.CO 221.8
2.40 -107.0 13.00 -2. 1 15.00 126.9 22.00 236.6
3.40 -93. 1 14.00 23.9 15.15 139.9 24.CO 251.0
4.50 -81.5 14.25 36.6 15.35 151.7 ■i
6.CO -68.5 14.45 52.0 15.70 165. 3
I
Titraticn Nc. 2
0.5C 338.8 22.00 232.5 33.80 69.2 50.00 -72.6I
2.00 333.7 24.00 224.3 34. 10 49. 3 52.CO
J
-83.6
■ia
4.00 325.9 26.00 215.2 34.60 30.7 54.00 -96.3
6.CC 317.8 28.00 204.3 35.40 14. 5 56.00 -116.9
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Table 6 cent.
Added E Added E Added E Added E
Vol.ml mV Vcl.ml mV Vcl.ml fV Vol.ml mV
Tiliatiii Kc, 2 cert.
8.CO 306.9 30.CO 189.9 36.00 6.1 58.00 -158.7
10.CC 294.0 31.CO 179.9 37.00 -4.5 58.40 -170.3
12.CO 280.5 32.CO 165.2 39.00 -19. 5 58.80 -18C."
14.0 0 26 8.2 32.50 154.0 40.00 -25.5 59.40 -192.3
16.00 256. 1 33.00 136. 1 42.00 -35,9 50,00 -2CC.G
18.00 2 49.0 33.30 117.4 44.OG -45.3
20.CO 240.6 33.50 98.9 46.00 -54. 1
Tilralicn Kc. 3
l.CC 338.3 12.CO 232.8 26.30 127.8 30.CO 18.3
2.50 323.5 14.00 223.4 26.70 110.0 31.50 7.6
3.50 31C.C 16.00 214.5 27.00 9 2.0 33.20 -C. 8
4.50 294. 4 18.50 20 3.0 ‘ 27.20 79.5 35.00 -7.6
6.GO 274.2 20.CO 195.6 27.50 64. 3 36.CO -10.8
7.CO 264. 1 22.50 180.4 27.90 50.3
8.50 252.5 24.00 168.0 28,50 36.9
10.00 243.2 25.40 149.8 29.50 23.2
APPENDIX 2 : EXPERIMENTAL DATA FOR LIGAND-METAL COMPLEX FORMATION CONSTANT 
DETERMINATION .
Tatle 1 IXIEEIC5KTAL lATA
Titc. Starting Scluticc
Kc. A kS 5 itM H .cK
1 19.94 4.9O9 9.016
z 9.952 4.909 9.0 16
3 E. 142 4.909 9.016
4 20.21 2.45 6 4.5 1C
5 10. 16 2.456 4.510
6 Z .E7C 4.907 9.012
Added 5 Added E
Vcl.ml nV Vcl.%1 eV
Titratier Kc, 1
0.1C 2 87.4 11.60 185.4
1.CC 28 1- 2 12.40 175.2
2.CC 273.5 13.50 156.6
3.CO 265.9 13.90 147.6
5.CC 2 4 8 .3 14.30 13 6.4
6.CC 2 39 .C 1 4.60 126.7
7.CC 2 2 9 .8 14.80 119.8
7.9C 221.6 15.20 105.5
S.EC 2C6.9 15.40 9 8.j
1C.CC 2C2.1 15.6C 90.S
ic.ec 19 4.2 15.80 63.5
Titraticr Kc. z
0.1C 3CC.2 7.30 2 0 2 .8
1.CC 2 9 2 .7 8.3C 18 1.8
2.CC 283.1 8.70 171.3
2.8C 2 7 4.2 9.CC 16 1.3
3.EC 2 6 5 .2 9.55 136.6
4. 9C 2 4 4 .C 9.7C 128.6
5 • E C 2 3 4 .C 9.8 0 12 3.2
EC5 ieae-aseabtate ikteeactice
Titrating Scluticn Initial E°
A nM E rnK H EM Vcl. k i nV
-40.07 2C.01 438.0
-40.07 2C.01 438.0
-40.07 2C.01 43 8.4
-40.07 2C.01 438.7
-40.07 20.0 1 43 8.6
-40.07 2C.01 438.5;
Added E Added e ;
Vcl.ml EV Vcl.ml g V j
16.20 67.4 17-23 -39.8
16.40 58.C 17.27 -46.5'
16.60 46.9 17.35 -56.7
16.70 40.3 17.40 -61.7!
16.90 . . 22. 1 17,45 -66.0
16.95 15.9 17.55 -73.0
17.CC 8.7 17.7C -80.8
17.C5 -0 .8 17.90 -8 6.7;
17.13 - 18.7 18.1C -95.1J
17.16 - e cZ-.5 18.40 -1C3.3
17.2C -34.C J1t
1C.2C 102.7 11.7C 2 6.8
1C.3C 97.8 11.80 17.6
10.4C 93.3 11.85 11.S
1C.EC 88.8 12.CO -1C.1
10.80 75.7 12.C5 -19.5
1 l.CC 66.8 12.C9 -26.3
11.15 59.8
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1 a i 3 e 1 cent.
Added E Added E Added E Added E
Vol.ml m V Vcl.ml mV Vol.ml mV Vol.ml mV
Tilralicn Nc, 2 cent.
r?
6. 10 223.9 9.90 117.9 11.30 52.2
6.70 213.6 10.10 107.6 11.60 34. 3
Titraticn Nc. 3
0.10 309.0 5.30 224.7 7.30 128. 4 8.60 51.0
1.00 301.3 5.90 206.0 7.50 111.9 8.75 4 4.3*
2.CO 291.0 6.20 195.4 7.60 104.8 9.00 32.7
2.80 280,7 6.45 185.3 7.70 98.4 9.10 27.6
3.40 271.1 6.70 173.3 7.85 89. 3 9.30 16.9
4.30 2 5 2.2 7.GO 154.0 8.15 73. 1 9.50 4.5
4.70 241.9 7.10 145.8 8.30 65. 5 9.60 -2.2^
5.00 233.5 7.20 137.3 8.45 58. 1
Tilralicn Kc. 4
0. 10 270.0 11.70 141.2 13.50 23.8 13.89 -62.3
1.00 262.5 12.00 131.0 13.54 13. 8 14.05 -74. f
2.00 253.4 12.50 108.0 13.60 -5.9 14.15 -79.6
3.50 239.2 12.70 97.0 13.63 -16.5 14.30 -66.3
6.CO 216. 1 12.85 88.0 13,65 -23.3 14.50 -93.5
7.20 205. 1 13.00 78.4 13.67 -28. 4 15.10 -108.1
8. 40 193.5 13. 15 67.2 13.74 -43. 6 15,50 -116. l
10.60 165.8 13.40 41.2 13.78 -49.9 i
11.20 154.2 13.45 33.4 13.83 -56.2
Titration Nc. 5
0. 10 279.4 6.80 156. 1 8.10 70.5 8.66 -23.5
1.00 268. 1 7.00 147.1 8.20 62.2 8.68
1
-31,41
1.70 257,8 7.20 135.9 8.30 52.8 8.72 -44.7
2.40 246.4 7.30 129.5 8.40 41, 4 8.74 -50.C
3. 10 234.5 7.50 115.3 8.45 34.7 8,77 -56.4
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Table 1 cent.
Added I Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml rV Vol-ml mV
Titraticn Kc. 5 cent.
4.30 213.7 7.60 107.9 8.50 26.2
r?8.80 -61.4
4.90 203.3 7.70 100.-5 8.55 15.4 8.90 -72.9
5.50 191,7 7.80 93.3 8.61 -3. 1
6.00 180.7 8.00 78.5 8.63 -10.8
Titraticn Kc, 6
0. 10 313.9 4.80 227.6 5.85 142.0 6.22 94.8
1.0 0 306.5 5.25 202.3 5.90 134. 3 6.40 79.9
2.80 285.6 5.40 191.9 5.95 126.6 6.55 70.3:
3.40 274.7 5.55 179.4 6.05 113.0 6.85 56.8'
4.30 249.5 5.65 169.4 6.10 107.0 7.00 51.6
4.60 237.0 5.80 149.8 6.15 101.7
Table 2 EXIEBIMENTAL EATA BOB LEAD-CYSTEINATE INTEEACT3CN
Tit n. Starting Solution Titrating Solution Initial E°
No. A biM E mM H mM A mM B rnM H mM Vol. ml mV
1 7 .994 0.981 1. 802 -20.02 20.01 448.6
2 4.889 0.981 1. 802 -20.02 20.01 452.8
3 2 .031 0.980 1. 802 -10.01 20.01 4 52.7
:l
Added E Added E Added E Added £
Vol.ml mi Vcl.ml mV Vol.ml mV Vol.ml m V <
Titraticn Nc. 1
0. 10 263.4 3.67 143.2 3.97 53. 1 5.90 -30.5
1.00 245.3 3.69 138.7 4.01 47.5 6.30 -38.1
1.90 218.9 3.71 133.3 4.05 42.8 6.80 “46.5
2.40 204.7 3.73 126.5 4. 10 37.6 7.30 -53.9
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Table 2 cent.
Added E Added E Added E Added E
Vol.fl i V Vcl.ml mV Vol.ml mV Vol.ml mV
Titraticn Nc. 1 cent.
2.60 19 9.3 3.75 118.3 4. 17 31.4 7.80 -61.2
2.80 193.8 3.77 109.2 4,25 25. 4 8.30 -68.4
2.95 189.2 3.79 100.0 4.3 5 18.9 8.8 0 -75.6
3.10 ' 184. 1 3.81 91.9 4.4 5 13. 2 9.40 -84.4
3.25 178.2 3.8 3 8 4.5 4.60 6.2 10.00 -9 3.7
3.35 173.4 3.85 78.0 4.75 0.2 10.60 -103.7
3.45 167.5 3.87 7 2.4 4.90 -5.0 11.20 -113.8
3.55 159.6 3.89 67.5 5. 10 -11.3 11.80 -125.0
3.60 154. 3 3.91 63.4 5.35 -18,2
3.65 147. 1 3.94 57.7 5.60 -24. 2
Titraticn Nc. 2
0.10 273.0 2.01 214. 6 3.70 115. 6 7.90 -106.1
0.30 269.6 2.12 210.8 3.75 88.5 8.10 -111.9
0.50 265.6 2.27 206.0 3.80 66.3 8.30 -117.9
0.70 261.2 2.42 201.4 3.85 52.6 8.50 -124.O-
0.90 256.2 2.60 196. 1 3.95 35. 5 8.70 -12 9.9.
1. 10 250.1 2.80 190.3 4,15 14.8 8,90 -136.0
1.25 244.9 3.00 183.9 4.35 1. 2 9.10 -141.8
1.35 241.0 3. 10 180. 3 4.80 -19.6 9.30 - 1 47.6
1.45 236.9 3.20 176. 1 5.40 -39.5 9.50 -153.1
1.55 232.7 3.30 171.6 6,10 -58.4 9.70 -158.2
1.65 228.5 3.40 165.9 6.80 -76.5
1.77 223.6 3.50 158.3 7,50 -94.9
1.89 218.9 3.65 135.7 7.70 -100.4
TitraticD Nc, 3
t
1.40 270.3 3.40 224.6 5.30 182.9 7.80 26.0
1.80 264.7 3.55 219.5 5.80 174.8 7.90 11.6
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Table 2 cent.
Added E Added E Added E Added E
Vol.ml IV Vol.ml mv Vol.ml m V Vol.ml m V ;
Titraticn No, 3 cent.
2.10 259. 7 3.70 214.9 6.40 164.0 8.CO 0.9"
2.30 255. 9 3.90 209.6 6.80 154.9 8.20 -14.8^
2.55 250. 4 4.10 204.8 7.30 135.2 8.50 -32.1
2.75 • 245. 4 4.30 200.4 7.50 112. 6 8.90 -50.4
2.95 239. 7 4.50 196.5 7.60 82.4 9.40 -70.5:
3.10 234. 9 4.70 192.9 7.65 63.6
3.25 229. 8 4.90 189.5 7.70 48.1
Table 3 EXEEBIMEKTAL EATA ECE ZINC-CYSTEINATE INTERACTION
Titn. Starting Scluticn Titrating Solution Initial £ 0
Ko. A IM E mM H mM A mM B mM H mM Vol. ml mV 1
1 4.658 2.354 4.72 2 -20.00 20.01 453.4
2 9.448 2.354 4.72 2 -20.00 20.0 1 453.8"
3 14.11 2.354 4.722 -50.04 2C.01 45 3.4<
4 2.379 2.356 4.726 -20.00 20.01 4 53.6j
5 9.415 4.711 9.450 -50.04 20.01 4 52.8'
6 4. 724 2.354 4.72 2 -20.02 20.01 4 48.8]
7 11.76 2.354 4.722 -20.02 20.01 4 50.0
Added E Added E Added E Added
'I
E i
Vol.ml mV Vcl.ml mV Vol.ml mV Vol.ml m V
Titration Nc. 1 ■1I
4.65 187. 3 4.90 146.3 7.50 103. 8 12.70 29.9j
4.68 179. 5 5.00 140.3 8.50 94.8 13. 10 17.7
4.70 174. 4 5.15 134. 1 9.50 84.7 13.40 3.«
4.72 169. 5 5.30 129.8 10.00 78. 9 13.60 -12.7
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Tatle 3 cent.
Added
Vol.ml
E
HtV
Added
Vcl.ml
E
mV
Added
Vcl.ml
E
mV
Added
Vcl.ml
E
mV t;
Titraticn Kc. 1 cent,
r?
4.74 165.3 5.50 125.5 10.70 69.3 13.82 -61.7
4.77 160.3 5.90 119.5 11.30 59.6 13.90 -80.9
4.80 156.0 6.40 113.9 11.90 48. 3
4.85 15C.5 6.90 109.2 12.30 39.8
Titraticn Kc, 2
4.56 200.8 6.00 133.5 13.60 39. 1 16.90 -65.3?
4.60 195.6 7.00 123.6 14.00 24. 9 17.40 -75.8
4.65 188.7 8.CO 115.6 14.30 9.9 17.80 -84.7
4.72 178.6 9.50 102.9 14.50 -0.4 18.20 -94.5?
4.78 171.8 10.50 92.3 14.80 “13.2 18.60 -105.3-
4.85 165.3 11.30 81.5 15.10 “23. 5 19.00 - 116 . r
4.95 158.6 12.00 70.4 15.50 “34.9 19.30 -125.3^
5.15 149.9 12.60 60.2 15.90 “44.3 19.60 -133.4
5.40 143.2 13. 10 50.9 16.40 “55. 1 20.00 -143. 1;
Titraticn Kc, 3
1.80 201.6 3.30 125.0 5.65 23.8 8.00 -71.3
1.83 194.2 3.70 116.3 5.75 14. 4 8.40 -82.6
1.86 187.2 4. 10 105.2 5.85 6.2 8.75 -93.4
1.90 179.0 4.40 93.8 5.95 “1. 1 9.05 -103.6!
1.95 171. 1 4.60 84.8 6.10 “10.5 9.30 -112.9
2.00 165.4 4.80 75.7 6.30 “20. 5 9.55 -122.5+
2. 10 157. 4 5.00 66.3 6.55 -30.4 9.85 -133.3!
2.25 149.9 5.20 56. 4 6.90 -41.7
1•
2.50 141.8 5.40 44.4 7.20 -50.2
2.80 135.0 5.55 32.9 7.60 -60.9
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latle 3 cent. '
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m V i
TitratieD Nc, 4
4,73 153.1 4.90 131. 1 5.85 105. 5 8.05 - 75.4’
4,76 146.7 5.05 123.0 6.60 95,8 8.50 65.8J
4,80 140.7 5.35 114.1 7.40 85.5
, T.ilraticn Nc. 5
3,74 183.8 3.82 169.4 4.15 147.8
3,78 ’175.6 3.95 157.5 4.45 139. 6
Titraticr Nc, 6
4,70 155.9 5.50 120.6 10.00 75. 1 12.80 24.6
4.72 153.0 5.80 116.3 10.40 69.9 13,00 19.1:
4.75 149.4 6,20 111.8 10.80 64. 1 13,15 14.2:
4.78 146.3 6.60 107.8 11.10 59.3 13,35 6,4!
4.82 143.0 7. 10 103.3 11.30 55,9 13.50 - 1.2
4.89 138, 4 7.60 99.0 11.60 50.4 13.60 -7,7
4.97 134.5 8. 10 94,7 11.85 45.7 13,70 -16.4
5,07 133.6 8.60 90.1 12, 10 40,7 13.75 -22.5
5.18 127.3 9. 10 85.2 12.35 35, 3 13.80 -30.5
5.30 124. 4 9.50 80.9 12.56 30.5
Titraticn Nc, 7
4.50 195.7 7.45 120.8 13,30 45.3 15.70 -30.4
4.55 190.1 8. 10 115,6 13,50 40.3 16.00 -36.0
4.59 185. 4 8.70 110.7 13,70 34.6 16.25 -40.4
4.64 179.7 9,30 105.6 13.85 29,7 16,55 -45.21J
4.68 175.5 9.80 1C0.7 14.00 24.2 16.90 -50.5
1
4.73 170,7 10.00 98,6 14.10 20.0 17.20
1-54.8
j
4.78 166. € 10.70 90.1 14.20 15.8 17.60 -60.Sj
,4.87 161,0 11.00 85.9 14.35 9.3 17.95 -65.2
4.98 155.7 1 1.30 81,3 14.45 5,1 18,35 -70.8
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Table 3 cent *
Added E Added E Added E Added E
Vol.ml mV Vcl.ml mV Vol.ml mV • Vol.ml mV
Titraticn Nc, 7 cent.
5.12 150.7 11.70 74.7 14.60 -0.7 18.65 '-75.1
5.30 145.8 11.90 71.4 14.70 -4.3 19.00 -80.1
5.55 140. 8 12.30 64.5 14.90 -10.8 19.35 -85. 4
5.90 135.6 12.60 59.2 15. 10 -16. 6 19.65 -90. O
6.30 131.0 12.80 55.6 15.25 -20.4 20.00 -958
6.85 125. 8 13.05 50.7 15.45 -25. 1
Table 4 EXEEBIMENTAL EATA BOB LEAD-GLOTAMATE INTERACTION
Titn. Starting Scluticn Titrating Solution Initial E0
• No. A mM E mM H mM A mM B mM H mi Vol. ml ml
1 19.97 9.805 18.0 1 -40.05 20.01 4 50.g
2 9.986 4.903 9.006 -40.05 2 0.01 4 50.2.'
3 20.00 4.900 9.000 - *-40.05 20.01 450.2'
4 0. 00 2.450 4.501 -40.05 20.01 4 49 . S
5 19.99 2.450 4.501 -40.05 2 0.01 4 49.8
Added E Added E Added E Added E
Vol.ml mV Vol .ml mV Vol.ml ml Vcl.ml mV
Titraticn Nc. 1
1.C0 313.2 9.50 243.4 17.00 160. 1 20.00 70.2
2.0O 306.9 10.00 237.7 17.70 147.8 20.40 63.C
3.50 296.9 11.00 226.6 18.20 136. 3 21.00 54.2
4.50 289.8 12.00 215.9 18.70 119.7 21.80 43.%
5.50 282. 1 13.00 205.6 19.00 106.6 22.60 31.5
6.50 273.9 14.00 195.4 19.20 96.6 23.20 21.%
7.50 264.5 15.00 185.0 19.50 83. 6 23.80 n.d
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lafcle 4 cent.
Added E Add 6d E Added E Added E
Vol.ml mV Vcl.ml mV Vcl.ml iV • Vol.ml mV
Titraticn No. 1 cent.
16.00 173.7 19.80 74.7 24.40 -1.08.50 2 54. 3
Titraticn Nc. 2
€.10 306.0 4.60 240.6 8.20 164. 3 9.65 83.4
0.70 ' 300.5 5. 10 229.7 8.60 152.4 9.75 76. 1
1.40 292.8 5.50 221.0 8.90 1 41.0 9.90 6 8.4^;
2.00 285.6 5.90 212.7 9.10 130.8 10.00 64.4
2.60 277.4 6.30 204.7 9.25 120.8 10.40 52.2;
3.20 268.2 6.80 194.9 9.35 112.6 10.80 41.7
3.70 259.2 7. 30 184. 8 9.45 102.8 11.20 30.8
4.20 249.3 7.80 174. 1 9.55 92.7 11.60 18.8
Titraticn Nc. 3
0. 10 287.9 5.60 2 31.4 11.80 163.9 14.65 80.9)
0.50 284.7 6.30 223. 2 12.50 153. 8 14.85 6 6.6-
1.00 280.6 7. 10 214.2 13.10 143.2 15.10 5 6.6
2.00 271.7 8.00 204.7 13.60 131. 4 15.40 46.0
3.00 261.7 9.0 0 194.5 14.00 118.2 15.75 360
4.CO 250.6 10.00 184. 3 14. 30 103. 8 16. 10 26. 1
4.80 241. 1 10.90 174.7 14.50 91.1
Titraticn No, 4
0.20 278.5 4.40 192.9 6.90 120.6 7.40 62.3
1.10 264. 1 4.90 183. 1 7.00 112. 4 7.50 53.2
1.80 249.9 5.40 172.6 7.10 101.9 7.65 43.0
2.4C 236. 1 5.80 163.3 7.20 89. 1 7.85 32.4
2.80 2 26.7 6.20 152.2 7.25 81.6 8.05 21.7
3.30 215.5 6.50 141.5 7.30 74. 4 8.2 5 10.3
'..90 203.0 6.70 132. 4 7.35 67.9 8.50 -6.0
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Table 4 cent.
Added E Added T?Xl Added TPXI Added E
Vol.ml BiV Vcl.ml mV Vol.ml mV ' Vol.ml mV
Titraticn Nc. 5 •r
0.20 265.7 6.40 193.9 11.50 121.4 12.55 47.5
1. 10 255.7 7.40 183.9 11.75 111. 3 12.65 40.2
2.CO 24 4.8 8.40 173.6 11.90 103.4 12.80 30.6
2.80 234.6 9.30 163.3 12. 10 89. 1 12.95 21.1
3.60 224.5 10.00 153.9 12.20 80.3 13.10 12.9
4.50 213.9 10.60 143.9 12.35 65. 5 13.30 C . 7 ■
5.50 203.2 11.10 133.3 12.45 56.0
5 EXEEBIMENTAL EATA FCBLEA E-ETHYLENE ElAMINETETBAACETATE INTERACTION
Starting Solution Titrating Solution Initial E°
Table
Titn.
Ko.
1
2
3
4
5
6
7
Added E Added E
Vol.nil mV Vcl.ml mV
Titraticn Kc.
A mM E mM H mM
29.91 4.906 -31.05
19.99 4.906 -31.05
10.OC 2.455 -15.54
9.969 4.906 -11.03
4.976 2.453 -15.55
5.019 4.906 -11.04
10.00 4.906 -11.04
B mM H mM Vol. ml mV
311.4 2C.01 438.7
311.4 2C.01 439.1
155.9 2C.01 439.2
155.9 2C.01 4 39 -3
77.96 20.01 439.2
77.96 2C.01 433.0;
77.96 2C.01 43 3. T
Added E Added E
Vol.ml mV Vol.ml m V '
1
0.10 -1.5
0.2C 5.5
0.30 12.2
1.25 93. 1 1.43 196.8 2.55 276.0
1.30 108.6 1.45 203.2 2.80 282.0
1.33 123. 4 1.48 210. 8 3.10 288.2
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Table 5 eont.
Added
Vol.ml
E
kV
Added
Vcl.ml
E
mV
Added
Vol.ml
E
mV •
Added
Vol.ml
E
mV
Titration Kc. 1 cent.
0.40 18.5 1.34 130.6 1.52 218.7 3.60 297.1
0.55 27.6 1.35 139.9 1.57 226.2 4.10 304.6-
0.70 36.8 1.36 149.3 1.63 233.0 4.60 311.4
0.85 46.8 1.37 158.4 1.70 239.3 5.10 317.6
1.00 58.7 1.38 167.5 1.80 246. 5 5.60 323.3;
1. 10 69.0 1.39 175.4 1.95 254.9 6.10 328.5-
1. 15 75.4 1.40 182.7 2. 10 261.6 6.70 334.3
1.20 83.0 1.41 187.7 2.30 268.7 7.30 339.6
Titraticn Kc. 2
0. 10 -73.3 0.90 30.8 1.41 191.5 2.40 281.6-
0.20 -61.0 1.00 41.3 1.40 186.5 3.10 299.7,
0.30 -46. 5 1. 10 53.6 1.43 200.2 2.70 2 90.3.
0.35 -38.2 1.20 69.3 1.49 218. 4 3.60 309.5!
0.40 -29.7 1.25 80.2 1.46 210.4 4.60 325.2
0.45 -21.4 1.28 89. 1 1.54 228.0 4.10 317.91
0.50 -14.2 1.31 101.4 1.70 246. 5 5.10 331.6'
0.55 -7.6 1.34 123.3 1.60 236.2 6.10 3 42.1
0.62 1. 1 1.36 145.3 1.81 255. 1 5.60 337.2'
0.70 10.2 1.38 169.2 2. 15 272.6 6.70 347.2
0.80 20.7 1.39 179.7 1.95 263.4 7.30 351.6
Titraticn Kc. 3
0.10 -72.7 1.25 81.2 1.85 254.8 4.30 312.2
0.20 -60.2 1.30 97.7 1.90 257.7 4.70 316.7
0.25 -53.2 1.23 113.2 2.00 262.8 5.20 321.8
0.30 -45.6 1.37 153.6 2. 10 267.2 5.70 326.2
0.35 -37.2 1.39 173.3 2.20 271.0 6.20 330.0
0.45 -20.8 1.41 187.6 2.35 276. 1 6.80 334.1
•
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Tatle 5 cent.
Added E Added E Added E Added p
Vol.ml mV Vcl.ml mV Vcl.ml mV ’ Vol.ml mV
Titraticn Nc. 3 cent.
0.55 -6.3 1.43 198.4 2.50 280.5 7.50 338.2
0.60 0. 1 1.45 205.9 2.70 285. 5 8.30 342.1
0.70 11.4 1.50 218.9 2.90 290.0 9.10 345.5
0.80 21.7 1.55 227.7 3.1C 294.0 10.00 348.8
0.90 31.8 1.65 239.7 3.35 298. 6
1.05 48.2 1.75 248. 1 3.60 302.6
1.20 70.3 1.80 251.6 3.90 306.9
Titraticn Ng, 4
0.10 112.8 0.22 206. 4 0.95 269. 4 3.20 215.7'
0. 11 124. 4 C. 24 211.5 1.05 273.1 3.60 320.2
0.12 137.1 0.28 219.7 1.20 278. 1 4. 10 325.1
0.13 150. 1 C.33 227.7 1.35 282.5 4.60 329.4
0.14 162.9 0.40 236. 1 1.50 286. 6 5.20 233.8
0. 15 172.4 0.47 242.7 1.70 2*91.2 6.00 338.7
0.16 18C.1 0.55 248.8 1.90 295.5 6.80 342.7
0. 17 186. 4 C.65 255.2 2.20 301.1 7.80 347.0
0.18 191.4 0.75 260.5 2.50 306. 1 9.GO 351.1
0.20 200.0 0.85 265.2 2.80 310.5
Titraticn Nc. 5
1.80 -77.8 2.54 60.2 2.84 206.4^ 4.90 291.4
1.90 -60.2 2.60 74.8 2.90 217.7 5.20 295.5
1.95 -49.7 2.65 92.5 2.96 225.9 5.60 300.2
2.CO -37.9 2.67 102.4 3.05 234.9 6.CO 204.2
2.05 ~ 0 C 0Z • X. 2.69 116.8 3.15 242.5 6.50 308.6
2.10 -13.5 2.70 125.7 3.25 248. 5 7.20 213.7
2. 15 _ q cx- • 2.71 135.9 3.40 255.9 8.00 318.5
2.20 5.2 2.72 145. 1 3.60 263.6 9.CO 323.5
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Table
Added
Vol.ml
5 cent.
E
mV
E
mV
Added
Vcl.ml
E
mV
Added
Vol.ml
E
mV
Added
Vol.ml
Titraticn Nc. 5 cent.
2.25 13. 4 2.74 162.4 3.80 269.7 10.00 ' 327.5
2.30 21.2 2.76 176.8 4.0 0 274.8 11.50 332.4-
2.38 33.1 2.78 188. 1 4.30 281.4
2.46 45. 5 2.80 195. 1 4.60 286.8 '
Titraticr Nc. 6
0.44 213.4 1.40 264.3 5.50 314.3 18.00 3 42.7,
0.52 221.9 1.80 274.3 7.00 321. 3 20.00 3 44.6
0.62 230.3 2.30 283.9 8.50 326.5 25.00 348.1
0.75 238.6 2.90 292.7 10.00 330. 5 30.CO 350.8
0.90 246. 3 3.60 300.5 12.00 334.6
1.10 254.5 4.50 308.0 15.00 339.3
Titraticn Nc. 7
0.05 73.4 0.32 183. 8 1.20 246. 1 8.00 314.6
0. 10 83.9 0.36 192. 4 1.50 254.2 10.00 321.9■
0.20 126.9 0.41 200.4 2.00 264. 5 13.00
!
329.;
0.22 141.5 0.50 210.7 3.00 279.2 16.00 335.1
0.24 153.6 0.60 218.9 4.00 289. 8 20.00 340.3
0.26 163.8 0.75 228.2 5.00 297.9 25.00 344.7
0.29 175.6 0.95 237. 3 6.50 307. 4 30.00 347.8
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Table
Titn.
6 EXPERIMENTAL EATA TOEZINC-ETHVLENEEIAM INETETRAACETATE INTERACTION
Starting Scluticn Titrating Solution Initial £0
No. A mB E mM H mM A mM E mM H mM Vol. m.
1 7.967 3.997 8. 175 -20.02 20.01
2 7.986 3.997 20.64 62.34 20.01
3 8.007 3.997 -11.84 124. 6 20.01
4 4.C07 2.CCC -5.927 62.34 20.01
5 16.02 3.997 -31.88 311. 4 20.01
6 3.987 3.997 -11.86 124. 6 20.01
7 23.94 3.997 -31.88 311. 4 20.01
Added E Added E Added E Added
Vol.ml mV Vcl.ml mV Vol.ml mV Vcl.ml
mV
4 3 4.0
*135. 1
435.2
434.6
435.7
4 34.2
434.6
mV
E
Titration Nc, 1
0.10 303.5 1C.CO 262.5 15. 10 201.1 16.00 124.9
0.30 302.9 10.50 259.3 15.20 197.7 16.C2 121.1
0.70 301.6 11.CO 25 5.8 15.25 ' 195.7 16.05 115.5
1.50 299.0 11.40 252.8 15.30 193.7 16.08 11C.4
2.00 297. 4 11.80 249.6 15.35 191.6 16.11 105.7
3.CO 294.0 12.20 246. 1 15.40 189.2 16.14 101.4
4.00 290.4 12.50 243.3 15.45 186.6 16.17 97.8
4.50 288.5 12.80 240.3 15.55 180. 8 16.30 84.6
5.00 286.7 13.10 237.0 15.60 177.4 16.50 71.1
5.50 284.7 13.40 233.4 15.70 169.2 16.80 57.4
6.00 282.6 13.70 229.5 15.75 164.5 17.20 4 3.9
6.50 280.5 13.90 226.7 15.78 161.0 17.70 30.2
7.00 278.3 14. 10 2 2 3.5 15.81 157.2 18.30 15.2
7.50 276.0 14.30 220. 1 15.87 148.6 19.00 -3.2
8.00 273.6 14.50 216.2 15.90 143.7 20.00 - 3 8 . c
8.50 271.0 14.70 211.9 15.93 138. 3
9.00 268. 4 14.85 208.3 15.96 132.7
9.50 265.5 15.00 204.3 15.98 128. 9 J
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Table
Added
ol • ml
6 cont.
Added
Vol.ml
E
mV
Added
Vol.ml
E -
mV
E
mV
Added
Vcl.ml
E
ml
Titraticn Nc, 2
0. 10 325.9 3.00 332.7 8.50 340.4 18.00 3 47.5
0.20 326.2 4.C0 334.5 10.00 341.9 20.00 348.5.
0.40 326.8 5.00 336.0 12.00 343. 6 22.00 3 49.4.
1.00 • 328. 4 6.00 337.4 14.00 345. 1
2.CO 330.6 7.00 338.7 16.00 346. 4
Titraticn Nc. 3 •j
0.05 -20.9 0.54 70.3 0.74 198. 1 2. 15 283.2'
0.06 -18. 1 0.56 77.2 0.76 202.7 2,50 290.8
0.07 -15.9 0.58 86.8 0.79 208.7 -2.90 297.]
0.08 -13.6 0.60 99.6 0.82 213.8 3.40 304.9
0.10 -9.3 0.61 107.4 0.86 219. 3 4.00 311.6
0. 12 _ c c5. 5 0.62 118.6 0.90 224.2 4.60 317.0
0.14 -1.7 0.63 132.2 0.95 229.5 5.30 322.1
0.16 1.8 0.64 146. 1 1.02 235.7 6.20 327.4
0.20 ' 8.6 0.65 155.0 1. 10 241. 8 7.20 332.1
0.25 16.3 0.66 164.5 1.18 247. 1 8.50 3 37.0
0.30 23.9 0.67 170.8 1.28 252. 8 10.00 3 41.4
0.35 31.7 0.68 177.2 1.40 258,6 12.00 346.2
0.40 39.7 0.69 181.9 1.55 265.0 14.00 349.9
0.45 48.6 0.70 185.9 1.70 270.4, 17.00 354.4
0.50 59.3 0.72 192. 4 1.90 276. 6
Titraticn Nc. 4
0.02 -27.4 0.58 83.7 0.77 197.7 2.90 286.4J
0.04 -22.0 0.60 93.6 0.79 201.9 3.20
•­
290.31
0.06 -17.2 0.61 100.5 0.82 207. 1 3.60 294.(3
,0. 10 — 8.8 0.62 107.8 0.85 211.6 4.10 299.5
0. 13 -3.1 0.63 116.8 0.89 216. 6 4.70 304.2
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Table 6 cent
Added E Add^d E Added E Added E
Vol.ml mV Vcl.ml mV Vol^l mV Vcl.ml m V
Titraticn No. 4 cent.
0. 16 2.2 C.64 128.6 0.94 222-0 5.407 308.7.
0.20 8.7 0.65 142.9 1.00 227. 6 6.20 312.82
0.24 14.9 0.66 152.5 1.08 233. 8 7.20 317.1 .
0.29 22.5 0.67 160.2 1.18 240. 1 8.40 321.2-
0.35 31.5 0.68 166.7 1.28 245. 5 9.CO 323.03
0.40 39.5 0.69 171.8 1.40 251.0 11.00 327.8
0.45 48.1 0.70 175.9 1.55 256. 8 14.00 3 33.1
0.50 58.4 0.71 180.2 1.75 263.3 17.00 337.0;
0.53 66.2 0.72 184.0 2.00 269. 9 19.30 339.4-
0.55 71.8 0.73 187.3 2.30 276.5
0.57 79.2 0.75 193.0 2.60 281.8
Titraticn Nc. 5
0.65 -59.6 1.45 73.4 1.64 209.0 2.70 268.93
0.75 -40.2 1.50 92.4 1.67 ' 216.6 3.00 2973
0.80 -29.8 1.53 112.9 1.72 227.2 3.30 304.6;
0.85 -20.0 1.55 140.8 1.77 234.6 3.70 312.7
0.90 -11.1 1.56 156. 5 1.85 244.2 4.10 319.7
0.97 — 0.2 1.57 168.8 1.95 253.3 4.50 325.6
1.05 10.9 1.58 179.0 2.05 260. 5 4.90 330.7
1. 15 23.5 1.59 186.5 2.15 266.5 . 5.30 335; 1
1.25 36.5 1.60 193.0 2.30 274.0 5.70 339.0
1.35 51.8 1.62 201.8 2.5b 282. 1 6.20 343.1
Titration Nc. 6
0.63 80.5 0.77 208.2 1.40 268.4 3.80 317.4
0.64 115.2 0.80 214.4 1.50 273.3 4.30 3.1.4
0.65 141. 1 0.84 221.3 1.65 279.5 5.CO 326.1
0.66 157.5 0.88 226.8 1.80 284.7 5.80 330.4
• 1
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Table 6 cent.
£Added E Added E Added E Added
Vol.ml m.V Vcl.ml mV Vol.ml jV Vol.ml m V
Titraticn Nc. 6 cent j
0.67 167.2 0.95 235.3 2.00 290.5 6.80 3 3 4.9
0.68 175. 4 1.00 240.3 2.20 295.4 8.00 339.3
0.69 181.7 1.07 246. 6 2.40 299.5 9.20 342.8
0.70 186.6 1.14 252.2 2.70 304.6 10.00 344.9
0.72 194.7 1.22 257. 8 3.00 308.8 12.00 349.2
0.74 200.9 1.30 262.9 3.40 313.5
Titraticn Nc. 7
0. 10 -58.2 1.4 0 73.1 1.54 201. 1 2.45 268.5
0.18 -48.7 1.45 83.8 1.66 206.5 2.60 273.4
0.25 -39.7 1.50 100.4 1.69 213.0 2.80 279.2
0.33 -29.6 1.52 110.7 1.72 218. 2 3.00 264.3
0.42 -19.0 1.54 125.6 1.76 224.2 3.30 291.0
0.50 -10.6 1.55 136.4 1.80 229. 1 3.60 296.8
0.60 -1.3 1.56 147.5 1.85 234.6 4.CO 303.7
0-70 7.0 1.57 160.2 1.93 241.7 4.40 309.9J
0.85 18.5 1.58 168.7 2.01 247.5 4.80 315.5
1.C0 30.0 1.59 179.8 2. 10 252.9 5.20 320.7
1. 15 42.7 1.60 185.0 2.20 258. 1 . 5.60 325.3
1.30 58.2 1.62 193.5 2.30 262.7 6.10 330.6
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Table 7 EXPERIMENTAL EATA BOR LEAD-D-PENICIILAMINATE
INTERACTION
Titn. Starting Scluticn Titrating Scluticn Initial
Ko. A mM E mM H mM A mM B mM H mM Vol. ml m V
1 9. 904 2.457 4. 513 -50.14 20.01 433.9%
2 20 .05 4.912 9. 022 -50.14 20.01 43 4. 1%
3 9. 958 4.912 9. 022 -50.14 20.01 435.2;
4 5. 153 4.912 9. 022 -50.14 20.01 434.93
5 30 .01 4.912 9. 022 -50.14 20.01 434.7-
6 5. 100 2.457 4. 51 3 -50.14 20.01 435.5'
7 15 .00 2.457 4- 513 -50.14 20.01 4 3 4.9
Added E Added E Added E Added E
Vd. ml mV Vcl.ml mV Vd-ml mV Vol.ml m V
Titraticn Nc. 1
0.10 270.0 3.79 126.8 4.10 -5.5 7.50 -146.7
0.70 257.9 3.81 103. 4 4.20 -14.7 8.10 - 178.5
1.60 234. 4 3.82 90.4 4.50 ■ -33.4 8.40 -192.2
1.90 226.7 3.84 66.9 4.70 -42. 4 9.00 -213.3
2.50 212-4 3.85 58.5 5.20 — 60.6 9.30 -221.8
2.90 202.7 3.88 39.8 5.50 -70.3 10.CO -237.6
3.60 174. 1 3.90 31.6 6.30 -96.0
3.70 162.1 3.97 13.2 6.60 -106. 8
3.77 141.3 4.01 6.2 7.20 -131.8 '
Titraticn He. 2
0. 10 279.2 6.CO 208.8 7.82 39.5 ' 13.10 -98.Q
1.00 270.0 6.80 195. 4 7.87 30.5 14.70 -130.1
2.00 258. 1 7.20 184.2 8.05 11.1 15.30 -145.3
2.40 252.9 7.50 165. 8 8.20 1. 1 16.30 -1731.
3.20 242. 4 7.60 148.8 8.70 -19.6 16.80 -185.6
3.60 237.4 7.67 114. 1 9. 10 -30. 5 17.80
J
-205.g1
4.40 227.8 7.69 96.3 10.00 — 48. 8 19.10 -225.3
I
•3
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latle 7 cent.
Added E Added E Added E Added E
Vol. ID 1 mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration Nc. 2 cent,.
4.80 223.3 7.73 67.8 10.70 -60. 4
5.60 213.9 7.75 59.0 12.30 -85.0
Titraticn Nc. 3
0.10 295. 2 5.20 213.2 7.74 106.0 8.35 -36.0
1.00 284.9 5.50 209.0 7.76 82. 5 8.50 -44.4
1.50 278. 1 6. 10 200.2 7.77 71.6 9.00 -67.0
2.50 261.2 6.40 195.3 7.79 52.7 9.30 -79.3
2.80 255. 1 7.00 183.0 7.81 39.8 10.00 -108.4
3.40 242.5 7.30 173.5 7.86 19.6 10.30 -121.4=
3.70 236.6 7.60 153.4 7.90 9.5 10.90 -148.8
4.30 226.3 7.65 145.5 8.00 -6. 6 11.10 -158.8
4.60 221.7 7.72 121.4 8.10 -17.6 11.50 -180.0
Titraticn Nc. 4
0. 10 304. 6 3.CO 256.5 4.80 209.8 7.00 159.0
0.50 3*00.5 3.40 243.5 5.20 202.5 7.30 142.5
1.00 294.7 3.70 234.2 5.70 193.3 7.50 122.4•i
1.70 284.9 4.00 226.4 6.20 182.9 7.55
3
113.7j
2.40 272.0 4.40 217.4 6.60 172.7 7.60 100.3j
Titraticn Nc. 5
0. 10 269.7 6.CO 211.6 18.50 -126.2 .x 21.50 -179.6
1.C0 262. 1 6.70 200.4 19.00 -134.5 22.50 -193.11
2.00 252.5 7.20 186.4 19.50 -143.7 23.50 -204.4i
3.CO 242.7 16.00 -93.8 20.00 -153.2 i
4.00 232.9 17.00 -105.2 20.50 -162.7
5.00 223.0 18.00 -118.5 21.00 -171.6 i
I
167
lafcle 7 cent.
Added E Added E Added E Added E
Vol.ml mV Vcl.ml mV Vol.ml mV Vol.ml ffi V
Titration Ne. 6
0.10 282.2 3.20 188.3 3.90 14. 6 5.00 -112.0S
0.50 274.2 3.40 180.3 3.92 5.7 5.15 -125.1|
1.20 254. 3 3.75 151.1 3.98 -11.7 5.45 -151.81
1.40 3*6.7 3.80 134. 1 4.02 -19,7 5.60 -165.G1
1.80 230.8 3.83 101.7 4.20 -43.5 5.95 — 19 4.6;
2.00 22 3.7 3.84 80.4 4.30 -53. 4
2.40 211.5 3.86 47. 3 4.55 -74.7
2.60 206.0 3.87 35. 6 4.70 -86.7 >
Titraticn Nc. 7
0. 10 263. 1 3.83 128.9 4.05 21.6 6.50 -65.0
1.00 246.9 3.85 108.4 4.12 12.9 7,70 -87.7J
2.00 226.8 3.86 96.8 4.30 -2.3 8.40 - 102.%
2.50 216.9 3.88 77.0 4.45 -11,0 9.50 -133.0
3.40 192.7 3.89 68.5 4.80 -25.2 10.00 -1^0 ..3;
3.70 171. 4 3.92 52.7 5,10 -34.5
3.80 147.9 3.94 45.3 6,00 -55.2
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Table 8 EXIEBIMENTAL EATA FCB lEAE-GLUTATHIONATE
INTERACTION
Titn. Starting Scluticn Titrating solution Initial E°
No. A mM E mM H mM A mM B rnM H mM Vol. ml mV
1 19.99 2.452 4.504 -50.04 20.01 451.3;
2 3.933 0.981 1.802 -50.04 2C.01 450.5
3 6.004 0.981 1.802 -50.04 2 0.01 449. Il
Added E Added E Added E Added E
Vol.ml k7 Vol . il m V Vc1.m1 mV Vol.ml m V
Titration Ne. 1
0.20 276.3 9.50 181.4 11.50 76.7 12.95 -19^4;
0.50 273.8 10.00 169.8 11.55 71.5 13.15 -28.13
1.C0 269.7 10.20 163.6 11.60 66.8 13.40 -37.5
2.00 261.0 10.40 156.8 11.70 57.6 13.70 -46.3
3.00 252.2 10.60 148.4 11.80 49.3 14.00 -53.4-
4.00 243. 3 10.)80 138.0 11.90 41.5 14.40 -61.3
5.00 234.2 10.90 131.8 12.00 ‘ 34. 3 14.90 -69.1
6.00 225.0 11.00 124.7 12.10 27.3 15.50 -77.T
7.00 215.2 11.10 116.5 12.20 20.9 16.20 -6 4.9
7.50 209.9 11.20 107.4 12.30 14.9 17.20 -94.4
8.00 204.3 11.30 97.5 12.45 6. 3 18.20 -103.1
8.50 197.9 11.40 87.0 12.60 -1.8
9.00 190.5 11.45 81.8 12.75 -9. 6 ‘ •
Titration Nc. 2
0.10 274.9 2.10 188.2 2.83 86.8 3.29 -22.0
0.20 272.0 2.20 181.0 2.85 80.8 3.35 -30.5
0.40 255.9 2.30 172.9 2.88 71.9 3.40 -37.3
0.50 2 6 2.6 2.40 163.6 2.90 65. 8 3.45 -43.7
0.70 255.8 2.50 152.6 2.93 56. 8 3.50 -49.4
0.90 248. 5 2.55 145.8 2.95 50.7 3.60 -59.7
1.C0 24 4.6 2.60 138.2 2.98 42.0 3.70 -68.6
j4
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Table
Added
Vol.ml
8 cent.
£
m V
E
' mV
Added
Vol.ml
E
ml
Added
Vol.ml
E
ml
Added
Vol.ml
Titration No, 2 cent.
1.20 236. 4 2.65 129.7 3.01 33.8 3.8(P -76.4
1.40 227.6 2.70 119.4 3.04 25.9 3.95 - 86.6.
1.55 220.4 2.72 114.7 3. 10 12.0 4.10 -95.55
1.70 212.9 2.75 107.6 3.15 1.9 4.30 -106.2';
1.85 204.4 2.78 100.2 3. 19 -5. 6
2.00 195. 1 2.80 95.2 3.24 -14.0
Titration No. 3
0. 10 270.5 3. 10 169.2 3.72 73.4 4.13 -7.6
0.40 263.5 3.20 161.7 3.74 67. 8 4.20 -16. S
0.70 256.2 3.30 152.5 3.76 62.3 4.27 -25.2
1.00 248.3 3.35 147.2 3.78 56.8 4,34 -33. 1
1.30 240,0 3.40 140.8 3.80 51.7 4.42 -41.2
1.55 232.6 3.45 133. 4 3.82 46.9 4.50 -48.3
1.80 225. 1 3.50 125.3 3.85 40.0 4.60 -55.9
2.05 216.9 3.54 117.8 3.88 33. 6 4.70 -62.5'
2.30 207.8 3.58 109.7 3.91 27.5 4.80 -68* 1
2.50 199.8 3.61 102.7 3.95 19.9 4,95 -75.6
2.70 191. 1 3.64 95.3 3.99 12.9 5.10 -82.2
2.85 184.0 3.67 87.6 4,03 6.4 ' 5.30 -89.7
3.00 175.8 3.70 79.2 4.08 -1.0
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FCE ZINC-GLDTATHICNATE 
Titrating Scluticn Initial
Table 9 EXBEBIEEKTAL ESTA 
INTERACTION
Titn. Starting Scluticn E0
Nc. A mH E mM H mM A mM B -.mM H mM Vcl. ml mV
1 4.702 2.354 4.722 -50.04 20.01 451.2
77
2 2. 370 2.354 4.722 -50.04 20.01 4 51.2
3 1. 178 2.354 4.722 -50.04 20.01 451.2i
4 9.482 4.711 9.450 -50.04 2C.01 451.8^
5 2. 362 1. 176 2.360 -50.04 20.01 451,8 i1
Added E Added E Added E Added
ti
E
Vcl.ml mV Vcl .ml mV Vcl.ml mV Vcl.ml mV ;
Titraticn Nc. 1
1.60 263.4 3.60 16 6.3 4.45 88.3 6.15 -9.;
1.90 254.4 3.65 158.9 4,60 81.9 6.20 -15.1
2.10 247.9 3,68 153.8 4.80 73.7 6.25 -21.3
2.30 >240.9 3.71 148.6 5.00 65.2 6.30 -28.03
2.50 233.5 3.74 143.6 5.20 56.0 6.35 — 34.0
2.70 225,8 3.78 137. 4 5.35 48.5 6.42 -44.2
2.90 217.5 3.83 130.6 5.50 40. 4 6.49 -53.1
3. 10 207. 6 3.88 124,5 5.65 31.6 6.56 -61.8
3.20 201.9 3.95 117.6 5,80 21.9 6.65 -71.7
3.30 195.5 4.05 109.7 5.90 14,7 6.75 -81.8
3.40 187.7 4. 15 103.3 6,00 6. 3
3.50 178.3 4,30 95.3 6.10 -3,7 11T
Titraticn Nc, 2
I
2.78 154.2 2.94 113.9 3.60 64.4 4.50 5.j
2.80 148.2 2.98 108.4 3.75 56.6 4.55 -0.31
2.82 142.0 3.05 ICO.3 3.90 48.8 4.60
i
-6.;
2.84 135.9 3.12 93.9 4.05 40.2 . 4.65
1-13.d
J
2.86 130. 5 3.20 87,8 4.20 30.7 I1
2.G8 125.6 3.30 81. 1 4.30 23.4 .11j1
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Table 9 cent.
Added E Added E Added E Added E
Vol.ml m V Vol.ml mV Vol.ml mV Vol.ml E V
Titration No. 2 cent.
2.90 121.3 3.45 72.4 4.40 15.0
Titration Ko. 3
2.35 133.5 2.44 101.8 2.65 73.2 3.05 36.9:
2.36 127.3 2.48 94. 3 2.75 64. 1 3.15 25.3:
2.37 123. 1 2.53 8 6.8 2.85 55,3
2.38 *119.1 2.58 80.6 2.95 46.6
Titration No. 4
3.5C 263.6 7,25 170.8 9.80 83. 6 12.50 -11.6!
4.00 255.2 7.40 161.3 10.00 78,6 12.65 -21.2
4.50 246.2 7.55 154.5 10.40 67.9 12.80 -31.3:
5.00 236.9 7.65 145.4 10.70 59.3 12.90 -38.2:
5.40 228.9 7.80 137.3 11.00 50.0 13.00 -45.0
5.80 220.3 7.95 130.7 11.30 39.9 13.15 -55.0'
6.10 213.2 8. 10 125.2 11.50 32.9 13.30 — 64.3
6.40 205. 1 8.30 119.1 11.70 25.9 13.45 -7 2.8
6.70 195.6 8.60 111.3 11.90 18.2 13.60 -80.3
6.90 188. 2 S.GO 102.2 12.10 9.7 13.80 -89.25
7.10 179.0 9.40 93.1 12.30 -0. 1 14.GO -97.4
Titration No. 5
0.80 258.5 1.80 167.2 2.05 95. 3 2.95 10.4
0.95 250.6 1.82 160.8 2.10 89.0 3.00 2.7
1.10 242.0 1.84 153.7 2.20 79.0 3.05 — 6 • S
1.25 232.3 1.86 145.8 2.30 70.5 3.10 -17.4
1.35 225.0 1.88 136.7 2.40 62. 6 3.15 -28.8
1.45 216.7 1.90 128.7 2.50 54.9 3.20 -39.3’’
1.55 207.2 1.92 121.7 2.60 47. 1 3.25 -50.7
1.65 195.2 1.94 115.9 2.70 38.6 3.30 -61.1
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Table 9 cent.
Added E Added 15 Added EE Added E
VcLm1 wV VoC.nl mV Vol. ml mV Vol.ml mV
Titraticn No, 5 cent,
1.70 118,3 1^7 110.9 2.^0 291 1 3.35 -71.
1.75 117. .5 2.C0 113. .3 2.90 17.7
17 3
Table 10 EXPERIMENTAL EATA EOR LEAD-GLYCINATE INTERACTION
Titn. Starting Solution Titrating Solution Initial E8
No. A mM I mM fi mM A mM B m M H mM Vol. ml mi
1 19.98 4.903 8.70 6 -10.02 20.01 453.7
2 40. 10 9.813 17.42 -10.01 20.01 4 52.7
3 12.33 6.128 0.873 -10.01 20.01 452.7
4 14.80 7.361 13.07 -10.01 20.01 4 5 4.2
5 12.31 6.128 10.87 -10.01 20.01 4 55.5
6 40.13 4,906 8.711 -10.01 20.01 4 5 4.0
7 5.036 4.90-3 8.706 -20.01 20.01 4 57.5
8 2.560 4,906 8.711 -20.01 2C.01 459.5
9 74.66 4.911 9.021 -20,04 2C.01 4 58.2
Added E Added E Added E Added E
Vol.ml. mV Vcl . ml mV Vol.ml D V Vol.ml hi V
Titration No. 1
10.00 251.0 16.GO 174.6 19.30 ‘ 102.2 25.00 4 4.7
11.50 244.9 18.20 164.3 19.50 96.5 26.20 36.0;
13.00 2 37.8 18.35 154.9 19.80 89. 8 27.40 2 6.7
14,50 228.7 18.45 147.9 20.00 86.2 28.60 16.6:
15.50 220.6 18.60 137. 1 20.40 80.4 29.50 7.94
16.40 210.8 18.70 130.4 21.00 73.9 30.30 -0.0
17.00 201.8 18.80 124.2 22.00 65. 5
17.50 191. 1 18.95 116.1 23.00 58.4
17.80 182.3 19. 10 109.4 24.00 51.6 1j
Titration No, 2 ]
0.50 283. 1 16.00 260.5 36.00 172. 1 43.00 73.5j
1.00 282.6 18.GO 2 57.0 36.40 161.0 45,00 65.8
1.50 281.9 20.00 253.3 36.70 151.3 47.00 58.g1
2.00 281.2 2 2.GO 249.2 37.00 141.1 50.GO 47.7j
3.00 279.8 24.00 244.7 37.40 128.7 52.00 39.8
4.00 278. 4 26.GO 239.5 37.60 123.4 54.00 31.3-I
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Table 13 cent.
Added T Added E
Vcl.ml mV Vcl.al mV
Titraticn Nc, 2 cent.
5.33 277,3 28.33 233.5
6.CO 275.7 3G.GG 226.1
7.33 274.3 32.33 216.4
8.33 272.8 33.33 213.1
13.33 27G..3 34.33 231.2
12.33 26 6.2 35.33 123.5
14.33 263.8 35.53 182.5
Titraticn Nc. 3
3.13 235.4 2. 83 174.7
3.53 231.3 2.23 167.4
1.G3 225. 1 3.33 152.3
■ 1.53 217.4 3. 13 142.2
2.33 237. 1 3.23 141.5
2.23 231.6 3.33 133.8
2.53 123.2 3.43 127.4
2.65 183.7 3.55 112.6
Titraticn Nc, 4
12.33 24.63 225.6
14.33 275.3 25.43 216.2
16.33 2 62.2 26.33 236.5
17.33 265.2 26.53 124.7
18.33 262.4 26.83 184.8
2'3.G3 254.4 27.33 176.3
21.33 242.2 27.23 164. 4
22.53 241.8 27.33 157.2
23.63 234.3 27.43 153.7
Added E Added E •
Vcl.ml mV Vcl.ml mV
38.33 114,7 56,33 22.5
38.53 136. 1 57.33 17.2
32.33 22.5 58.33 12.7
32.53 .. 24.2 52.33 7.4
43.33 82.2
41.33 83.2
42.33 78.3
3.73 113.7 2.33 65.1
3.23 137.7 13.33 52.4“
4.23 131. 1 11.33 53.5
4.53 26.5 13.33 43.7
5.33 23.8 14.23 32.4
6.33 82.8 15.53 22.6
7.33 76. 4
8.33 73.7
27.53 143.8 33.33 81.6
27.65 134.2 31.33 75.2
27.83 125.7 32.53 67.7
28.33 116.3 34.33 61.3
28.23 138.3 36.33 52.3?
28.43 132. 5 38.CO 43.1
28.73 26.1 43.33 33.2
22.13 23.2 42.33 22.5
22.63 84.2 43.53 13.7
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latle 10 cent.
Added E Add6d E Added E Added E
Vcl. ml mV Vcl.ml mV Vcl.ml mV Vol.ml mV
Titraticn Nc. 5
8.00 287.C 21.50 213.7 23.20 134.0 27.00 67.7
10.00 280.9 22.00 203. 1 23.30 126.5 28.00 ’ 62.3
12.CO 274.3 22.30 194.0 23.45 117.0 30.00 51.9
14.00 267.0 22.50 186.0 23.60 109.5 32.00 41.0
15.50 260.8 22.70 175.5 23.80 102. 1 34.00 29.2
17.00 253.6 22.80 168.8 24.10 94.2 35.00 23.1
18.50 244.8 22.90 160.9 24.50 87. 4
19.90 233.9 23.CO 152.2 25.00 81.7
20.80 224.3 23. 10 142.8 26.00 73. 8
Titraticn Nc. 6
14.00 212.9 17.70 163.3 19.00 114. 1 22.00 68*6
15.00 205.7 17.90 156.3 19.30 106. 1 23.00 60.1
16.00 195.9 18. 10 148.2 19.60 99. 4 24.50 48.4
16.50 189. 4 18.30 139.7 20.00 92.2 26.00 36.1
17.00 181.0 18.50 131.4 20.50 84.7 27.50 22.7
17.50 169.J 18.80 120.4 21.00 78.6
Titraticn Nc, 7
4.00 295.9 8.60 227.9 9.20 153. 1 9.60 94.6
5.00 287.8 8.80 217.0 9.22 146. 1 9.80 88.3
6. CO 278. 1 8.90 209.3 9.25 136.4 10.’00 84.0
6.80 268.6 9.00 198.8 9.28 128.0 10.50 76.0
7.20 262.8 9.05 191.6 9.32 119.4 11.20 67.1
7.60 256.0 9.10 182.0 9.36 112.5 12.GO 57.2
8.00 247.6 9. 15 1.69.5 9.42 105.4
j4
1j
8.40 235.9 9. 17 163.4 9.50 99.3
II
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Table 10 cent.
Added E Added E Added E Added E
Vol.b! I V Vcl.ml mV Vcl,ml mV Vcl.ml m '
Titration Nc, 8
0.50 328.6 8.00 261.3 9.10 200.0 9.32 124,
2.00 321.0 8.20 256. 1 9. 15 188.9 9.35 117
3.50 312.1 8.40 249.8 9.18 179.9 9.40 109
5.00 301.1 8.60 242.0 9.21 168. 1 9.45 103
6.00 291.7 8.80 231.6 9.24 155.3 9.55 97
6.50 286. 1 8.91 223.6 9.26 146, 6 9.70 92
7.00 279.6 9.C0 214.8 9.28 138.2 10.00 85
7.50 271.6 9.05 208.3 9.30 131.0 10.50 77
Titraticn Nc. 9
7.5C 196.9 9.15 146. 8 10.60 94.0 13.50 3 6
•8.00 187.9 9.30 139.0 11.00 85.2 14.00 24
8.30 180.8 9.50 129.3 11.40 77. 2 14.50 12
8.60 171. 4 9.70 120.9 11.80 69.7 15.00 2
8.90 159.3 10.00 110.4 12. 40 58. 5 15.50 -7
9.00 154.5 10.30 101.5 13*00 46.8
5
5
1
9
6
0
2
.5
,o;
6
,8
,2
, 1
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Table 11 EXPERIMENTAL lATA FOR LEAD-GLYCYLGLYCINATE
INTEEAGTIGN
Titn. Starting Solution Titrating £ oluticn Initial E°
No. A mM E wM H mM A mM B mM H wM Vol. ml mV
1 60.32 6.135 11.27 -40.02 20.01 4 52.9
2 30. 18 3.069 5.637 -40.02 20.01 452.9*
3 59.99 12.26 22.53 -40.02 20.01 4 51.9!
4 24.25 12.27 22.54 -40.02 20.01 4 51.9
5 12.06 12.26 22.53 -40.02 20.01 451.8
6 119.9 12.26 2 2.53 -40.02 20.01 451.65
7 5.983' 12.27 22.54 -40.02 20.01 451.3
8 12.13 5.141 11.28 -40.02 20.01 451.3
9 6.069 3.071 5.641 -20.01 20.01 451.3
Added E Added E Added E Added E
Vol.ml mi Vcl . ml mV Vol.ml mV Vol.ml mV
Titraticn No. 1
4.10 170.0 5.70 112.7 6.30 79.2 7.60 49.7-
4.60 160.2 5.80 105,8 6.4 0 75. 7 8.00 4 3.5"
4.90 152. 4 5.90 99.3 6.50 72.5 8.50 36.1
5.40 132.0 6.00 93.2 6.70 67.2 9.00 29.2
5.20 141.7 F.10 87.9 7.00 60. 6 9.50 22.7
5.60 119.6 6.20 83.2 7.30 54.9 10.10 15.8
Titraticn No, 2
2.60 138.0 2.95 92.4 3.80 46.3 6.00 -1.8
2.70 127. 6 3.GO 86.5 4.0 0 40.5 6.50 -9.0
2.75 121.2 3. 10 77.0 4. 20 34.9 7.00 -15.2
2.80 114.0 3.20 70.0 4.50 27.2
2.85 106.4 3.40 60.0 5.00 15.9
2.90 99. 1 3.60 5 2.5 5.50 6.2
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Table 11 cent,
Added E Added E Added E Added I
Vol.ml mV Vcl.ml Vi Vol.ml Vl Vol.ml m V J
Titraticn Nc. 3
0. 10 235.3 6.00 207.0 11.20 135.3 13.80 68. 1
0.50 23 3.5 8.00 193.2 11.50 119.7 15.00 56.4
1.C0 231.C 9.20 181. 1 11.80 105.0 16.50 41.9
2.CO • 226.7 10.00 169.6 12.20 91.4 18.00 27.2
4.CO 217.6 10.70 153.9 12.70 81. 4 20.00 9.7
Titraticn Nc. 4
1.C0 287.2 9.00 210.5 11.70 108. 8 16.60 43.7
2.00 277. 1 10.00 194.7 11.90 100.4 17.70 29.8
3.00 267.6 1C.50 183.2 12.20 93.7 18.50 19.5
4.50 253.9 11.C0 165.3 13.00 82.6
6.00 240.6 11.40 136.4 14.00 72. 1
7,50 226.9 11.60 116.8 15.50 56.6
Titration No. 5
4.00 304.0 8.70 238.7 11.20 164.7 11.80 102.8
5.00 29 1.8 9.50 224.8 11.30 153.5 12.60 8 8.6
6.00 277.8 10.00 214.5 11.40 138.4 14.00 74.0
7.00 263.5 10.50 201.7 11.50 122. 3 16.CO 52.3
8.00 248.8 11.00 180.4 11.60 112.4
Titraticn Nc, 6
0.20 207. 5 8.CO 172.8 11.40 117.7 13.80 66.1
1.00 205.1 9.00 163.8 11.70 108.0 15.00 54.1
2.00 201.8 10. 10 149.4 12.10 96.0 16.20 44.1
4.00 194.5 10.39 144.3 12.50 86. 3 17.60 33.5
6.00 185.4 11.00 130. 1 13.00 77. 1 19.00 24.0
Titraticn Nc, 7
6.00 308.8 10.00 237.1 11.40 141.6 12.20 94.5
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Table 11 cent.
Added E Added E Added E Added E
Vol. il mV Vcl.ml m V Vol.nl mV Vol.ml E V
Titraticn Nc, 1 cent.
7.50 290.5 10.50 2 20.1 11.45 129.0 13.00 84.9
8,50 272.5 11.00 196,1 11.50 119.8
9.00 261.9 11.20 178. 1 11.60 110.5
9.50 250.2 1 1.30 164.1 11.80 102.5
Titration Nc, 8
0.20 282.7 4.40 210.3 5.70 123.0 6.60 71.4)
1.00 269 .4 4.80 198.9 5.80 104. 1 7.30 58.0
1.70 258. 2 5.10 187. 1 5.85 98.2 8.00 4 4.0
2.50 245.5 5.30 175.9 5.90 94,0 8.70 28.2;
3.30 232.5 5.50 158.4 6.00 88. 3 9.20 16.5
3.90 221.5 5.60 144.0 6.20 80. 9 9.50 9 . 0*
Titration Ne. 9
5.60 119.7 5.90 79.6 8.00 34. 8 10.00 -6.7.
5.65 108,0 6.30 66.4 8.80 19. 1
5,75 91.0 7.20 49.3 9,40 6. 4
Table 12 EXPERIMENTAL EATA FOR LEAD-GLYCYLGLYCYIGIYCINATE
INTERACTION
Titn. Starting Solution Titrating Solution Initial E°
No. A mM E rnM H mM A mM E mM H mM Vol. ml mV
1 20.10 9.807 18.01 -20.01 20.0 1 4 5 1.2
2 10.06 4.907 9.013 -20.01 20.01 450.6
3 5.029 2.454 4.508 -20.01 20.01 450.6
4 2. 48 1 4.904 9.007 -20.01 20.01 4 51.4
5 5.011 4.901 9.002 -20.01 20.01 4 50.4
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Table 12 cont.
Titn. Starting Solution Titrating Solution Initial £0
No . A mK E mM H vl A mM B vl H vl Vol. ml mV
6 24.99 4.901 9.002 -20.01 20.01 450.2
r?
7 99.51 9.807 18.01 -40.03 20.01 448.8
8 49.75 4.903 9.006 -40.03 20.01 449 . 1
9 24.88 2.452 4.504 -40.03 20.01 4 49.7
10 2.481 4.904 9.007 -40.03 20.01 449.6
Added E Added E Added E Added B
Vol.ml mV Vcl.ml mV Vol.ml mV Vol.ml m V
Titration Nc. 1
0.20 287.2 11.00 2 2 6.2 18.20 130.6 21.50 69.3
1.00 281.8 13.0-0 214.0 18.40 117.4 23.00 60.3
3.CO 269.2 15.00 198.5 18.60 105.7 25.00 48. 1'-
5.00 258.0 16.20 185.2 18.90 95.2 27.00 35.0
7.00 247.4 17.00 172. 4 19.30 87. 6 29.00 21.7
9.00 237.0 17.80 150.6 20.00 80.0
Titraticn Nc. 2
0.20 274.0 5.20 225. 1 8.90 141.0 10.60 65.2
1.00 266.0 ■ 6.50 209.9 9. 10 117.6 11.70 52.5
2.00 256.2 7.60 192.1 9.30 95.0 13.00 37.3
3.00 246. 6 8.20 177.3 9.40 88.9 14.30 2 1.3J
4.00 237. 2 8.60 161.3 9.80 77. 1 15.30 9.0
Titraticn Nc. 3
0. 10 26 6.2 3.50 199.6 4.55 101.4 5.60 49.9>
0.50 259.4 3.90 184.4 4.60 90.2 6. 10 39.3.
1.00 2 51.0 4.20 165. 4 4.65 82.9 6.70 26.3
1.70 238.9 4.30 155. 2 4.75 74.9
2.30 227.9 4.40 140.2 4.90 68.0
2.90 215.6 4.50 115.8 5. 10 61.7
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Table 12 dont.
Added
Vol.ml
E
m V
Added
Vcl.ml
E
mV
Added
Vol.ml
E
mV
Added
Vol.ml
E
mV
Titraticn Nc. 4
0.20 323.8 6.20 268,9 8.50 202. 8 9.15 115.8
1.00 320.0 6,90 254,3 8.70 190,4 9.25 97.9
2.00 313.9 7.50 239.0 8.90 171.7 9.40 88,4
4,00 - 298,4 7.90 227.2 9.00 156. 3
5.50 280.5 8.20 216.5 9.10 131.2
5
Titraticn Nc, 5
0.20 311.6 6.20 239.6 9.10 117,3 11,00 60.9
1.00 306.1 7.20 221,2 9.20 100. 5 13.00 36.6
2.50 292. 3 8.00 201.8 9.30 91.9 -
4.00 273.7 8.80 162.9 9.50 83.7
5.20 266.7 9.00 138.4 10.00 73.7
Titraticn No. 6
0.10 223.9 6.00 187.2 9.10 110,1 10.50 63.5
1.G0 219.7 7.00 175.9 9.30 96.2 11.50 51.9
2.00 214.7 8.00 158.4 9.50 85.7 13,00 37. 1
3.50 206.1 8.50 143.3 9.80 75.9 14.50 23.3
5.00 195.8 8.80 129.7 10.00 71.6
Titraticn No. 7
0. 10 198.6 7.80 147.2 10.60 68.7 18.20 7,3
1.00 195.6 8.40 134,7 11.50 56, 4 19.50 1.3
2.00 191.6 6.80 123.2 12.50 46.3 21.00 -4.7
4.00 182.0 9.10 112.3 14.00 33.8 22.50 -10.1
6.00 168. 4 9.50 96.8 15.60 22.2
7.00 158.5 10,00 81.3 17.00 13.7
Titraticn Nc. 8
0.20 197.6 4.00 142.3 4.90 82, 4 7.40 2 6.6
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Table 12 cent.
Added E Added E Added E Added E
Vol.ml mV Vcl.ml mV Vol.ml mV Vol.ml mV
Titraticn No. 8 cent.
r?
1.00 191.3 4.30 127.2 5. 10 72. 3 8.20 16.7
2.00 181.6 4.50 112.6 5.40 62.0 9,20 6.3
3.00 167.9 4.60 104.2 6.00 48. 8
3.60 155.0 4.70 96. 1 6.60 38. 4
Titraticn Nc. 9
0.20 193.2 2.05 134. 2 2.45 76. 3 3.60 27.0
1.00 179.0 2.20 115.4 2.55 66.9 4.00 17.3
1.40 168.3 2.30 98.6 2.70 57. 5
1.70 157.0 2. 35 90.2 2.90 48,7
1,90 146.3 2.40 82.5 3.20 38. 4
Titraticn Nc.10
0.20 323.3 3.50 254.0 4.50 160.4 5.00 77.4
1.00 314.9 3.80 238.3 4.55 135.5 5.50 6 4.6
2.00 300.3 4.00 225.9 4.60 106. 3
2.70 284.5 4.20 210.3 4.65 95.6
3. 10 271.3 4.35 193.2 4.75 87. 6
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Table 13 EXPERIMENTAL DATA FOR LEAD-CHLORIDE INTERACTION
Titn. Starting Solution Titrating Solution Initial 303
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 5. 028 4.910 9. 018 199.9 20.0 1 62. 50
2 4.910 9. 018 199.9 20.01 62.60'
3 9.815 18 .03 199.9 20.01 63.00’-
4 6.134 11 .27 198.6 20.01 63.00
Added E Added E Added - E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1
0- 10 -71.1 1.30 -45.8 2.80 -32.6 6.20 -18.2:
0.15 -69.2 1.40 -44. 6 3.00 -31.3 6.60 -17.1i
0.20 -67.5 1.50 -43.5 3.20 -30. 1 7.00 -16.1
0.30 -64. 3 1.60 -42.5 3.40 -29,0 7.50 -14.9?
0-40 -61.7 1.70 -41.5 3.60 -28.0 8.00 -13.93
0.50 -59.2 1.80 — 40.5 3.90 -26.5 8.50 -12.9:
0.60 -57. 1 1.90 -39.6 4.20 -25. 2 9.00 -12.0
0.70 -55. 1 2.05 -38. 1 4.50 -23.9 9.60 -10.9;
0.80 -53.2 2.20 -36.9 4.80 -22.8 10.30 -9.il
0.90 -51.6 2.35 -35.7 5.10 -21.7 11.00
1.10 -48. 5 2.50 -34.6 5.40 -20.7 11.80 -7.1\
1.20 -47.3 2.65 -33.5 5.80 -19.4
Titration No. 2
0.40 -81. 1 2.50 -39.1 4. 10 -28.4 6.80 -18.3?
0.50 -75.6 2.60 -38.2 4.30 -27.4 7.10 -17.5
0.70 -67.9 2.70 -37.4 4.40 -26.9 7.40 -16.8^<
0.90 -62. 1 2.80 -36.6 4.60 -26.0 7.70 -16.1
1.10 -57.6 2.90 -35.8 4.70 -25. 6 8.00 -15.4
1.30 -53.8 3.00 -35. 1 4.90 -24.7 8.30 -14.7
1.50 -50.5 3. 10 -34.3 5. 10 -23.9 8.60 -14.
1.70 -47.8 3.20 -33.7 5.30 -23.2 9.00 -13..2:
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Table 13 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
1.90 -45.2 3.30 -33.0 5.50 -22.4 9.40 -12.5
2.00 -44. 0 3.40 -32.3 5.70 -21.7 9.80 -11.8
2.10 -42.9 3.50 -31.7 5.90 -21.0 10.20 -11.1
2.20 • -41.9 3.60 -31. 1 6. 10 -20. 4 10.70 -10.3
2.30 -40.9 3.-80 -30.0 6.30 -19.8
2.40 -39.9 4.00 -28.9 6.50 -19.2
Titration No. 3
0.10 -114.4 2. 10 -43.9 4.00 -29.6 7.70 -16.5
0.20 -98.7 2.20 -42.8 4.20 -28.6 8.10 -15.6
0.50 -77.0 2.30 -41.8 4.40 -27. 6 8.50 -14.7
0.70 -69. 1 2.40 -40.9 4.60 -26.7 8.90 -13.9
0.90 -63.3 2.55 -39.5 4.80 -25.8 9.30 -13.0
1. 10 -58.7 2.70 -38.3 5.05 -24.8 9.80 -12.2
1.30 -54.8 2.85 -37.0 5.30 -23.8 10.30 -11.2
1.50 -151.5 3.00 -35.9 5.60 -22.7 11.10 -10.2
1.60 -50.0 3. 15 -34.8 5.90 -21.6 11.70 -9.1
1.70 -48.6 3.30 -33.8 6.20 -20.6 12.50 -8.1
1.80 -47.3 3.45 -32.8 6.50 -19.8
1.90 -46. 1 3.’60 -31.9 6.90 -18.6
2.00 -45.0 3.80 -30.7 7.30 -17. 5
I
ii
Titration No. 4
0.30 -87.5 2.25 -41.6 5.00 -24.5 8.40 -14.5
0.45 -78.2 2.40 -40.2 5.25 -23. 5 8.90 -13.5
0.60 -71.4 2.60 -38.4 5.50 -22.6 9.40 -12.5
0.75 -66.6 2.80 -36.8 5.75 -21.7 9.90 -11.7
0.90 -62.3 3.00 -35.3 6.00 -20.9 10.30 -11.0
1.05 -59.0 3.20 -33.9 6.25 -20.0 10.70 -10.4
iI
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Table 13 cont;.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 4 cent. ■
1.20 -55.7 3.40 -32. 6 6.50 -19. 3 11 .1 0_ -9.8
1.35 -53. 1 3.60 -31,4 6.75 -18. 6 11.50 -9.1
1.50 -50.7 3. 80 -30.2 7.00 -17.9 11.90 — 8.6
1,65 -48.5 4.00 -29. 1 7. 25 -17.2 12.40 -8.0
1.80 — 46.6 4.25 -27.9 7.50 -16.6 12.90 -7.3
1.95 -44. 8 4.50 -26.7 7.80 -15.9
2. 10 -43. 1 4.75 -25.6 8.10 -15.2 ,4-
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APPENDIX 3 : CALORIMETERIC DATA FOR LIGAND PROTONATION AND POTENTIOMETRIC
DATA AT 10, 25 AND 40°C FOR LEAD(II)-LIGAND INTERACTION
TABLE 1 : CALORIMETRIC DATA FOR GLYCINATE PROTONATION
Titn. Starting Solution Titrating Solution Initial
no. AmM HmM AmM HmM Vol. ml
1 25.12 18.79 -150.2 99.57
2 30.18 18.79 -160.2 99.57
3 40.16 18.79 -160.2 99.57
4 20.01 9.399 -160.2 99.57
Added 
Vol. ml
AT Added 
Vol. ml
AT Added 
Vol. ml
AT Added 
Vol. ml
AT
Titration No. 1
1.00 0.0150 8.00 0.0285 20.00 0.0040 27.00 0.0028
4.00 0.0448 12.00 0.0523 22.00 0.0016 30.00 0.0012
6.00 0.0287 16.00 0.0051 24.00 0.0017
187
Titration No. 2
1.00 0.0169 7.00
... 3.00 0.0325 9.00
5.00 0.0320 13.00
0.0301 17.00 0.0062 29.00
0.0305 21.00 0.0065
0.0328 25.00 0.0059
0.0030
Titration No. 3
2.00 0.0327 10.00 0.0306 22.00 0.0059 34.00
6.00 0.0630 14.00 0.0214 26.00 0.0064
8.00 0.G309 18.00 0.0071 30.00 0.0053
0.0054
Titration No. 4
2.00 0.0314 8.00 0.0039 14.00 0.0028
4.10 0.0344 10.00 0.0034 16.00 0.0025
6.00 0.0182 12.00 0.0031 18.00 0.0020
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TABLE 2 CALORIMETRIC DATA FOR GLYCYLGLYCINATE PROTONATION
Titn.
No,
Starting
AmM
Solution
HmM
Titrating
AmM
Solution
HmM
Initial
Vol. ml
1 20.10 18.79 -160.2 99.57
2 30.19 18.79 -160.2 99.57
3 25.08 18.79 -160.2 99.57
4 ' 20.07 18.79 -160.2 99.57
Added
Vol. ml
at Added 
Vol. ml
AT Added
vol. ml
at Added
Vol. ml
Titration No. 1
3.00 0.0443 12.00 0.0443 18.00 0,0039 26.00
6.00 0.0449 14.00 0.0115 20.00 0.0049
9.00 0.0441 16.00 0.0055 23.00 0.0058
0.0070
z
at
Titration No. 2
12.00 0.0385 21.00 0.00543.00 0.0503
6.00 0.0498 15.00 0.0051 24.00 0.0053
9.00 0.0492 18.00 0.0055 27.00 0.0052
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Titration No. 3
3.00 0.0505 12.00 0.0334 221.^57 0.0054
- 6.00 0.0498 15.00 0.0357 24.00 0.0059
9.00 0.0484 18.00 0.0353 27.00 0.0057
Titration No. 4 .
9.00 0.0484 18.03 0.00502.00 0.0344
4.00 0.0341 12.00 0.0330 21.03 0.0053
6.00 0.0332 15.00 0.0356 24.00 0.0051
*>*-
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TABLE 3 : CALORIMETRIC DATA FOR GLYCYLGLYCYLGLYCINATE PROTONATION
Titn.
No.
Starting
AmM
Solution
HmM
Titrating
AmM
Solution
HmM
Initial 
Vol. ml
1 25.04 18.79 -160.2 99.57
2 20.12 18.79 -160.2 99.57
3 30.13 18.79 -160.2 99.57
4 25.11 18.79 -160.2 99.57
Added 
Vol. ml
AT Added
Vol. ml
AT Added
Vol. ml
AT Added
Vol.. ml
AT
Titration No. 1
3.00 0.0527 12.00 0-0393 21.00 0.0055
6.00 0.0512 15.00 0.00 53 24.00 0.0051
9.00 0.0504 18.00 0.0)54 27.CO) 0.0059
Titration No. 2
3.00 0.0513 9.C00 0.0502 i5.(x> 0.0058 21..03 0.0052
6.00 0.0514 12.C0> 0.0377 18.00 0.0052 24.C00 0.0057
*
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Titration No. 3
3.00 0.0503 12.00 0.0320 23.00 0.0061
6.00 0.0496 15.00 0.0054 27.00 0.0068
9.00 0.0488 19.00 0.0072 31.00 0.0060
Titration No. 4
3.00 0.0503 9.00 0.0497 15.00 0.0053 21.00 0.0049
6.00 0.0506 12.00 0.0345 18.00 0.0055 24.00 0.0052
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TABLE 4 : CALORIMETRIC DATA FOR GLUTATHIONATE PROTONATION
Titn.
No,
Starting
AmM
Solution
HmM
Titrating Solution
AmM HmM
Initial
Vo]_. ml
1 20.13 28.19 -250.5 99.57
2 25.12 28.19 -250.5 99.57
3 20.08 18.79 -250.5 99.57
4 25.17 18.79 -250.5 99.57
Added 
Vol. ml
AT Added 
Vol. ml
AT Added
Vol. ml
AT Added
Vol. ml
AT
Titration No. 1
4.00 0.0957 16.00 0.0986 28.00 0.0327
8.00 0.1045 20.00 0.0852 32.00 0.0292
12,00 0.1002 24.00 0.0359 36.00 0.0165
Titration No. 2
4.00 0.0998 16.00 0.0955 28.00 0.0335
8.00 0.1006 20.00 0.0931 32.00 0.0311
12.00 0.0978 24.00 0.0461 36.00 0.0282
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Titration No. 3
3.00 0.0798 12.00 0.0761 24.00 0.0337
6.00 0.0784 16.00 0.0864 28.00 0.0297
9.00 0.0767 20.00 0.0381 32.00 0.0177
Titration No. 4
4.00 0.1011 16.00 0.0933 28.00 0.0322
8.00 0.0993 20.00 0.0539 32.00 0.0300
12.00 0.0993 24.00 0.0354 36.00 0.0258
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Table 5 POTENTIOMETRIC DATA FOR LEAD-GLYCINATE INTERACTION
AT 10 C
Titn, Starting Solution Titrating Solution Initial E°
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 10.08 4. 913 9.023 • -20.04 20.01 419.5
2 10.08 4. 912 9.021 -20.03 20.04, 420.7
3 5.010 2. 455 4.509 -20.03 20.01 420.7
Added E Added E Added E Added E
Vol,ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1
0.10 277.4 8.85 181.3 9.38 93.5 11.20 38.3
1.00 272.7 8.95 174.3 9. 40 89.7 11.60 33.3
2.00 266.9 9.00 170.1 9.42 86.4 12.00 28.3
3.00 260.8 9.05 164.9 9.45 82. 5 12.40 22.3
4.00 254.3 9.10 158.6 9.49 78.1 12.80 16.9
5.00 246.9 9.14 152.4 9.54 73.7 13. 10 12.1
5.80 240. 1 9.18 144.6 9.59 70. 1 13.40 6,9
6.50 233.0 9.21 137.4 9.65 66. 9 13.60 3.4
7. 10 225.7 9.24 129.4 9.71 64,3 13.85 -1.0
7.50 219.8 9.26 123.6 9.80 61. 1 14. 10 -5.6
7.80 214. 6 9.28 118.0 9.90 58.4 14.40 -11.4
8.10 208.4 9.30 112.5 10. 10 53.9 14.60 -15.5
8.40 200.3 9.32 107.5 10.30 50.4
8.60 193.5 9.34 102.5 10.60 46.0
8.75 186.9 9.36 97.6 10.90 42. 1
Titration No. 2
1.00 271.9 8.80 190.9 9.47 110.8 10.60 49.3
2.00 266.4 8.95 183.8 9.49 105. 4 11.00 43.S
3.00 260.4 9.05 177.8 9.51 100.9 11.40 38.S
3.80 255.4 9,15 169.9 9.53 96.8 11.80 34.1
4.60 249.8 9.20 165.1 9.55 93.0 12.30 27. S
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Table 5 cont. .
Added E Added E Added E Added B
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
5.30 244.6 9.25 159. 1 9.58 88. 1 12.80 2 1.0
6.00 238.7 9.29 153. 1 9.62 8 3.0 13.20 15.0
6. 60 232.8 9. 32 147. 8 9.66 78.6 13.40 11.8
7.20 225.7 9.35 141.3 9.71 74. 5 13.70 6.9
7.70 218. 3 9.37 137.0 9.77 ' 70.5 14.00 1.7
8.00 213.0 9. 39 131.8 9. 85 66.6 14.30 -3.5
8.30 206.5 9.41 126.2 9.95 62.8 14.60 -9.2
8.50 201.3 9.43 121. 1 10. 10 58. 5
8. 65 196. 6 9.45 115.6 10.30 54.3
Titration No. 3
0. 10 268.9 4.35 189.7 4.69 1 10.3 5.25 41.2
1.00 260.6 4.40 185. 4 4.70 104. 8 5.40 37.1
1.50 255.4 4.45 180. 1 4.71 99.3 5.60 32.3
2.00 249.6 4.50 173.9 4.72 95.0 5.90 25»2^
2.50 242.9 4.53 169. 1 4.73 89.9 6.20 17.9*
2.90 236. 6 4.56 163. 4 4.74 85. 4 6.40 12.7
3.20 231. 1 4.58 158.9 4.76 78.4 6.60 6.9
3.50 224.5 4.60 153.7 4.78 73. 6 6.80 , 1.0
3.70 219. 3 4. 62 147.0 4.80 68.8 7.00 -5.3-
3.85 214.6 4.64 137.9 4.83 64. 1 7.20 -12.2
3.95 211. 1 4.65 • 132.7 4. 87 59.4 7.35 -17.8
4.05 207. 1 4.66 127.8 4.92 55. 1 7.50 -23.7
4. 15 202. 5 4. 67 122.7 5.00 50.5
4.25 196.9 4.68 116.4 5. 10 46. 1
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Table 6 POTENTIOMETRIC DATA FOB LEAD-GLYCINATE INTERACTION
AT 25 C
Titn. Starting Solution Titrating Solution Initial E°
No. A mM B mM H mM A mM B mM H mM Vol. ml ml
1 9.863 4.912 9.021 -20.03 20.01 433.6
2 5.063 2.455 4.509 -20.03 20.61 433.7'
3 12.31 6.128 10.87 -10.01 20.01 455.5%
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1
0. 10 288.7 7.70 223.5 9.09 154. 1 9.43 91.7'
1.00 283.7 8.00 217.2 9.12 148.5 9.50 85.5
2.00 277.7 8.20 211.9 9. 15 142.0 9.60' 79.2
3.00 271.3 8.40 205. 6 9.18 135.1 9.75 72.6!
3.80 265.7 8.60 197.3 9.20 130. 5 9.95 66.7
4.60 259.6 8.70 192.4 9.22 125.8 10.20 61.3
5.30 253.7 8.80 186.3 9.25 119.6 10.50 56.2.
5.90 248.0 8.90 178.4 9.28 113.4 11.00 49.2
6.50 241.4 8.95 173.6 9.31 108. 4 11.50 42.7
7.00 235.0 9.00 167.9 9.35 101.5
7.40 228.9 9.05 160.8 9.39 95.9
Titration No. 2
0.10 277.4 4.30 193.5 4.62 116.0 5.40 ' 42.8
1.00 268.8 4.35 188.3 4.63 111.4 5.60 37.7
1.50 263.3 4.40 182.0 4.64 107. 1 5.80 32.8
2.00 257.2 4.45 174.4 4.66 99.1 6.00 27.9
2.50 250.0 4.48 168.5 4.68 92.8 6.20 22.g
2.90 243. 3 4.50 164.1 4.70 87.4 6.40 17.7
3.20 237.3 4.52 158.7 4.72 82.9 6.60 12.0
3.40 232. 6 4.54 152.3 4.75 76.7 6.80 6.2
3.60 227.2 4.56 144.7 4.78 72.4 6.95 1.5
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Table 6 cont.
Added E Added E Added E Added 2?2
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m V
Titration No.
3.80 220.8
2 cont:.
4.57 139.5 4.82 68.0
r?
7. 10 -3.
3.90 217.0 4. 58 135. 4 4.90 61.6 7.25 -9.
4.00 212.7 4.59 130.5 5.00 56. 2 7.40 -15.
4. 10 207. 5 4.60 125.8 5.10 52.0 7.50 -20.
4.20 201.4 4.61 120.6 5.25 47. 1 7.60 -25.
Titration No. 3
8.00 287.0 21.50 213.7 23. 20 134.0 27.00 67.
10.00 280.9 22.00 203. 1 23.30 126.5 2 8.00 62.
12.00 274.3 22.30 194.0 23.45 117.0 30.00 51.
14.00 267.0 22.50 186.0 23. 60 109.5 32.00 4 1 .
15.50 260.8 22.70 175.5 23.80 102. 1 34.00 29.
17.00 253.6 22. 30 168.8 24. 10 94.2 35.00 23.
18.50 244.8 22. 90 160.9 24.50 87. 4
19.90 233.9 23.00 152.2 25.00 81.7
20.80 224. 3 23. 10 142.8 26.00 73.8
Table 7 POTENTIOMETRIC DATA FOR LEAD-GLYCINATE INTERACTION
AT 40 C
Titn. Starting Solution Titrating Solution Initial E 0
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 9. 970 4.913 9.023 -20.04 20.0 1 450
2 9.810 4.912 9.021 -20.03 20.01 453
3 5.090 2.455 4.509 -20.03 20.01 453
6
:
3
0
1
7
3
9
0
2
1
6
d
aI■1
j
j
i
j
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Table 7 cont.
Added E Added E Added E Added E j
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV j
Titration No. 1 - j
0.10 302. 1 8.45 213.0 • 9.27 132. 1 10.90^ 61.8
1.00 296.8 8.60 206.6 9.30 126.9 11.20 57.6,
2.00 290.6 8.70 201.4 9.33 122.1 11.60 52.1;
2.80 285.2 8.78 196.5 9.36 117.6 12.00
i
46.8 |
I
3.60 279.4 8.85 191.5 9.40 112.4 12.40 41.3]
4.30 274.0 8.90 187.6 9.44 107.9 12.80 35.7
5.00 268.0 8.95 182.9 9.49 102.9 13. 10 31.3
5.60 262.3 9.00 177.6 9.54 98.7 13.40 26,6
6. 10 257. 1 9.05 171.2 9.60 94.6 13.70 21.8
6.60 251.1 9.09 165.2 9.70 89. 1 14.00 16.7
7. 10 244.2 9. 12 160.2 9.80 84.8 14.30 11.3
7.50 237.5 9. 15 154.8 9.90 81.3 14.60
j
5.5;I
7.80 231.6 9. 18 149.2 10.00 78.4 14.80 1.3>
8.00 226.9 9.21 143.4 10. 15 74.7
I
i
!
8. 15 222.9 9.23 139.4 10.35 70.7
1
iJi
8.30 218.4 9.25 135.7 10.60 66. 3
I
t
Titration No. 2
i
4
i
0.10 304.7 8.60 212.8 9.39 133.7 10.90 66.5
i
1.00 299.2 8.75 206.1 9.41 130.3 11.30
j
60.8
J
2.00 292.9 8.85 200.6 9.44 125. 5 11.70 55.5
3.00 286. 1 8.95 194.0 9.47 121.2 12.20 48.9
3.80 280.2 9.05 185.6 9.5-1 115.9 12.70 42.2j
4.60 273.9 9. 10 180.4 9.55 111.3 13.20 35.
5.10 269.7 9.14 175.7 9.60 106. 2 13.60 29. G
5.60 265.1 9. 18 170.5 9.65 102.0 13.90 24.5
6.10 259.9 9.21 165.9 9.72 97. 1 14.20 19 J
I
6.60 254.0 9.24 161.1 9.80 92.6 14.50
1
13.«4
7.00 248.8 9.27 155.9 9.90 88. 2 14.70 9 J
£1
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Table 7 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
7.40 242. 6 9.30 150.6 10.00 84.7 14.90 5.2
7.80 235. 3 9. 33 144.8 10.15 8G. 4 15.10 0.3
8.10 228.6 9.35 141.0 10.35 75. 8 15.30 -4.9
8.40 220. 1 9.37 137.2 10.60 71.2
Titration No. 3
0-10 291.8 4.40 196.0 4.68 122.7 5.80 47.2
1.00 282.2 4.45 189.2 4.69 118.9 6.00 42.3
2.00 270.0 4.49 182.8 4.71 112.6 6.20 37.2
2.50 262.7 4.51 179. 1 4.73 106.9 6.40 32.0
2.90 255.7 4.53 174.8 4.75 101.9 6.60 26.8
3.20 249.6 4.55 169.9 4.77 97. 8 6.80 2 1. 1
3.40 244.9 4.57 163.7 4.80 92.6 7.00 15. 1
3.60 239.5 4.58 161.1 4.84 87.0 7.20 8.1
3.80 233.0 4.59 157.7 4.88 82.7 7.35 2.0
3.95 227.2 4.60 153.8 4.93 78.2 7.45 -2.5
4.05 222.6 4.61 150.2 5.00 73.6 7.55 -7.5
4. 15 217.2 4.62 146.8 5. 10 68.5 7.65 -13.3
4.25 210.4 4.64 138.9 5.20 64.3 7.75 -19.8:
4.30 206.3 4.65 134.2 5.40 57.8 7.85 -27.3
4.35 201.6 4.66 130.2 5.60 52.4 -
j
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Table 8 POTENTIOMETRIC DATA FOR LEAD-GLYCYLGLYCINATE 
INTERACTION AT 10 C
Titn, Starting Solution Titrating Solution Initial E°
No, A mM B mM H mM A mM B mM H mM Vol. ml mV
1 10.09 4.912 9.021 - -20.04 20.01 419.8
2 10.24 4.912 9.021 -20.03 20.0J 418.8
3 5.071 2.455 4.509 -20.03 20.01 419.3
Added E Added E Added E Added T?ij
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No, 1
0. 10 254.6 7.50 180.5 9,10 111.0 9.70 56.6
1.00 246. 3 7.90 172.7 9. 14 104.9 9.90 52.1
2.00 237.4 8.20 165. 3 9. 17 100.2 10.20 47. r
2.80 230.3 8. 40 159. 1 9.20 95. 1 10.60 41.8-
3.60 223.3 8.55 153.4 9.23 90. 6 11.00 37.1
4. 40 216.3 8.70 146. 4 9.27 84.9 11.50 31.4
5.20 208.9 8.80 140.6 9.32 77.5 12.00 25.7
5.90 201.9 8.90 133.4 9.38 71.6 12.50 19.7
6.50 195.0 9.00 123.9 9.45 66. 5 13.00 13.3
7.00 188. 4 9.05 118. 1 9.55 61.6
Titration No. 2
0. 10 250.3 7.20 183.7 9.10 110.9 9.90 51.3
1.00 242.4 7.60 177. 1 9. 13 106.5 10.20 46.5,
1.50 238. 1 7.90 171.1 9.16 102.0 10.50 42.6
2.00 233,9 8. 10 166.4 9. 19 97.4 10.90 37.7
2.50 229.8 8.30 160.9 9.22 92.4 11.30 33.2
3.00 225.7 8.50 154.0 9.25 87.9 11.80 27.4
3.50 221.5 8.60 149.8 9.30 80.6 12.20 22,6i
4.00 217.4 8.70 145.2 9.35 74.2 12.50 18,9
.1
4.60 212.2 8.80 139.5 9.40 69.3 ' 12.90
j
13.85
5.20 206.7 8.90 132,4 9.45 65. 6 13.40
■I
7.2 -to
.
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Table 8 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
5.80 200. 7 8.95 128.0 9.50 62.9 13.70 3.
6.30 195. 3 9.00 123.2 9.60 58.7
6.80 189. 0 9.05 117.4 9.75 54. 3
Titration No. 3
0. 10 244.2 3.95 170.8 4.61 98. 3 5.05 41.
0.50 238. 3 4.05 166.4 4.62 95.2 5.20 37.
0.90 232.6 4. 15 161. 1 4.63 91.6 5.40 32.
1.30 226.7 4.25 154.7 4.64 87.9 5.70 25.
1.70 220.5 4.30 150.8 4.66 81.0 5.95 20.
2.00 215.7 4.35 146. 4 4.68 75.0 6.20 14.
2.30 210.7 4.40 141.0 4.70 69. 4 6.40 10.
2.60 205. 4 4.45 134.5 4.72 65. 1 6.60 5.
2.90 199.7 4.48 129.9 4.75 60. 4 6.80 0.
3.20 193.3 4.51 124.6 4.78 56.6 7.00 -3.
3.45 187.1 4.54 118.4 4.82 52. 6 7.20 -8.
3.65 181.5 4.57 110.9 4.87 49.3
3.80 176.6 4.59 105.0 4.95 45. 4
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Table 9 POTENTIOMETRIC DATA FOR LEAD-GLYCYLGLYCINATE 
INTERACTION AT 25 C
Titn. Starting Solution Titrating Solution Initial
No. A mM B mM H mM A mM B mM H mM Vol. ml
1 9. 874 4 .912 9. 021 -20.03 20,01
2 4. 935 2 . 455 4. 509 -20,03 20,01
Added E Added E Added E Added
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml
Titration No. 1 -
0. 10 266. 4 7.00 196.0 9.10 127.8 9.75
1.00 257. 6 7. 40 189.7 9.15 122.3 9.90
1.50 252,7 7.60 186. 1 9, 20 116, 1 10.10
2.00 247.9 7.80 182. 3 9.24 110.8 10.40
2,50 243.2 8.00 177.9 9.27 106. 4 10.80
3.00 238. 6 8.20 172.8 9.30 102.2 1 1.20
3.50 2 33,9 8.40 166.9 9.34 96.7 11,60
4,00 229. 3 8.60 159.7 9.38 91.6 12.10
4.50 224.5 8.70 155. 4 9.42 86. 7 12.60
5.00 219-6 8.80 150.4 9.46 83. 1 13,00
5.50 214.4 8.90 144. 4 9.51 79.0 13.40
6.00 208.9 8.98 138.7 9.57 75.4
6.50 202. 8 9.04 133. 6 9. 65 71.6
Titration No. 2
0. 10 256.4 3.80 182. 1 4.5 6 107. 4 5.35
0.50 250. 1 3. 90 177.9 4.58 101.1 5.55
0.90 243.6 4,00 173. 3 4.60 94.8 5.80
1.20 238.7 4. 10 167.7 4.62 89.2 6.10
1.50 233.7 4.20 161. 1 4.64 83.8 6.40
1.80 228. 6 4. 28 154.5 4.66 79. 1 6.60
2.10 223. 3 4.33 149.6 4.68 75. 1 6.80
2. 40 217.7 4. 38 143.8 4.71 70.3 7.00
E°
mV
4 36.6
436.6
E
mV
68.0
64.0
59.9
55.0
49.7
44.9
40.2
I
34.5
i28.7
23.9
i
19.4
41.61J37.0:
31.5
25.0
)
18.4
13.
9.
s.d
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Table 9 cont.
Added E Added E Added E Added E -
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
r?2.70 211.8 4.43 136.5 4. 75 65. 6 7.20 0.2:
3.00 205. 3 4.47 129.4 4.80 61.5 7.40 — 4.6
3.30 198.0 4. 49 125. 3 4.90 55.8
3.50 192.3 4.51 120.6 5.00 51.7
3.70 185. 8 4.54 113. 1 5. 15 46.9
Table 10 POTENTIOMETRIC 
INTERACTION AT
Titn. Starting Solution
DATA FOB LEAD-GLYCYLGLYCINATE
40 C
Titrating Solution Initial E°
No. A mM B mM M mM A mM B mM M mM Vol. ml mV
1 10.87 4.912 9.021 -20.04 20.01 452.:
. 2 10.24 . 4.912 9.021 -20.03 20.01 452.5
3 4.965 2.455 4.509 -20.03 20.01 451.:
Added E Added E Added B Added E '
Vol.ml mV Vol.ml mV Vol.ml mV VoV.kV mV ]
Titration No. 1
0. 10 271.0 7.70 188.4 9.25 116.7 10.50 66.4
1.00 262. 4 8. 10 179.4 9.30 111.3 10.80 62.2
1.70 255.6 8.30 173.8 9.35 106. 1 11.10 58.5
2. 40 249.0 8.50 167.0 9.40 101.3 11.50 53.5
3.00 243.5 8.65 160.9 9.45 97.2 11.90 49, a
3.60 237.9 8.75 156.2 9.50 93.5 12.40 43,7
'4.20 232.3 8.85 150.8 9.55 90.2 12.90 38.2
4. 80 226. 4 8.95 144.3 9.65 85.4 13.40 J32.5
5.40 220.2 9.05 136.6 9.75 81.7 13.90 27.0
■ ;;S
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Table 10 cont •
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1 cont.
17
6.00 213.6 9.10 132. 1 9. 85 78.7 14.40 21.2
6.60 206. 1 9. 15 127.3 10.00 75. 1 14.90 15.5
7. 20 197.4 9.20 122. 2 10.20 71.2 15.30 10.7
Titration No. 2
0. 10 275.7 7.40 196.6 9.25 121.6 11.00 59.7
1.00 266.5 7.70 191.0 9.30 116.1 11.40 54.9
1.50 261.6 7.90 186.8 9.35 110.4 11.80 50.44
2.00 256.7 8. 10 182.0 9.39 106.2 12.30 44.9
2.50 251.9 8.30 176.5 9.43 102.2 12.80 39.3
3.00 247. 1 8.50 169.9 9.47 98.6 13.30 33.7
3.50 242. 3 8.65 164. 1 9.53 93.8 13.70 29.2
4.00 237.5 8.75 159.6 9.59 90.0 14.20 23.6
4.50 232.5 8.85 154.4 9.70 84,8 14.60 18.9
5.00 227.4 8.95 148.3 9.80 81. 1 15.00 14.2
5.50 222. 1 9.05 140.8 9.95 76.7 15.50 8.3
6.00 216.4 9.10 136.6 10. 10 73.4 16.00 2.2
6.50 210. 1 9. 15 132. 1 10.30 69.6 16.50 -3.7
7.00 203.1 9.20 127. 1 10.60 65.0
Titration No. 3
0. 10 266.1 3.90 185.2 4.67 101.8 6.15 37.9
0.50 259.5 4.05 177.9 4.69 97»4 6.40 32.8!
0.80 254.5 4.15 172.2 4.72 91.8 6.65 27..£
1. 10 249.4 4.25 165.2 4.75 87. 4 6.90 22.7
1.40 244.2 4.32 159.4 4.78 82.8 7.15 17 Jj
1.70 238.9 4.38 153.4 4.81 79.8 7.40 12.2
2.00 233.5 4.43 147. 3 4.86 75. 4 7.65 6.£!
2.30 227.9 4.47 142.0 4.93 70.7 7.85
2.1
2
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Table 10 cont.
Added
Vol.ml
E
mV
Added
Vol.ml
E •
mV
Added
Vol.ml
S
mV
A dded
Vol.ml
E
mV
Titration No. 3 cont.
2.60 221.8 4.51 135.5 5.00 67. 1 8.05 -2.0
2.90 215.4 4. 54 130.1 5.10 63.0 8.25 -6.4i
3.20 208. 2 4.57 123.9 5.25 58. 2 8.50 -11.9
3.40 202. 6 4.59 119.7 5.4 5 52.9
3.60 196.5 4.61 115.3 5.65 48. 3
3.75 191.2 4. 64 108. 1 5.90 43.0
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Table 11 POTENTIOMETRIC DATA FOR LEAD-GLYCYLGLYCYLGLYCINATE 
INTERACTION AT 10 C
Titn. Starting Solution Titrating Solution Initial. go
Mo. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 9. 400 4. 912 9.021 -20.03 20.01 419
2 5. 096 2. 455 4.509 -20.03 20.071 419
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m'
Titration No. 1
0. 10 252. 9 7.40 179.6 9.19 108.0 10.05 49
1.00 244. 3 7. 70 174.4 9.23 102.4 10.30 45
1.50 239.6 8.00 168.4 9. 26 97. 8 10.60 41
2.00 235. 1 8. 20 163. 6 9.29 92.9 11.00 36
2,60 229.6 8.40 157. 8 9. 32 87.9 11.40 32
3.20 224. 2 8.55 152.8 9.35 83.2 11.90 26
3.80 218,8 8.70 146.8 9. 40 76. 3 12,30 22
4.40 213. 4 8, 80 141.9 9. 43 72.7 12.70 17
5.00 207.8 8.90 136.1 9.47 69.0 13.00 13
5.60 201.9 9.00 129.0 9.52 65. 3 13.30 10
6.20 195. 5 9.05 124. 5 9.60 61. 1
6.70 189. 5 9. 10 119.4 9.70 57.5
7.10 184. 1 9. 15 113.3 9. 85 53. 4
Titration No. 2
0.10 243.0 3.65 177.7 4.54 1 12. 3 4.78 54
0.50 236. 8 3.80 172.8 4.56 107.3 4.82 50
0.80 232. 1 3.95 167.0 4,5 8 101.2 4,87 47
1.20 225.8 4. 10 159.8 4.60 95.6 4.95 44
1.50 221.0 4.20 153.8 4.62 88. 8 5.05 40
1.80 216. 2 4.25 150.3 4.63 85.4 5.20 36
2.10 211.2 4.30 146.3 4.64 82. 2 5.40 31
2.40 205.9 4.35 141.6 4,65 78.5 5.60 27
6
6
4
5
5
8
2
7
0
3
7
1
0
8
9
2
7
4
6
1
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Table 11 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
2.70 200. 3 4. 40 136. 1 4.67 72.7 5,80 22.9
3.00 194.3 4.45 129.3 4.69 67.2 6.00 18.5
3.25 188.6 4.48 124. 4 4.71 63.1 6,20 14,2
3.45 • 183. 5 4. 51 118.8 4.74 59.0
Table
Titn.
12 POTSNTIOHETRI 
INTERACTION
Starting Solution
C DATA FOR LEAD-GLYCYLGLYCYLGLYCINATE
AT 25 C
Titrating Solution Initial E®
No. A mM B mH H mM A mM B mM H mM Vol. ml mV %
1 10 .03 4.912 9.021’ -20.03 20.01 4 36.5■
2 5. 096 2.455 4.509 -20.03 20.01 4 36.5
Added E Added E Added S Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1
0.10 263.8 6.50 197.9 9.04 126.7 9.70 66.6
0.50 259.6 6.90 192.5 9.09 121. 6 9.85 62.7
1.00 254.4 7.30 186.3 9.13 117.3 10.05 58.3
1.50 249.2 7.60 181.0 9,17 112.5 10.30 54.1.j
2.00 244.2 7,90 174.9 9.21 107.2 10.60 50.6
2.50 239. 3 8. 10 170.1 9.25 101.9 11.00
45.1
1
3.00 234. 5 8. 30 164,5 9.29 96.1 11 .50 40.11
3,50 229.7 8.50 157.8 9.33 90.9 12.00 34.!
4.00 224.9 8.60 153.9 9.36 87.3 12.50 28.(1
4.50 220.0 8.70 149.5 9.40 83.2 12.80 25.{
5.00 215.0 8.80 144.3 9.45 78.8 13,20 20. i
208
Table 12 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1 cont.
5.50. 209.7 8.90 138. 1 9.50 75.4 13.60 16.
6.00 204. 1 8.98 132. 1 9.60 70.5
Titration No. 2 *
0. 10 ' 251.8 3.60 184.1 4.54 116.2 4.95 54.
0.50 245.2 3.75 179. 1 4.56 111.7 5.05 50.
0.80 240. 3 3.90 173.3 4.58 106.8 5.20 46.
1.10 235.2 4.00 168.7 4.60 101. 5 5.40 40.
1.40 230. 1 4.10 163.3 4.62 96.3 5.60 36.
1.70 225. 1 4.18 158.5 4. 64 90.6 .5.85 31.
2.00 219.8 4.26 152.6 4.66 85.8 6.10 26.
2.30 214.3 4.32 147.6 4.68 80.9 6.35 20,
2.60 208.6 4.37 142.5 4.70 76.6 6.60 15.
2.85 203.4 4.41 137.8 4.73 71.7 6.85 10.
3.05 199.0 4.45 132.3 4.76 68.0 7.10 5.
3.25 194. 1 4.49 126.0 4.80 63. 6 7.35 0.
3.45 188.7 4.52 120.3 4.85 59.9 7.60 -4.
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Table 13 POTENTIOHETRIC DATA FOB LEAD-GLYCYLGLYCYLGLICINATE
INTERACTION AT 40 C
Titn, Starting Solution Titrating Solution Initial eOE
No. A mM B mM H mM A m M B m M H mM Vol. ml mV
1 10.09 4. 912 9.021 -20.03 2 0.01 453.0%
2 5.001 2. 455 4.509 -20.03 20.cn 453.2-,
Added E Added E Added E , Added E
Vol.ml mV Vol.ml mV Vol.ml mV V ol.ml m V
Titration No. 1
0. 10 274. 4 6.90 199.9 9,05 130, 1 10.40 65.6-
1.00 264.7 7. 20 195. 1 9.10 125. 1 10.80 60.2
1.50 259. 3 7.50 189.7 9. 15 119.9 11.30 54.2
2-00 254. 2 7.70 185.7 9,20 114.4 11.80 48. 6
2.50 249.0 7.90 181.3 9. 25 108,9 12.30 43. 1
3.00 243.9 8, 10 176.2 9.30 103. 8 12.80 37.7:
3.50 238.7 8.30 170.3 9.35 99. 1 13.30 32.3
4.00 233.7 8.50 163.2 9.45 91.4 13.80 26.3
4.50 228.6 8.60 159.0 9. 53 86. 8 14.30 21.44;
5.00 223. 4 8.70 154.2 9.63 82, 4 14.80 16.0
5.50 217.9 8.80 148.8 9.75 78. 4
6.00 212.1 8.90 142.3 9.90 74. 6
6.50 205. 6 9.00 134.6 10. 10 70.5
Titration No. 2
0.10 264.0 s 3.50 194.5 4. 49 126. 1 4.95 66.4
0.50 256. 9 3.65 189.4 4.52 120.0 5. 10 60.83
0.80 251.6 3.80 183. 6 4.54 115. 4 5.25 56. 5
1- 10 246. 2 3.95 176.8 4.56 111,2 5.45 51.7
1.50 239.0 4.05 171.4 4.58 106. 6 5.70 46.3
1.80 233. 4 4. 15 165.2 4.60 102.1 5.95 41 .2;
2. 10 227.7 4,23 159. 1 4. 63 96.6 6.20 36.3
2.40 221.6 4. 30 152.8 4.67 88.8 6.45 31.4
Table 13 cont
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml r V
Titration No. 2 cont;.
2. 65 216. 3 4.35 147. 4 4.70 84,3 6.70 26.8
2.90 210.8 4.40 140.9 4.74 79.8 6.95 . 21.9
3.10 205.9 4.43 136.4 4.79 75. 3 7. 15 18.0
3.30 200.5 4.46 131.6 4. 85 71.4 7.40 12.9
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Table 14 POTENTIOMETRIC DATA FOR LEAD-CYSTEINATE INTERACTION 
AT 10 C .
Titn. Starting Solution Titrating Solution Initial E°
No. A rM B rM H rM A mM B rM H r M Vol. ml mV
1 4 . 970 1 .228 2.256 -20.03 20.01 420.'3
2 4 .970 1 .228 2.256 -20.03 20.01 420.1;
Added E Added E Added E . Added E
Vol.ml mV Vol.ml mV Vol.ml l'V Vol.ml mV
Titration No. 1
0. 10 257. 7 2.40 193. 5 4.05 148,0 5.20 -8.7
0.50 252. 1 2.50 189.7 4.20 142.8 5.35 -19.7s
0.90 245.2 2.60 186.3 4.35 136. 3 5.50 -28,8'
1. 10 241. 1 2.70 183.2 4.50 127.3 5.70 -39.2
1,30 236.4 2.80 180.4 4.60 117.8 5-90 -48.3
1.50 230. 9 2.90 177.7 4.70 100.7 6-20 — 60.3;
1.65 226. 1 3.00 175. 1 4.75 33.4 6.50 -71.3
1.80 220. 6 3. 15 171.3 4.80 59.4 6-80 -81.3
1.90 216.3 3.30 167.7 4. 85 40. 8 7. 10 -91.0
2.00 211.8 3. 45 164.0 4.90 28,4 7.40 -100.4
2. 10 207.0 3.60 160.0 - 4.95 19. 2 7.70 -109.7
2.20 202. 3 3.75 156.3 5.00 11,8 8.00 -1 19.2
2.30 197.8 3.90 152.5 5. 10 0. 1 8.30 -128.9
Titration No. 2
0.10 " 257.8 3.75 155.9 5.26 -14, 4 6.55 -74.3
0.50 252. 1 4. 10 145. 5 5.33 -19.4 6,70 -79.3
1.00 243.2 4.4-0 132. 4 5.40 -24.0 6.85 -84.2
1.50 230.8 4.60 115.2 5.50 -29.9 7.05 -90.6
1.90 215.9 4.70 95.3 5.60 -35. 4 7.25 -96.7
2. 10 206. 5 4.80 53.7 5.70 -40.4 7.45 -102.9
2.30 197.4 4. 90 26.0 5.80 -45, 3 7,65 -109 . 1
2.50 189. 5 5.00 10.4 5.95 -51.7 7.85 -115.4
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Table 14 cont
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m V
Titration No. 2 cont,
2.75 181. 4 5. 10 -0.9 6.10 -57.9 8.05 - 121.5
3.05 173. 3 5. 15 -5.4 6.25 -63. 6 8.25 - 128.0
3.40 164.7 5.20 -9.6 6.40 -69, 1 8.45 - 134.5
Table 15 POTENTIOMETRIC DATA FOR LEAD- CYSTEINATE: INTERACTION
AT 25 C
Titn. Starting Solution Titrating Solution Initial E°
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 4. 788 1 . 228 2.256 -20.03 •20.01 437.0
2 4. 788 1 . 228 2.256 ’ -20.03 20.01 437.2
3 3. 898 0, 981 1.802 -20.02 20.01 451.3
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ral mV Vol.ml mV .
Titration No. 1
0.10 265.4 2.00 219.9 3.25 181.2 4.70 86.4
0.50 259.4 2.10 215.9 3.45 176. 3 4.75 60.7
0. 80 254.2 2. 20 212.0 3.65 171.3 4.80 44.9
1.00 250.3 2.35 206.5 3.85 165. 9 4.85 32.9
1.20 245.7 2.50 1.4 4.00 161.3 4.90 24.6
1,40 240. 5 2.65 196.8 4. 15 155. 8 4.95 17,4
1.60 234, 4 2,80 192.6 4.30 149.0 5.00 9,6
1.75 229.3 2.95 188.7 4.45 139. 4
1.90 223.7 3.10 184.9 4.60 121.1
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Table 15 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m V
Titration No, 2
0. 10 265.9 3,20 182.5 4.95 19.6 7. KP -76,1
0.50 259,9 3. 40 177.6 5.00 13. 4 7.50 -87,1
0.80 254.7 3.65 171.4 5.05 8.0 7.90 -97.8
1. 10 248. 5 3.90 164. 6 5.10 3.2 8.20 -106-2:
1.30 243. 6 4.15 156.3 5. 15 -0.8 8.40 -111.8
1.60 234.9 4.40 144. 4 5. 25 -8.1 8.70 -120.4
1.80 227.9 4. 60 125.0 5.45 -20.0 9.00 -129.3':
2.00 220.2 4. 65 114.3 5.65 -29.5 9.30 -138 .4,
2.20 212.3 4.70 96. 1 5.85 -37.6 9.60 -147. &
2.40 204. 9 4.75 69.1 6.05 -44.7 9.90 -157.1
2.60 198. 4 4.80 49.4 6. 25 -51.5 10.10 -163,3
2.80 192. 6 4. 85 36. 5 6.50 -59.3
3.00 187.5 4.90 27.1 6.80 -67,9
Titration No. 3
0.10 275.4 3.67 138. 1 3.91 38,6 5. 15 -42.6;
1.00 255. 2 3.70 130.1 3.94 33, 1 5,35 -49.1
1.70 226. 3 3.72 122.7 3.97 28. 3 5.60 -58.2
2.20 206.2 3.73 117.5 4.00 24.3 5.85 -66,2
2.35 201.3 3.74 111.6 4.04 19.2 6. 10 -74.3;
2.50 196. 6 3.75 104. 6 4.08 15.0 6.40 -84,2;
2.70 190.6 3.76 97. 4 4. 13 10, 1 6.60 -90.9
2.90 184.7 3.77 90.4 4.19 5.0 6.80 -97,7;
3.05 179,7 3.78 83. 1 4.26 -0.2 7.00 -104.6
3. 20 174. 2 3.79 77.2 4.34 -5.7 7.20 -112.oj
3.30 170.0 3.80 71.8 4.4 3 -11.2 7.40 -119.5;
3.40 164. 8 3.81 67.5 4.52 -16. 1 7.60
j
-127,0
3.50 158.3 3.82 63. 3 4.62 -21.0 7.80 -134.5j
3. 55 154. 3 3. 84 56.4 4.75 -27,0 8.00 -141.3
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Table 15 cont.
Added E Added E Added E Added E i
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m V
Titration No. 3 cent.
3.60 149.0 3. 86 50.3 4.88 -32.3 8.20 -148.6-
3.65 141.9 3. 88 45. 1 5.00 -37.0
Table
Titn.
16 POTENTIOHETRIC DATA FOR LEAD-CYSTEINATE 
. AT 40 C
Starting Solution Titrating Solution
INTERACTION
Initial E®
No. A mM B mM H mM A mM B mM H iM Vol. ml mV
1 2. 460 1. 228 2. 256 -20.03 20.01 457.8
2 4. 854 1. 228 2. 256 -20.03 20.01 457.8
3 4. 854 1. 228 2. 256 -20.03 20.01 457.9
Added E Added E Added E Added E .E .
Vol.ml mV Vol.ml mV Vol. nil mV Vol.ml mV
Titration No. 1
0. 10 285.8 2.28 220.0 4.20 158.6 4.91 12.0
0.30 282.8 2. 36 216.4 4.30 154. 3 4.93
-
6.8
0.60 277.8 2.44 212.9 4.40 149. 3 4.95 2.6
0.90 271.9 2.52 209.7 4.50 143.0 4.98 n -1
1.10 267.3 2.60 206.7 4.60 134. 3 5.02 -9.6
1.30 261.9 2.70 203.3 4.65 128.0 5.06 -15.5
1.40 258.7 2.80 200.0 4.70 118.8 5. 10 -20.6-
1.50 255- 4 2.95 195.6 4.75 100.6 5.14 -25.2
1.60 251.9 3.10 191.3 4.80 61.0 5.18 -29.5
1.70 247.9 3. 30 185.8 4.82 46.9 5.23 -34.4
1.80 243.9 3.45 181.6 4. 84 36.4 5.28 -39.3
1.90 239. 1 3.60 177.6 4. 85 31.9 5.33 -43.6
A
O
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Table 16 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1 cont:.
2.00 234.2 3.75 173.3 4. 86 27.3 5.40 -49.5
2, 10 228.9 3.90 168.9 4.88 20.5 5.50 -57,5
2.20 223.9 4.05 164. 1 4.89 17.2
Titration No. 2
0.10 278.7 3.00 203.5 4.77 88. 2 6.50 -47.8
0.50 272. 5 3. 15 199.7 4.79 77, 1 6.90 -58.9'
0.80 267.3 3.30 196.0 4.82 64.0 7.30 -69.6
1. 10 260.9 3.50 191.1 4.84 57.8 7.70 -80.2
1.30 255.9 3.65 187.3 4.86 51.7 8.10 -91.0:
1-50 250.3 3.80 183.3 4.90 42.6 8.50 -102.#‘ts.
1.70 244.2 3.95 179.0 4.95 33. 4 8.90 -113.1
1.90 237. 6 4. 10 174. 1 5.00 26.3 9.30 -125.6"
2.00 233.9 4.20 170.4 5.10 • 15. 3 9.70 -137.7
2. 10 230. 4 4. 30 166. 1 5.20 6.8 10.00 -146.7
2.25 225.2 4. 40 160.7 5.35 —3. 3 10.30 -155.3
2.40. 220. 1 4.50 153.9 5.50 -11.5 10.60 -163.4
2.55 215.7 4.60 143.8 5.70 -20.6 11.00 -173.2
2.70 211. 4 4.70 123.6 5.90 -28.4 ■
2.85 207.4 4.75 100.5 6.20 — 38. 6
Titration No. 3
0.10 278.3 4.20 169.2 5.45 -10.0 8.60 -105.7
0.40 273. 8 4.40 159.3 5.55 -14.9 8.80 -111.4
0.70 268.6 4.50 152.2 5.70 -21.6 9.00 -117.2j
1. 10 260. 4 4.60 141.2 5.85 -27.6 9.30 -126.2
1.50 249.8 4.70 118.7 6.00 -32. 9 9.50 -132.3?
1.70 243- 4 4.75 94. 1 6.20 -39.7 9.70 -138.3
1.90 236.5 4.80 68.7 6.40 -45.9 9.90 -144,4
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Table 16 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Tltratlon No. 3 cont.
2. 10 229,4 4.85 52, 4 6, 65 -53. 1 1O.1QP -150.4
2.30 222.6 4,90 41.1 6,90 -59.9 10.30 -156. 1
2.50 216. 3 4.95 32. 5 7.15 -66.6 10.50 -161.7
2,80 207.9 5.00 25.6 7.40 -73. 3 10.70 -167.0
3.00 202. 8 5.05 19.7 7, 60 -78.5 10.90 -171.9
3.30 195.2 5.10 14.7 7.80 -83.7 11.10 -176.6
3.60 187, 6 5. 15 10.2 8.00 -89.0 11.40 -183, 1
3,80 182.3 5.25 2.7 8. 20 -94. 5
4.00 176. 3 5.35 -4. 3 8.4 0 -100.1
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Table 17 POTENTIOMETRIC DATA FOR LEAD-GLUTATHIONATE
INTERACTION AT 10 C
Titn. Startlng Solutlon Tltratlng Solutlon Inltlal S®
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 2.480 1.228 2.256 -20.03 20.01 422.1
2 2.480 1.228 2.256 -20.03
r7
20.0 1 422.6
3 2. 480 1.228 2.256 -20.03 20.01 422.6
Added E Added E Added E Added 'h1E
Vol. ml fl»V Vol.ml mV Vol.ml mV Vol,ml mV
Tltratlon No. 1
2.00 236.9 5. 8 5 105. 3 6.80 -2.5 7.80 -9 7.7
2.60 225.0 5.95 96.7 6,85 —9«0 7.95 -105.5
3.20 211.2 6.05 87. 1 6.90 -15.7 8. 15 -114.6
3.70 197. 6 6.15 76.6 7.00 -28.4 8.35 -122.7
4.20 181.4 6.25 65.7 7. 10 -40.2 8.60 -13177
4.80 160. 3 6,35 54.3 7.20 -51.2 9.00 -145.7
5.10 148.8 6.45 42.3 7.30 -61.2 9.40 -159.1
5-30 139.9 6.55 30.2 7.40 -70. 5 9.70 -169,n
5.50 129.5 6.65 17.3 7.50 -78. 5
5.70 116.8 6.75 4. 1 7.65 -88.9 .
Tltratlon No. 2
2.00 234. 6 5. 2 5 143.2 6.35 57.1 7.10 -38.4
2.50 225.2 5.40 136.1 6.40 51.0 7. 15 -44.3
3. 10 212.6 5.55 128. 1 6.45 45. 1 7.25 -55.0
3.30 207.7 5.70 118.7 6.50 38.9 7.35 -64.3
3.50 202.6 5.75 115.2 6.55 32.7 7.45 -73,1
3.70 197.2 5.80 111.6 6. 60 26. 2 7.55 -80. t
3.90 191. 3 5. 85 107.6 6.65 19.8 7.65 -86.5
4.05 186.5 5.90 103.3 6.70 13.0 7.80 -9 5.6
4.20 181.4 5.95 98.8 6.75 6.4 7.95 -103.2
4.35 176,3 6.00 94, 3 6. 80 -0. 1 8. 10 -109.6
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Table 17 cont.
Added E Added S Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 2 cont.
4.50 171.2 6.07 87.5 6. 85 -6.5 8.30 -118.3
4. 65 165.9 6. 13 81.4 6.90 -13. 4 8.50 -125.7
4.80 160.7 6. 19 75.0 6.95 -19.8 8.80 -136.0
4.95 155.3 6.25 68.4 7.00 -26. 2 9. 10 -146.3
5. 10 149.5 6.30 62.8 7.0 5 -32.2
Titration No. 3
2. 20 233.0 6. 15 81. 1 7.20 -48.7 8.05 -107.8
2.80 220.9 6.25 70.1 7.25 -54.2 8. 17 -113.0
3.40 206. 5 6.35 58.9 7.30 -59.0 8.30 -117.9
3.90 192.2 6.42 50.7 7.35 — 63. 8 8.45 -123.5
4. 10 185.7 6. 50 41.0 7.40 -68.2 8.60 -128.9
4.40 175.3 6.60 28.4 7.45 -72. 1 8.75 -134.4
4.70 164.7 6.70 15.5 7.50 -75.9 8.90 -139.3
5.00 153.9 6.80 2.0 7.55 -79.7 9.05 -144.3
5.30 141.2 6.90 -11.4 7. 60 — 83.1 9.20 -149.3
5.60 125.6 6. 98 -22.0 7.67 -87. 7 9.35 -154.2
5.80 112.3 7.05 — 30 • 8 7,75 -92.4 9.50 -159.1
5.95 100.4 7. 10 -37.4 7.83 -96.9
6.05 91. 1 7. 15 -43.2 7.93 -102.0
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Table 18 POTENTIOMETRIC DATA FOB LEAD-GLUTATHIONATE 
INTERACTION AT 25 C
Titn. Starting Solution Titrating Solution Initial E°
No. A mM B mM HmM A mM B mM H mM Vol. ml mV
1 2. 382 1.228 2.256 -20.03 20.01 4 40.0
2 2. 382 1.228 2.256 -20.03 20.01 440.0
Added E Added E Added E , Added E
Vol.ml ml Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1
1.50 254,2 4.85 154.8 6.20 57. 6 7.05 -42.5*
2.00 245. 1 4.95 150.3 6.25 51.9 7. 15 -51.83
2.30 238.9 5. 10 143. 1 6.30 46.2 7.20 -56.0'
2.50 234.6 5.20 138.0 6.35 40.0 7.30 -63.7"
2.70 230.0 5.30 132.7 6.40 34.0 7.35 -67.47'j
3.00 222.6 5.40 126.8 6.45 27. 8 7.45 -74. lj
3.20 217.3 5.50 120.6 6.50 21.4 7.55 -80. r
3.40 211.6 5.60 113.6 6.55 15.0 7.65 -85.5i
3.60 205. 4 5.68 107.7 6.60 8.7 7.75 -90.7*
3.80 198.7 5.75 102.0 6.65 2. 5 7.90 -97.7;
3.95 193. 1 5.82 96. 1 6.70 -3.5 8.05 -104. 1
4. 10 187.2 5.90 88.9 6.75 —9 . 6 8.20 -110.1;
4.25 180.9 5.95 84.2 6, 80 -15.7 8.35 -115.7;
4.40 174.3 6.00 79.2 6-85 -21.5 8.55 -122.9
4.50 170.0 6.05 74.0 6.90 -27.1 8,75 -129.#
4,60 165.7 6.10 68.7 6.95 -32. 5 9.00 -138.2
4.70 161.4 6. 15 63.2 7.00 -37.8
js
Titration No. 2
1.30 258. 1 5.45 123.4 6.76 -12.2 7.77 -91.7i
1.60 252.9 5.60 113. 3 6. 80 -17.0 7.87 -96.3
1.90 247. 4 5.75 101.8 6.85 -22.7 7.98 -101.1
2.20 241.4 5. 85 93. 1 6.90 -28. 4 8.08 -105,2'
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Table 18 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No,. 2 cont.
2.50 234.9 5.95 83.8 6. 95 -33. 0 8.20 - 110.0
2.80 227. 8 6.03 75.7 7.00 -38. 8 8.35 - 115,6
3. 10 220.2 6. 11 67. 2 7.05 -43.7 8.50 - 121.0
3.40 211.7 6.20 57. 1 7. 10 -48. 5 8.65 - 126.2
3.70 202. 2 6.30 45. 6 7. 15 -52.8 8.80 - 131.2
4.00 191.3 6.40 33. 1 7.20 -57.0 8.95 - 136.2
4.25 180.8 6. 50 20.8 7.26 — 61.6 9.10 - 141.3
4.45 172. 1 6.55 14.4 7.3 3 -66. 7 9.25 - 146.2
4. 65 163. 3 6. 60 7.9 7.40 -71.6 9.40 - 151.2
4.85 154.6 6.64 2.7 7.48 -76. 5
5.05 145. 2 6.68 -2. 3 7.57 -81.3
5.25 135.0 6.72 -7.3 7.67 -86,7
Table 19 POTENTIOMETRIC DATA FOR LEAD-GLUTATHIONATE
INTERACTION AT 40 C
Titn. Starting Solution Titrating Solution Initial go
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 2 • 500 1.228 2.256 -20.03 20.01 460.0
2 2 • 5QQ 1.228 2.256 -20.03 20.01 460.0
Added E Added E Added E Added E
Vol.ml mV Vol.ml raV Vol.ml mV Vol.ml mV
Titration No. 1
0. 10 286. 2 3 80 210.^ 5.10 155.. 6.10 89.1
0.50 281.0 4.00 223..1 5.20 114.6 6.17 81.7
1.00 273.8 4. 15 119.6 5.30 U3, 4 8.50 -9 4.4
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Table 19 cont -
Added E Added E
Vol.ml mV Vol.ml mV
Tltratlon No. 1 cont.
1.40 267.2 4.30 191.
1.80 260.0 4.40 187.
2.20 251.9 4,50 182.
2.60 * 243.2 4.60 177.
3.00 233.5 4.70 173.
3.20 228. 3 4. 80 168.
3. 40 222.7 4, 90 163.
3.60 216.8 5.00 158.
Tltratlon No. 2
3.50 220. 1 5.60 126.
3.70 213.9 5. 68 121.
3,85 208.9 5.76 116.
4.00 203. 6 5.84 110.
4.15 197.9 5.90 105.
4.30 191.6 5.96 101.
4.40 187.2 6.03 95.
4.50 182.7 6. 10 89.
4.60 178.0 6. 15 84.
4.70 173. 4 6.20 79.
4.80 168. 6 6.25 74.
4.90 163, 8 6. 30 70.
5.00 158.9 6.35 64.
5. 10 154.0 6.40 59.
5.20 148.9 6. 45 54.
5.30 143. 8 6.50 48.
5.40 138,3 6.54 43.
5.50 132,6 6.58 39.
4
0
4
8
1
3
5
5
7
6
1
4
9
1
3
0
6
9
9
0
8
4
1
. 5
9
. 3
Added E Added E
Vol.ml mV Vol.ml mV
5, 40 138.0 8.65 -99.6
5.50 132. 4 8.80 — 104,6
5.6 0 126. 4 8.95 -109,5
5.70 120.0 9.10 -114.5-
5. 80 113.3 9.25 -119.2<
5.88 107.3 9.40 -124.1
5. 95 101.8 9.55 -128.8
6.02 96. 1 9,75 -135.2
6.62 34.7 7.71 — 60 » 9
6.67 28.8 7.81 -66,0
6,72 22. 9 7.91 -70.8
6.77 17.2 8.02 -75.9.
6.82 11.5 8. 14 -81.0"
6.87 5.8 8.26 -85.9
6.92 0.4 8.40 -91.4-;
6.97 -4.9 8,55 -96.8
7.03 -1J. 1 8.70 -102.T
7.09 -16.9 8.85 -107.1
7.15 -22. 6 9.00 -111.9
7.20 -27.0 9.15 -116,7;
7.25 -31. 2 9.30 -121.4
7.31 -36.0 9.50 -127.6
7.38 -41,2 9.65 -132.2
7.45 -46. 1
7.53 -51.2
7.61 -55.4
APPENDIX 4 : POTENTIOMETRIC DATA FOR BOVINE SERUM ALBUMIN - PROTON, 
-LEAD(II) AND -COPPER(II) INTERACTIONS
Table 1 EXPERIMENTAL DATA FOR BOVINE. SERUM -ALBUMIN
PROTONATICN
Titn. Starting Solution Titrating Solution In i tial E®
No. A mM B mM H mM A mM B mM M mM Vol. ml mV
1 0.058 40. 1 1 -80.07 20.0 1 413. 4
2 0.116 40. 1 1 -80.07 2 0.01 412.5
3 0.173 40.11 -80.07 20.01 412.6
Added E Added E Added E Added 1
Vol.ml ' mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 1
6.50 279.9 9.60 158.4 10.25 -9.9 10.57 -158.4
7.00 272. 8 9.70 149.4 10.27 -20.7 10.61 - 16 6.4
7.50 26 3. 6 9.80 137.6 10.29 -31.6 10.66 -175.1
8.00 251.2 9.88 125.5 10.31 -41.9 10.72 -183.6
8. 20 244.5 9.93 1i6.3 10.33 -53.2 10.80 -193.0
8.30 240.6 9.98 105.8 10.35 -64. 9 10.88 -200 .7
8.40 236. 4 10.02 95. 8 10.37 -76.4 10.98 -208.7
8.50 231.9 10.05 87.0 10.39 -89* 6 11.10 -216.4
8.60 227.0 10.08 76.9 10.41 -103.8 11.30 -226.3
8.70 221.7 10. 11 64.7 10.42 -109.6 11.50 -233.9
8.85 213. 1 10. 13 55.5 10.44 -120.6 11.80 -242.4
9.00 203.9 10. 15 45. 4 10.46 -129.2 12.20 -251.1
9. 15 193.9 10. 17 3 4.3 10.48 -137.0 12.60 -258.0
9.30 182.5 10.19 23.5 10.50 -143.9
9.40 174. 3 10.21 12.2 10.52 -145.7
9.50 166.2 10.23 0.9 10.54 -151.0
Titration No. 2
0.10 317.4 8.80 177.4 10.40 16, 8 11.40 -191.2
1.00 312. 6 9.00 16 8.7 10.45 1.4 11.50 -198.0
2.00 307.2 9.20 160.0 10. 50 -12. 3 11.60 -203.7
3.00 300. 4 9. 40 150.7 10.55 -26.1 1 1.75 -211.5
223
Table 1 cont.
Added • E Added £ Added E Added e ;
Vol.ml mV Vol.ml mV Vol,ml mV Vol.ml m V
Titration No. 2 cont:.
4.00 292. 1 9.50 145.2 10.60 -39.0 11,90 -217.9
5.00 281.8 9.60 138.7 O0.65 -52.4 12.10 -225.4-
6.00 267.5 9.70 131.4 10.70 — 66. 4 12.30 — 231.6 ;
6.70 253. 1 9.80 123.0 10.75 -82.1 12.60 -239.041
7.00 245. 1 9,90 113.3 10.80 -98.9 12.90 -244.9%
' 7.20 239.0 10.00 101.8 10.85 -OO5.0 13.30 -251.7
7.40 232.2 10.05 95,2 10.90 -128.3 -258.8■
7.60 224.9 10. 10 87.8 10.95 -138.9 14.30 -264.51
7.80 217.4 10.15 79.5 11.00 -148.1 14.80 -269.il!
8.00 209.9 10.20 69.7 11.05 -156.0 15,80 -277.3?
8.20 202.5 10.25 58.6 11. 10 -162.7 16.80 -183.Q0
8.40 194. 8 10.30 46.0 11.20 -174.3 18.00 -288,31
8.60 186.4 10.35 31.6 -183.4
Titration Ne. 3 -
2.00 300.3 9,20 149.4 00.80 -18. 5 11.95 —188.84
3.00 291. 8 9.50 136. 1 10.85 -27.3 -190.8*3
4.00 280.9 9.70 125.2 10.90 -36.8 12.10 -196.30
4.80 269. 3 9.85 115.4 -55,2 12.20 -201.0'
5.40 257.7 9.95 108.2 11, 10 -75. 3 12.40 -209.8-1
5.80 248.3 10.05 99.8 11.15 -87,1 12.70 -220,64
6.20 237.4 03.15 90. 1 11,20 -99. 4 -229.03
6.50 228. 6 10.25 78.6 11.25 -m^ -237,6*
6.80 219.9 10.35 64.7 -124.3 13.80 -244.21
7. 10 211. 5 10.40 56.8 11.35 -131.7 14.30 -251.4': m
7.40 203.6 00.35 48. 1 -139,8 15.00 -259.3;
7.70 195. 3 10.55 29.0 11.45 -145,9 06.00 -269.34
8.00 186.4 10.60 19.2 11.50 -152. 3 17.00 -276.3
8.30 177. 1 10.65 9.5 - 11.60 -162.6 18.50 -284.3:
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Table 1 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml ml Vol.ml l V
Tltratlon Nc. 3 cont:.
8.60 66. . 11.77) -0.4 11.70 -171.6
8.90 159.3 11.775 -9.4 11.80 -178.9
Table
Tltn.
2 EXPERIMENTAL DATA FOB BOVINE SERUM ALBUMIN-LEAD
• INTERACTION
Startlng Solutlon Tltratlng Solutlon Inltlal Eo
No. A mM E mM H mM A mM B mM H mM Vol. ml ml
1 . 0. 115 0. 491 41. 01 -80.07 • 20.01 411.5
2 0. 115 0. 985 41. 9 2 -80.07 20,01 412.6b
3 0. 116 4. 910 49. 13 -80.07 20.01 412.8
Added E Added E Added E Added £
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml m V
Tltratlon No. 1
0. 10 318. 3 9.30 164.9 10.83 -13.9 12.00 -206.O
1.00 313.7 9.50 156.7 10.88 -27.2 12,15 -210.9
2.00 307.8 9.70 147.1 10.93 -42. 2 12.30 -217.6
3.00 301.2 9.90 134. 4 10.98 -59.7 12.50 -229.2■
4.00 293.4 10.05 122.5 11.03 -78.9 12,80 -234.1
5.00 283.7 10. 15 113.0 11.05 -86.2 13.20 -242.93
6.00 270.7 10.25 101.8 11.07 -93.0 13.70 -251.3
6.80 255. 5 10.35 87.7 11.10 -102.0 14.20 -257,9
7.30 242.0 10.40 79.7 11. 15 -114.7 15.00 -266.7
7.60 232. 2 10.43 74.2 11-20 -126.1 16.00 -274.9
7.90 221.4 10.48 64.3 11.25 -539.6 17.50 -283.6"
8. 10 213.9 10.53 53. 5 11.30 -143.9 -291.6
225
Table 2 cont
Added
Vol,ml
E
mV
Added
Vol.ml
E
mV
Added
Vol.ml
E
rV
Added
Vol.ml
E
mV
Titration No. 1 cont.
8.30 206.5 10. 58 42.3 11.40 -157.7 22.00 -298.2'
8.50 198.9 10.63 31.2 11.50 -168. 9 25.00 -303.9
8.70 190. 8 10.68 20.4 11.50 -178.4
8.90 182.2 10.73 9.0 11.70 —186.6
9. 10 173. 3 10.78 -2.6 11.85 -197.1
Titration No. 2
0. 10 320.0 8.80 197.7 11.00 16.0 12.10 -181.6
1.00 315.4 9.00 189.3 11.05 4. 5 12.25 -192.4
2.00 309. 8 9.30 176. 5 11.10 -7.3 12.40 -201.6'
3.00 303.6 9.50 168. 1 11.15 -19. 9 12.60 -211.6
4.00 296. 2 9.80 155.7 11.20 -32.5 12.90 -223.3
.5.00 287. 3 10.00 145.5 11.25 -45. 1 13.20 -232.2?
6.00 275. 3 10.20 132. 1 11.30 -57.2 13.60 -240.7-
6.50 267.4 10.35 119.6 11.35 -69. 3 14.00 -247.5
7.00 257. 4 10.45 109.3 11.40 -81.4 14.50 -254.23?
7.50 244.3 10.55 97.2 11.45 -93. 3 15.50 -265.3;
7.80 234. 8 10.65 82. 8 11.50 -116.0 17.50 -279.41
7.90 231.3 10.70 74. 3 11.60 -125.6 18.50 -284.1
8.00 227. 5 10.75 65. 2 11.70 -141.4 20.00 -289.7,
8. 10 223. 9 10.80 55.6 11.80 -155.0 22.00 -2 95.3?
8. 30 216. 6 10.85 4 6.0 11.90 -163.1 25. 10 -301.5
8.50 209.2 10.90 36.0 12.00 -173.0
Titration No. 3
0.10 328.3 9.40 241.9 11.20 174. 3 16. 30 -221 .3
1.00 324. 2 9.60 235.6 11.40 166.2 1 6.70 -231.3
3.00 314.4 9.80 228.9 15. 10 -157.6 17. 10 -239.0
4.50 305. 8 10.00 221.8 15.20 -166.7 17.60 -246.3
226
Table 2 cont.
Added E Add&d E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vdl.ml al
Titraticn No. 3 cont. •
5.50 298.9 10.20 214.2 15.30 -174. 1 18.30 -255.
6.50 290.5 10.40 236.3 15.40 -181.2 09.30 -261.
7.50 279.6 10.60 198.5 15.60 -193.4 20.00 -269.
8.50 264. 1 10.80 190.5 15.80 -203.0 21.50 -277.
9.00 253.0 182.4 16.00 2 3.00 -283.
0
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Table
Titn.
3 EXPERIMENTAL EATA
INTERACTION 
Starting Solution
FOR BOVINE SERUM ALBUMIK-COPIER
Titrating Solution Initial E®
No. A mM E mM H mM A mM B mM H mM Vol. ml mV
. 1 0. 116 0.489 40.53 -80.07 20.0 1 3l1.
2 0. 116 0.489 •40. 53 -80.07 20.30 411.
3 0. 115 0.978 40.95 -80.07 20.01 410.
4 0. 115 2.454 42.21 - -80.07 20.01 410.
" 5 0. 116 0.098 40.20 -80.07 20.01 411.
Added E Added E Added E Added E
Vol.ml aV Vol. ml mV Vol.ml mV Vol. ml ai
Titration No' 1
0.10 318.2 8.80 185. 1 11.17 -99.0 12.40 -217.
1.00 313. 5 9.00 177.7 11.20 -106.2 12.60 -224.
2.00 307.7 9.20 169.8 11.25 -116.1 12.90 -232.
3.00 301. 1 9.40 161.6 -126.1 13.30 -242.
4.00 293. 2 9.60 152.8 11.35 -135.2 13.75 -250.
5.00 283.4 9.80 142.9 -033.0 14. 30 -258.
5.80 273. 1 10.00 130.7 11.45 -150.2 15.00 -266.
227
Table 3 cent.
Added E Added E Added E Added E
Vol.ml ®¥ Vol.ml mV Vol.ml mV Vol.ml mi
Titration No. 1 cent. •
6.40 262.8 10.80 17.6 11. 50 -156.5 16.00 -274.9
6.90 251.6 10.85 2.4 11.55 -162. 2 17.50 -282. 1
7.30 240.0 10.90 — 12.6 11.60 -167.6 19.50 -290.4
7.60 230.3 10.95 -28.8 11.70 -177.0 21.50 -296.1
7.90 219. 3 11.00 -45.8 11.80 -185.2 24.00 -301.1
8.10 211.7 11.05 -63.1 11.90 -192.0
8.30 204. 1 11. 10 -79.0 12.05 -201.1 .
8.60 192.6 11.15 -93.4 12.20 -208.7
Titration No. 2
0.10 317.2 8.20 206.3 10.96 -55.3 12.05 -203.3
1.00 312.6 8.40 198.6 11.00 -68.5 12.20 -210.4*
2.00 306.8 8.60 190.9 11.03 -77. 1 12.40 -218.55
3.00 300. 2 8.80 183.2 11.07 -88.3 12.60 -225.1
4.00 292.3 9.00 175.5 11. T1 -99.0 12.90 -2 3 3.7-
5.00 282.5 9.20 167.4 11.15 -108.9 13.30 -242.55
5.60 275.0 9.40 158.8 11.20 -1 19.7 13.70 -249.9
6.20 265. 5 9.60 149.6 11.25 -127.9 14.20 -257.4
6.60 257.5 9.80 139.0 11.30 — 136.4 14.80 -264.4
7.00 247.7 9.90 132.9 11.35 -144.2 15.80 -271.6
7.20 242.2 10.80 -3.7 11.45 -157.6 16.80 -278.4
7.40 235.9 10.85 -20.7 11.55 -168.3 18.50 -286.7'
7.60 228.8 10,87 -25.8 11.65 -177.5 20.50 -293.2
7.80 221.5 10.90 -35. 6 11.75 -185.0 2 3.50 -299.9
8.00 213. 9 10.93 -45.9 11.90 -195.3
Titration No. 3
0.10 317.8 8.50 204.3 11.95 -1 19.8 14.00 -236.3
1.00 313.2 8.80 194.0 12.00 -El." 14.40 -244.T
228
Table 3 cont.
Added E Added E Added E Added S
Vol.ml mV Vol.ml rV Vol.ml mV Vdl. ml mV
Titration No. 3 cont. •
2.00 307.5 9.00 187.2 12.10 -140.6 15.0CP -253.9
3.00 301.0 9.30 177.0 12. 15 -145.6 15.60 -261.5
4.00 293.4 9.60 166.4 12.25 -156.2 16.40 -269.4
5.10 282.9 9.80 158.9 12. 35 -164.7 17.40 -276.7"
6.00 271.3 10. 10 146.8 12.45 -172.5 19.00 -285.3 i
6.60 260.9 11.65 -61.2 12.60 -183. 1 21.00 -292.5
7.00 252. 3 11.70 -69.2 12.75 -192.3 24.00 -300.0
7.50 238.4 11.75 -82.0 12.90 -200.1 27.00 -305.0
7.80 228. 8 11.80 -92.5 13.10 -209.0
8.00 221.9 11.85 -101.6 13.35 -218.3
8.20 214. 8 11.90 -110.8 13.65 -227.7
Titration No. 4
0. 10 319. 6 8.10 232.4 13.45 -152.0 15.50 -234.2’
1.00 314.9 8.30 225.9 13.50 -155.3 15.90 -242.3
2.00 309. 4 8.50 219.3 13.60 -163.1 16.50 -251.7?
3.00 303.2 8.70 212.7 13.70 -170.0 17.20 -260.7J
4.00 296.2 8.90 206.3 13.80 -175.6 18.00 -268.3;;
5.00 287.6 9.20 196.8 14.00 -185.5 19.00 -275.7,
5.80 279.0 9.50 187.3 14.20 -194.4 20.00 -281.3'
6.60 267.9 9.80 177.3 14.40 -202.0 21.00 -285.83
7.00 260.7 10. 10 167.7 14.60 -209.1 23.00 -292.41
7.40 252.1 10.40 157.0 14.90 -219.1 25.00 -297.2,
7.80 241. 6 13.40 -148.2 15.20 -227.5 27.00 -301.1i
Titration No. 5
0.10 317. 3 9.00 166.9 10.60 -28.1 11.55 -194.8;
1.00 312.5 9.20 158.0 10.65 -42.2 11.70 -203.71
2.00 306.6 9.40 148.3 10.70 -57.4 11.30
•I
-213.31
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Table 3 cont.
Added E Added E Added E Added E
Vol.ml V Vol.ml ml Vol.ml mV Vol.ml m V
Titration No. 5 cont.
3.00 299.9 9.60 136. 3 10.73 -67. 3 12. 10 -221.0
4.00 291. 8 9.75 124.9 10. 76 -78. 1 12.40 -230.7
5.00 281.6 9.85 116.0 10-79 -88. 1 12.80 -240.6
5.60 273.6 9.95 105.7 10.82 -98.8 13.30 -249.8
6. 20 263. 5 03.05 93. 6 10.85 -108.9 13.80 -257.1
6.70 252.4 10.15 79. 1 10.88 -116.7 04.30 -264.3
7. 10 241. 1 10.20 70.7 10.91 -124.4 15.20 -271.6
7.40 230.9 10.25 61.0 10.95 -133.4 16.20 -278.7
7.60 223.7 10. 30 50. 3 11.00 -142.3 17.50 -285.5
7.80 216.2 10.35 38.4 11.05 -146.6 19.50 -293.1
8.00 208. 4 10.40 25.9 11.10 -153.6 22.00 -299.3
8.30 196.5 10.45 12.9 11.20 -165.8
8.50 188. 2 10.50 — 0.6 11.30 -175.7
8.80 175.6 10.55 -14.5 -184. 1
APPENDIX 5 : POTENTIOMETRIC RESULTS FOR THE "CHALLENGE” PROJECT
1
Tatle 1 EXPERIMENTAL EATA FOR GLYCINATE PROTONATICN IN 1M
Titn. Starting Solution Titrating Solution Initial E°
No. A mH E mM H mM A mM B mM H mM Vol. mll mV
1 10.18 15.04 9.939 -60.14 20.01 416.6'
2 19.99 30.07 19.93 -100.2 20.01 414.5
3 49.69 40. 11 49.91 -200. 1 20.01 414. GJ
4 99.97 80.18 99.77 -400.3 20.01 413.8*
Added E Added E Added E Added
j
E <i
Vol.ml mV Vcl.ml mV Vol.ml mV Vol.ml
-.1
mV d
i
Titraticn Nc. 1
0. 10 292.3 4.75 190.4 5.12 -64.2 7.50 -154.6
0.50 288. 4 4.83 178.2 5.14 -67.9 7.80 -160.3
1.00 283.1 4.87 168.6 5. 17 -72.7 8. 10 -165.9 •I
1.50 277. 4 4.90 158.4 5.20 -76. 8 8.40 -171.6
2.00 271.0 4.92 148.8 5.25 -82. 3 8.70 -177.5
2. 30 266.8 4.94 134.3 5.30 -87.1 8.95 -182.7,
2.60 262.3 4.96 102.9 5.36 -91.9 9.20 -188.2
2.90 257.4 4.98 43.5 5.43 -96.8 9.45 -193.9?
3.20 251.9 4.99 10.2 5.50 -100.9 9.70 -200.0
3.50 245.7 5.00 — 8.8 S'. 60 -105.9 9.90 -205.0
3.70 241.0 5.01 -20.9 5.75 -112. 4 10. 10 -210.1
j
-215. tj
i3.90 235.7 5.02 -29.3 5.90 -117.8 10.30
4.10 229.3 5.03 -35.9 6.05 -122.7 10.50 -220.Oj1
4.25 223.8 5.04 -41.1 6.25 -127.3 10.70
j
-224.51j
4.35 219.5 5.05 -45.2 6.50 -133.8 10.90 -223.61j
4.45 214.4 5.06 -49. 1 6.75 -139.5 1 1.20 -234. 1
4.55 208.5 5.08 -54.8 7.00 -144.8
4.65 200.9 5. 10 -60.1 7.25 -149.8 i
Titration Nc. 2 I1
0. 10 303.5 5.70 194.4 6.02 -14.9 6.80
I
-109.9i
i
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Table 1 dent.
Added E Added E Added E Added E
Vol,ml mV Vol.ml mV Vol.ml mV VOl.ml mV
Titraticn Ne, 2 cont. •
0.50 300.0 5.75 189.3 6.03 -23.7 6.95 -114.7
1.00 295. 1 5.SO 182.7 6.04 -30.4 7.15 -120.5
1.50 289.6 5.84 176.2 6.05 -36. 6 7.35 -125.4
2.00 283.4 5.87 170.0 6.06 -40.9 7.60 -131.2
2.50 276,8 5.90 161. 1 6.08 -48. 2 7.85 -136.2
2.90 271, 1 5.91 158. 1 6.10 -53.7 8.15 -141.7
3.30 265.0 5.92 154. 4 6.12 -53.6 8.70 -150.8
3.60 260.2 5.93 149.5 6.14 -63.2 9.50 -163.5
3.90 254.8 5.94 143.6 6. 17. -69.0 10.10 -172.6
4.20 249.2 5.95 133.2 6.20 -72.4 10.70 -182.2
.4.50 242.9 5.96 127.0 6.25 -78. 5 11.30 -193.4
4.70 238.0 5.97 114.0 6.30 -82.0 11.90 -206. 1
4.90 232.8 5.98 92. 1 6.40 -90. 1 12.30 -216,0
5. 10 226.6 5.99 59.2 6.50 -96.7 12.70 -226.4
5.40 214. 1 6.00 22.9 6.60 -101.7 13. 10 -235.9
5.60 202.6 6.01 -1.7 6.70 -106.1 13.50 -244.0
Titration No, 3
0.10 287.0 3.93 160.0 4.40 -85.9 9.00 -175.4
0.34 283.1 3.96 147.7 4.50 -92.3 9.40 -180.9
0.54 279.8 3.98 135.0 4.60 -r97.5 9.SO -186.7
0.74 276.5 4.00 108, 2 4 ..70 -102.0 10. 10 -191.4
1.00 272. 4 4.02 22.2 4.80 -105.9 10.40 -196.5
1.30 267. 1 4.04 -14.6 4.95 -110.8 10.70 -202. 1
1.60 261.7 4.05 -23.7 5.10 -115.3 10.90 -206.2
1.90 256. 1 4.06 -30.4 5.30 -120.4 11.20 -213.1
2. 10 252.2 4.07 -35.6 5.50 -124.9 11.40 -218.2
2.30 248.0 4.08 -39.4 5.75 -129.9' 11.60 -223,8
2.50 243. 3 4.10 -46.3 6.00 -134.4 11.80 -229.8
232
Table 1 cont-.
Added E Added E Added E Added E
Vol.ml mi Vol.ml mV Vol.ml mV Vol.ml mV
Titraticn Nc. 3 cont.
r?
2.70 238. 5 4. 12 -51.8 6.30 -139.4 12.00 -235.9)'
3. 10 226.8 4. 14 -56.3 6.60 -143.9 12.20 -241.9
3.40 215.0 4. 16 -60.2 7.00 -149.4 12.35 -246.3;
3.60 203.7 4. 19 -65. 1 7.40 -154.7 12.50 -250.3:
3.75 191.2 4.23 -70.6 7.80 -159.8 12.70 -255.2
3.83 181. 4 4.27 -74.9 8.20 -165.0
3.89 170.6 4. 33 -80. 6 8.60 -170. 1
Titraticn Nc. 4
0.10 291.7 3.88 172.0 4.2 4 -73. 3 8. 10 -165.3’-
0.50 283. 8 3.92 162.3 4.28 -77.7 8.50 -170.5
0.70 280.0 3.95 151.7 4. 34 -83. 1 8.90 -175.7
1.00 274. 3 3.97 141. 1 4.40 -87.6 9.30 -181. 1i
1.20 270.5 3.99 123. 2 4.50 -93}. 8 9.70 -187.0;
1.40 266. 6 4.01 73.8 4.60 -99.0 10.10 -193.2
1.60 262.8 4.02 15.0 4.70 -103. 4 10.40 -198.6
1.80 . 258.9 4.03 — 6.4 4.85 -109.0 10.70 -204.4
2.00 254.8 4.04 -18. 6 5.0 0 -113.8 11.00 -211.3
2.20 250.6 4.05 -26. 6 5.20 -119.3 1 1.20 -216.7
2.40 246. 1 4.06 -32.5 5.40 -1241. 1 11.40 -222.6
2.60 241.2 4.07 -37.6 5.65 -129.4 11.60 -229.6
2.80 236.0 4.08 -42.0 5.90 -134. 1 11.75 -235.3
3. 15 225.0 4. 10 -48.8 6.20 -139.2 11.90 -241.5
3.40 214.6 4. 12 -53.7 6.55 -144. 6 12.00 -245,7
3.60 203.2 4.14 -58.5 6.90 -149.6 12.15 -252.2
3.73 192.6 4. 17 -63. 8 7.30 -155.0
3.82 181.8 4.20 -68.3 7.70 -160.2
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Table 2 EXPERIMENTAL EATA FOR GLYCINATE PROTONATICN IN 1M 
ci or
Titn. Starting' Solution Titrating Solution Initial E®
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 9,810 14.23 9. 806 -60.14 20.01 415,2
2 5. 172 14, 23 5.010 —60.14 20.01 415.4
3 20.37 28.44 20. 38 -100.2 20.01 416.0
4 49.96 56,83 49.75 -200.1 20.01 416.0
5 100.1 113. 6 99.79 -400.3 20.01 415.2
Added E Added E Added E Added E
Vol.ml. bV Vol.ml mV Vol.ml mV Vol.ml fflV
Titration No. 1
0.10 288. 1 4.54 169.5 4. 8 5 -54. 6 6.50 -144.8
0.50 284. 1 4.67 161.5 4. 87 -61.0 6.70 -147.83
1.00 278. 6 4.69 15 4.0 4.89 -65.8 7.00 -154.0
1.40 273. 8 4.70 149.4 4.92 -7 1.6 7.30 -160.0
1.80 268. 5 4.71 144.2 4.95 -76.8 7,60 -165.8‘:
2.20 262.7 4.72 136.2 4,98 -81,0 7.90 -171.6
2.60 256. 2 4.73 126.8 5.02 -85.9 8.20 -177.6
3,00 248.9 4.74 113.5 5.07 -90. 9 8.50 -183.7
3. 40 240. 1 4.75 93.5 5,12 -95.2 8.80 -190.2#
3.70 232.2 4.76 60. 8 5. 18 -99. 5 9.00 -194.8
3.80 229. 1 4.77 24.8 5.25 -104.0 9.20 -199.6
3.90 225.7 4.78 -0.4 5.35 -109.4 9,40 -204.6
4.00 222. 1 4.79 -17.2 5.45 -114.1 9,60 -209.7
4. 15 215.6 4.80 -28.0 5.55 -118.2 9,80 -214.8
4.25 210.4 4.81 -35. 5 5.70 -123.5 10.00 -219.8
4.45 196,2 4,82 -41.7 5.85 -128.2 10.20 -224.6
4.55 185, 4 4.83 -46.9 6.05 -133.9
4.61 175.9 4.84 -51.1 6,25 -138.9
234
Table 2 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV '
Titration No. 2 •
0.10 296.6 4.55 196.3 4.81 -50.6 —75.5T -136.41
0.50 293. 1 4.60 188.4 4.82 -57.7 5.60 -140.7
1.00 288. 4 4. 64 179.9 4.83 -62.3 5.70 -144.8
1.50 282.9 4.66 174.8 4.84 -67.0 5.85 -150.9^
2.00 276.7 4.68 167.9 4.86 -73.5 6.00 -156.8
2.50 269.4 4.70 159.0 4.88 -79. 1 6. 15 -162.6
3.00 260. 6 4.71 153.3 4.90 -83.6 6.30 -168.4
3.30 254.3 4.72 144.3 4.93 -89.6 6.45 -172.7
3.50 249. 4 4.73 134.2 4.96 -94.2 6.60 -178.6
3.70 243.8 4.74 116.8 5.00 -99. 6 6.75 -184.5
3.90 237.4 4.75 89.8 5.05 -105.4 6.90 -190.7
4.10 229.4 4.76 53.2 5.10 -110.4 7.05 -197.2
4.20 224.5 4.77 12.5 5.15 -114.7 7.20 -203.8
4.30 218.8 4.78 -18.5 5.20 -118.3 7.35 -210.3
4. 40 211.7 4.79 -34.2 5.30 -125.1
4.50 202.3 4.80 -43. 4 5.40 -130.9
Titration No. 3
0.10 300.7 5.25 205.2 5.84 -60.4 9. 10 -163.5
0.50 296.6 5.42 192.4 5.89 -69.8 9.50 -169.4
1.00 290.9 5.52 181.3 5.96 -78. 8 9.90 -175.4-
1.50 284.7 5.58 171.2 6.05 -87.4 10.30
j
-181.8)i
2.00 278.1 5.62 161.8 6.20 -97.7 10.70 -188.5)
2.50 271.0 5.66 146.8 6.40 -107.5 11.10 -195.9!■
2.90 264.9 5.67 141.8 6.55 -113.2 11.40 -202.0)
3.20 260. 1 5.68 134.4 6.70 -118.1 11.60 -206.4?I
3.50 254.9 5.69 124.9 6.90 -123.8 11.90 -213.4)
3.80 249.4 5.71 79.3 7.10 -128.8 12.10 -218.4!
4.10 243.2 5.73 1^9 7-30 -l<3. 3 __
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Table 2 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vdl.ml mV
Titration No. 3 cont. •
4.30 238.7 5.75 -23.9 7.60 -139.2 12.60 -230.9
4.50 233.7 5.77 -37. 1 7.90 -144. 6 12.90 -237.8
4.70 228.0 5.78 -41.7 8.30 -151.3
5.05 215.4 5.80 — 49 . 6 8.70 -157.4 *
Titration No. 4
0.10 307. 3 5. 15 209.0 5.80 — 36. 2 9.80 -161.9
0.50 301.5 5.25 203.7 5.83 -47.5 10.20 —166-5
0.90 295.5 5.35 197. 1 5.87 -57. 2 10.70 -172.4
1. 30 289. 3 5. 45 188.8 5.93 -67. 4 11.10 -177.2
1.60 284. 5 5.55 177. 1 6.02 -77. 6 11.60 -183-5
•1.90 279.7 5.62 164.5 6.15 -87.9 12-00 -188.9
2.20 274.9 5.64 159.3 6.33 -97. 8 12.40 -194.7
2.50 270.0 5.66 152.9 6.43 -102.2 12.80 -201.2
2.80 265. 1 5.68 145.2 6.70 -111.6 13. 10 -206.7
3. 10 260. 1 5.69 139.6 6.90 -117. 1 13.40 -212.8
3.40 254.8 5.70 134. 2 7. 10 -122.0 13.65 -218.5
3.70 249. 3 5.71 125.2 7. 30 -126.2 13.85 -223.4
4.00 243.3 5.72 113.8 7.60 -131.8 14.05 -228.7
4.30 236.6 5.73 91.7 ' 7.90 -136.9 14-25 -234.3
4.50 231.5 5.74 48.3 8.20 -141.4 14.45 -239.9
4.70 226.0 5.75 10.0 8.60 -147.0 14.90 -251.4
4.90 219.4 5.76 -6. 1 9.00 -152.2
5.05 213.5 5.78 -25.7 9.40 -157.2
Titration No. 5
0. 50 310.9 5.47 183-6 5.95 -75.2 9.70 —162.8
1.00 301.3 5.56 170. 4 6.00 -80. 1 10.20 —168.8
1.50 290.9 5.60 161.9 6.05 -84.5 10.90 -174.4
236
Table 2 cent:.
Added E Added S Added E Added E
Vol.ml mV Vol.ml raV Vol.ml mV Vol.ml m V
Titration No.
1. 80 285.1
5 cont.
5.64 149.4 6.15 -91.4
r?
11.50 -181.8
2, 10 279.4 5.66 139.5 6.20 -94.3 11.90 -187.1
2.30 275.7 5.68 123.0 6. 30 -99. 3 12.30 -192.8
2.50 272.0 5.70 83.5 6.40 -103,7 12.70 -199.2
2.80 266.7 5.72 0.3 6.55 -109.3 13. 10 -206.4
3. 10 261. 1 5.74 -23.0 6,7 0 -114.0 13.40 -212.7
3.40 255. 5 5.75 -29.2 6.90 -119.4 13.70 -220.0
3.60 251. 6 5.76 -34.8 7.10 -124.2 13.90 -225.8
3.90 245.5 5.77 -39.6 7. 30 -128.3 14. 10 -232.2
4.20 238.8 5.78 -43. 8 7.60 -133,9 14,30 -239,4
4.40 233.8 5.80 — 49.8 7.90 -138.9 14,45 -245.2
4.60 228. 3 5.82 -55.0 8.20 -143.4 14.60 -250.9
4.80 222.0 5.84 -59. 3 8.55 -148.4
5.20 204.9 5.87 — 64.6 8.90 -152.9
5.36 194.2 5.90 -69. 1 9.30 -158.0
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FOB NICKEL-GLYCINATE INTERACTIONTable 3 EXPERIMENTAL DATA
IN 1M cr
Titn. Starting Solution Titrating Solution Initial E°
No. A mM B mM H mM A mM B mM H mM Vol. m.l mV
1 9.650 4.803 4.555 -20.04 20.01 414.1
2 4.637 4.799 4.551 -20.04 20.01 4 14.
3 14.87 4.803 4.555 -20.04 20.01 414.
4 19.35 4.803 4.555 -20.04 20.01 413.
5 24. 10 4. 803 4.555 -20.04 20.01 412.
6 28.68 9.602 9.105 -20.04 20.0 1 412.
7 3.665 1.201 1.138 -20.04 20.01 4 11.
Added E Added E Added E Added E
Vol.ml mV Vol . ml mV Vol.ml mV Vol.ml mV
Titration No. 1
0. 10 252.2 4.80 154. 3
0.50 249.2 4.86 147.4
1.50 240.7 4.92 140.7
2. 20 233. 5 4.98 134.2
2.90 224. 5 5.04 128. 2
3.40 216. 1 5. 10 122.9
3.80 207.3 5. 18 116.9
4.00 201.7 5.28 110. 4
4.20 ' 194.8 5.40 103. 8
4.40 185.7 5.55 96.9
4.55 176.7 5.70 91.1
4.65 169. 1 5.90 84. 1
4.73 161.7 6. 10 77.9
6.35 71.2 11.30 -25.1;
6.60 64. 9 11.70 -33.7;
6.90 58. 1 12. 10 -43.Q:
7.20 51.7 12.40 -50 • 4
7.60 43. 8 12.70 -58.3
8.00 36.3 13.00 -66.9
8.40 28.9 13.30 -76.6^
8.90 20.0 13.50 -8 3.7
9.30 12. 8 13.70 -91.5
9.70 5.6 13.85 -97.9
10. 10 -1.7 14.00 -105.1
10.50 -9.3 14. 15 -113. 1
10.90 -17.0
Titraticn No. 2
0.10 264.0 4.55 184. 5
0.50 261.0 4.65 174.9
1.00 256.9 4.70 168.5
5. 12 104. 4 7.00 28.2
5.20 97.9 7.25 21.3
5. 30 91.0 7.50 1H.2
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Table 3 cent.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml raV
Titration No. 2 cont:.
1.80 249. 4 4.75 161.1 5.40 85. 1 7.75l^ 6.9
2.50 241.2 4. 80 152.2 5.55 77.2 8.00 -0.4'
3.10 232,5 4.84 144,5 5.70 70. 4 8.25 -8.5
3.50 225.0 4.88 136.6 5.90 61.7 8.50 -17.4
3.80 218.0 4.92 129.4 6. 10 54.7 8,70 -25.22
4.00 212.2 4.96 123.0 6.30 48.4 8.90 -34.5:
4.20 204.8 5.Q0 117.3 6.50 42. 3 9.05 -42.6-
4. 40 195.0 5.05 111.4 6.75 35.2
Titration No. 3
0. 10 243. 1 5,00 139.8 9.00 35.7 15.55 -79.5
0.50 240.2 5. 10 132.4 . 9.50 28.0 15.90 -86.7
1.00 236. 4 5.20 126.1 10.00 20.3 16.30 -95.0
2.00 227,3 5.35 117.9 10.50 12. 6 16.70 -103.2
2.60 220. 5 5.50 111.1 11.00 4.8 17.10 -111.4-:
3.20 212.0 5.65 105.2 11.50 — 3. 2 17.50 -119.6<
3.70 202.4 5.85 98.5 12.00 -11.3 17.90 -128.0
4.00 194.7 6.05 92.5 12.50 -19.9 18.20 -134.5
4.20 188. 3 6.30 85.8 12.90 -26.9 18.60 -143.5/
4.40 1*0.2 6.55 80.0 13.30 -34. 3 18.90 -150.4:
4.55 172. 5 6.90 72.4 13.70 -41.9 19.20 -157.83-
4.70 163.2 7.30 64.4 14. 10 -49. 8 19.50 -165.3'
4.75 159. 3 7,70 57. 1 14.50 -57.8
4.80 155.5 8. 10 50.2 -4.90 -66. 0
4.90 147.7 8.50 43. 6 15.20 -72.3
Titration So. 4
0. 10 236. 5 5.20 130.3 10.40 23,8 17.40 -92.9
0.50 233.8 5.35 122.9 11.00 15. 2 17.90 — 100.8
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Table 3 cont.
Added E Added E Added E Added 2
Vol.ml mV Vol.ml mV Vol.ol ffiV Vol.ml mV
Titration No. 4 cont.
1.00 230.0 5.50 116.5 11.60 6.3 18,40"^ -108.3
2.00 221.2 5.70 109.4 12.20 -2.9 18.90 -115.6
2.80 212.0 5.90 103.0 12.70 -10. 9 19.50 -124.0
3. 30 204. 4 6. 15 96.2 13,20 -19.2 20,10 -132,1
3.80 194.7 6.40 90,0 13.60 -26. 1 20,70 - 140.0
4. 10 186. 6 6,70 83. 5 14.00 -33,2 21.30 -147,7
4.30 179.9 7. 10 75. 6 14.40 -40. 5 22.00 -156.7
4.50 171. 3 7.50 68.4 14.80 -47.8 22.70 ”166.0
4.65 163.9 8.00 59.8 15, 20 -55.2 23,30 -174.22
4.80 155.0 8.40 53.4 15.60 -62.4 23,90 -182.7
4.90 148.4 8.90 45, 8 16.00 -69. 5 24.50 -191.4!
5.00 142.0 9.40 38,4 16,50 -78.1
5.10 135.9 9.90 31. 1 16,90 “84. 8
Titration No. 5
0.10 229.8 5.35 125. 1 11.00 21. 4 18.40 -95.0
0.50 227. 1 5,50 119.2 11.50 14.2 19.00 -10 2.6
1.00 223.5 5,70 112, 5 12,00 6.9 19.60 -109.8
2.00 214. 8 5.90 106.5 12.50 -0,7 20.20 -116.6
2.60 ' 208. 3 6. 15 99,9 13.00 -8.5 20.90 -123,9
3.20 200.0 6.45 93. 1 13.50 -16.6 21.70 -131.6#
3.70 190.9 6,80 86,0 14.00 -25.0 22,50 -138.8
4.00 183.8 7.20 78. 4 14.50 -33.7 23.30 -145.7
4.20 177.9 7.60 71.4 14.90 -40.7 24.20 -152.3
4.40 170.8 8,00 64.9 15.30 -47.6 25.20 -160.4}
4.60 162.3 8.50 57. 1 15.70 -54.4 26.20 -168.6
4.75 154. 8 9.00 49.7 16.20 -62.7 27.20 -177. 1
4.90 146.9 9.50 42, 4 17.00 -75. 1 28.20 -186.2
5.05 139.0 10.00 35,4 ' 17.40 -31.1
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Table 3 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 5 cont.
5.20 131,7 10.50 28. 4 17.90 “88.2
Titration No. 6
0. 10 247.9 9.80 155.2 16.30 57.6 29.10 -55.0
0.50 246.5 10.00 148.2 17.20 50. 1 29.80 -62.4
1.00 244,5 10.20 141.6 18.20 41.8 30.50 -70.5
2.00 240.3 10.40 135. 6 19. 20 33,7 31.20 -78.2
3.60 232.9 10.65 128.9 20.20 25.8 31.90 -85.9
5.00 225.0 10.95 121.9 20.84 20.7 32.60 -93.9
6.00 218. 1 11.30 114.9 21.90 12.2 33.30 -101.9
7.00 209.7 11.70 108.0 22.90 3.9 34.00 -1093.9'
8.00 198.0 12.20 100.6 23.90 -4.6 34.70 -118.0
8,50 189.9 12.80 92.8 24.90 -13. 3 35.40 -125.9
8.80 184.0 13.40 85.6 25.90 -22.4 36.10 -134.6
9.10 177. 1 14.00 79.2 26.80 -31. 1 36.70 -142.6
9.40 168. 1 14,70 72.2 27.60 -39. 1 37.30 -150.9
9.60 161.9 15.50 64.9 28.40 -47. 4 37.90
Titration No. 7
1.60 46,0 2.55 -15. 1 3.53 -78.2 4.38 -135.8
1.70 37.9 2.70 -23,9 3.65 — 86.6 4.51 -144.0
1.80 30.9 2. 85 -33.0 3.77 -95. 1 4.'64 -152.1
1.95 20.8 3.00 -42. 3 3.89 -103.5 4.77 -160.1
2.10 11.4 3. 15 -52.0 4.01 -111.6 4.90 -168. 1
2.25 2. 4 3.29 — 61.4 4.13 -119.8
2.40 -6.4 3.41 -69.7 4.25 -127.4
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Table 4 EXPERIMENTAL .DATA FOR NICKEL-GLYCINATE INTERACTION
IN 1M cto;■ 4-
Titn. Starting Solution Titrating Solution Initial E®
No. A mM B mM H mM A mM B mM H mM Vol. ml mV
1 10. 34 5.237 4.077 -20.04 20.0 1 413. 8
2 5.249 5.232 4.073 -20.04 20.0? 413.7
3 15.78 5.237 4.077 -20.04 20.01 413,5
4 21. 11 5.237 4.077 -20.04 20.01 413.5
5 26.07 5-237 4.077 -20.04 20.01 413.6
6 31.40 10. 47 8. 150 -20.04 20.01 4 1 3 . 3
7 3.984 1.309 1.019 -20.04 20.01 413.3
Added E Added s Added E Added E
Vol.ml mV Vol.. ml mV Vol.mi mV Vol.ml mV
Titration No. 1
0.30 243,0 4.40 154.0 6.25 71,1 11.50 -23.2
1.00 237.0 4.50 144.7 6.75 60. 3 12.10 -35,4'
2.00 226. 4 4.60 135.8 7.30 49.9 12.50 -44.2
2.70 216.7 4.70 127. 8 7.90 39. 3 12.90 -53.9
3. 30 205. 1 4.82 119,7 8.50 29.2 13.50 -70.8
3.70 194.0 5.00 109.9 9. 10 19.2 14. ■ 10 -92.3
3.95 184.3 ' 5.20 101.2 9.7 0 9. 1 14.40 -106.2
4.15 173.5 5.50 90.7 10.30 -1.2
4. 30 162.7 5.80 82. 1 10.90 -11.8
Titration No. 2
0.50 253. 6 4.36 158. 8 5.05 89.8 7.30 21.5
2.00 238.1 4.43 148.0 5.25 80. 3 7.70 11.4
3.20 218. 4 4. 49 138,5 • 5.50 70.7 8,10 0.5
3.80 200.6 4.55 129.8 5.80 60.7 8.50 -11.4
4.00 191.0 4.63 120. 1 6.10 52.0 8.85 -22.9
4.17 179.4 4.73 110.6 6.50 41.5 9. 10 -33.3
4.27 170. 1 4.85 101.4 6.90 31.4 9.20 -38.0
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Table 4 cont.
Added E Added E Added E Added E
Vol.ml mV Vol.ml mV Vol.ml mV Vol.ml mV
Titration No. 3
0.50 231.5 5.00 118.9 10.20 20.0 16.50 -88.2;
2.20 214. 8 5.35 106. 1 11.20 5. 6 17.30 -104.41
3. 30 196. 8 5.85 92.4 12.20 -9.5 18.10 -121.0
3.90 “ 179.1 6.40 80.0 13. 20 -25. 8 18.85 -137.4:
a.25 162. 1 7.20 65.2 14.10 - 41.6 19.55 -154.4
4.50 146.2 8.20 49.2 14.90 -56. 6 19.90 -163.51
4.70 134.0 9.20 34. 4 15.70 -72.2
Titration No. 4
1.00 220. 6 6.00 96. 3 14.10 -26.1 21.60 -140.8:-
3.00 196.8 6.70 82.5 15.00 -41.2 22.80 -155.7
3.80 178.2 7.50 69.0 15.80 -54.9 24.00 -170.5 ■
4.30 158. 1 8.50 54.0 16.60 - 68. 3 25.20 -186.6:
4.50 148.0 9.50 40. 1 17.50 -82.9 25.80 -194.7
4.80 133.4 10.70 23.9 18.50 -98. 4
5. 10 121.2 11.90 7.3 19.50 -112.4
5.50 108.6 13-10 -10.3 20,50 -126.5
Titration No. 5
0.50 219.6 5.30 118. 6 11.80 16, 3 19.20 -95, 1
1.50 211. 1 5.80 105.8 13.00 -0.5 20.40 -110.1
2.90 194.0 6.50 91.5 14.20 -18.9 21.70 -124.4
3.70 177.2 7.30 78.0 15.20 -35. 1 23.30 -139.5
' 4.10 164.6 8.20 64.5 16,00* -48. 1 25,20 -155.1
4. 50 148.0 9. 40 48.0 17.00 -63. 8 27.20 -170.9;
4.90 131.9 10.60 32.2 18. 10 -79.9 29.50 -190.5
Titration No. 6
0.50 237.1 9.60 139.6 18.80 41.7 32.20 -73. 1
2.50 228.2 10. 20 126,7 21,00 25.5 33.60 -87.6;
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Table 4 cont «
Added E Added E Added E Added E •
Vol.ml mV Vol.ml mV Vol.ml rV Vol.ml mV =
Titration No. 6 cont. •
4.50 217.0 11.QO 113. 2 23.00 10. 5 35.00 -102.4
6.50 200.6 12.00 100.3 25.00 -5. 2 36.40 -117.9-
7.70 184. 6 13.40 85.8 27.00 -22.2 37.80 -134.3-
8.60 . 165.9 15.00 71.3 28.90 -39. 8 39.20 -152.3'
9.00 155. 3 16.80 56. 8 30.60 -56.6
Titration No. 7
0.40 208.2 1.20 100.0 2.3 5 4.2 4. 17 -106.8
0.70 193.5 1.26 88.0 2.65 -12?. 1 4.42 -122.9
0.90 175.9 1.35 75.0 2.95 -28.8 4.67 -138.5;
1.00 160.4 1.47 61.9 3. 25 -46. 3 4.93 -1^0.8';
1.07 141.9 1.62 48.9 3.45 -58.8 5.05 -158.i
1.11 127.9 1.85 33.0 3.69 -74. 5
1. 15 113.7 2. 10 18.0 3.93 -90.9
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